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ABSTRACT 
In mammals, the balance of energy storage and breakdown is essential for the maintenance of 
whole body energy homeostasis. An imbalance between energy intake and expenditure as well 
as an impaired adaption of the central metabolic organs to changes in nutrient availability (so-
called metabolic inflexibility) is tightly associated with the onset and progression of obesity and 
type II diabetes (T2D) and represents a hallmark of the metabolic syndrome. The metabolic 
syndrome is associated with a spectrum of liver abnormalities described as non-alcoholic fatty 
liver disease (NAFLD). Thereby, intracellular fat accumulation leads to hepatic lipotoxicity, cellular 
stress and dysfunction. While the liver is recognized as a key organ contributing to systemic 
metabolic control, the molecular mechanisms of liver metabolism in coordinating metabolic 
flexibility remain still puzzling.  
In order to determine the molecular mechanisms involved in metabolic flexibility and to find genes 
which display certain ‘inflexibility’ in conditions of metabolic dysfunction, a liver transcriptome 
analysis was performed on obese-diabetic db/db and wild type mice under fasting and fed 
conditions. Array results have uncovered one ‘inflexibility’ gene in the liver: GADD45β, a member 
of the “growth arrest and DNA damage-inducible 45” (GADD45) gene family. In particular, we 
have observed a strong upregulation of liver Gadd45b expression upon food deprivation in 
healthy animals, which was markedly less pronounced in db/db mice. While GADD45β is reported 
to be involved in hyperplasia of hepatocytes and in liver regeneration, there are no studies 
examining the role of GADD45β in metabolic function. 
In this work, we have characterised GADD45β as a nutrient starvation-induced gene, which is 
differentially expressed in disease and ageing. Congruently, liver Gadd45b mRNA levels were 
lower in fasted men with T2D than in healthy individuals. Gadd45b induction was liver specific and 
not compensated by an induction of the other GADD45 family members. Furthermore, we could 
show that the Gadd45b induction is reversible after re-feeding and intrinsic to hepatocytes. 
In the present work we describe for the first time a novel role for hepatic GADD45β in adaptive 
metabolism under the stress of food deprivation and nutrient overload. A whole-body deletion of 
the gene caused an accumulation of triglycerides and cholesterol in the liver under fasting 
conditions and in a mouse model for steatosis. Also, GADD45β KO mice were more insulin 
resistant after 4 months on high fat diet. Inversely, a liver-restricted GADD45β overexpression in 
systemic GADD45β KO mice could partially reverse their dysregulated fasting lipid metabolism, 
and GADD45β overexpression in db/db mice could partially reverse their diabetic phenotype. 
While the exact mechanism(s) by which GADD45β mediates its effects remain unclear we 
conclude that GADD45β may be a missing link between lipid and glucose homeostasis under 
conditions of nutrient stress, thereby protecting from metabolic dysfunction. 
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ZUSAMMENFASSUNG 
Für Mensch und Tier ist die Ausgewogenheit zwischen Energiespeicherung und –verwertung 
essentiell für die Aufrechterhaltung der Körperhomöostase. Ein Ungleichgewicht hierbei sowie 
eine beeinträchtigte Anpassungsfähigkeit der zentralen Stoffwechselorgane an wechselnde Nähr-
stoffbedingungen (sogenannte metabolische Inflexibilität) sind eng verknüpft mit der Entstehung 
und dem Verlauf von Fettleibigkeit und Diabetes Mellitus Typ 2 (DM2) und sind ein Kennzeichen 
für das Metabolische Syndrom. Dieses ist mit einer Reihe von Störungen der Leber assoziiert, bei 
denen intrazelluläre Fettanreicherung zu Lipotoxizität, zellulärem Stress und zur Dysfunktion 
führen (Nicht-alkoholische Fettlebererkrankungen). Während es allgemein anerkannt ist, dass die 
Leber eine Schlüsselfunktion in der systemischen Stoffwechselkontrolle einnimmt, sind die mole-
kularen Mechanismen zur Koordination der metabolischen Flexibilität nicht vollständig aufgeklärt. 
 
Um die molekularen Mechanismen zu entschlüsseln, die der metabolischen Flexibilität zugrunde 
liegen, und dabei Gene zu bestimmen, die bei Stoffwechselstörungen ‚inflexibel‘ reguliert sind, 
haben wir eine Transkriptom-Analyse an Lebern von adipös-diabetischen db/db und gesunden 
Wildtyp-Mäusen unter verschieden Nahrungsbedingungen durchgeführt. Dabei haben wir einen 
Kandidaten gefunden: GADD45β, ein Mitglied der „growth arrest und DNA damage-inducible 45“ 
(GADD45) Familie. Wir konnten in Wildtyp-Mäusen eine starke Hepatozyten-spezifische Hoch-
regulation von Gadd45b bei Nahrungsentzug beobachten, welche in db/db Mäusen deutlich 
weniger ausgeprägt war. Es ist bekannt, dass GADD45β in der Hyperplasie von Hepatozyten und 
in der Leberregeneration involviert ist, jedoch gibt es noch keine Studie, in welcher die Rolle von 
GADD45β in der Stoffwechselkontrolle untersucht wurde. 
In der vorliegenden Arbeit haben wir GADD45β als ein durch Nährstoffmangel induziertes Gen 
charakterisiert, dessen Expression in metabolischen Krankheiten und im Alter dysreguliert ist. 
Übereinstimmend damit waren die Leber-Gadd45b mRNA-Spiegel in nüchternen Männern mit 
DM2 geringer als in gesunden Individuen. Die Induktion von Gadd45b war dabei nicht durch die 
Induktion der anderen GADD45 Familienmitglieder kompensiert. Des Weiteren beschreiben wir 
zum ersten Mal eine neuartige regulatorische Funktion für GADD45β im adaptiven Metabolismus 
unter Nahrungsentzug und -überschuss. Ein „knockout“ (KO) dieses Gens führte zu einer 
stärkeren Akkumulation von Triglyzeriden und Cholesterin in der Leber von nüchternen Mäusen 
sowie bei einem Mausmodel für Steatose. Zudem waren KO-Mäuse nach 4 Monaten auf einer 
Hochfett-Diät insulinresistenter als Wildtyp-Mäuse. Umgekehrt konnten wir mit einer Leber-
spezifischen GADD45β-Überexpression in gefasteten KO-Mäusen deren dysregulierten Fettstoff-
wechsel sowie in db/db Mäusen deren diabetisches Erscheinungsbild teilweise verbessern. 
Obwohl noch nicht geklärt ist auf welche Weise GADD45β seine Effekte vermittelt, so können wir 
trotzdem aus unseren Beobachtungen schließen, dass GADD45β unter Stresssituationen wie 
Nährstoffmangel und –überschuss eine Verbindung zwischen Fett- und Glukose-Homöostase 
darstellen könnte, wobei es eine schützende Rolle vor Stoffwechselschäden einnimmt. 
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1. INTRODUCTION 
1.1 Metabolic flexibility – a hallmark of human metabolic health 
The discontinuity in supply and demand for energy requires the adaptation and coordination of the 
metabolic organs, a concept referred to as metabolic flexibility [1]. Metabolic flexibility is defined 
as the ability of a system (i.e. whole organism, organ, tissue, or cell) to adjust fuel oxidation to fuel 
availability [2] and to switch from lipid oxidation during fasting to carbohydrate oxidation during 
feeding conditions [3].  
The maintenance of body weight relies on the fine balance between energy intake and energy 
expenditure. Energy can be expended by performing physical activity and producing heat 
(thermogenesis). Also, energy is used by basic cellular functions which include adenosine 
triphosphate (ATP) turnover such as Na+-K+-pumps and Ca2+-pumps in the endoplasmic and 
sarcoplasmic reticulum. Indirect calorimetry is used to determine energy expenditure by 
calculating the heat that living organisms produce by measuring their O2 consumption and CO2 
production from consuming substrates (such as carbohydrate, lipid and proteins) [4]. Each 
substrate produces a different amount of energy (kcal) and a different cost in terms of CO2 to be 
removed. The ratio of CO2 produced to O2 consumed is referred to as the respiratory quotient 
(RQ). 
𝑅𝑄 = 𝑉𝐶𝑂2
𝑉𝑂2  
Depending on the nutrient energy source the RQ lies between 0,7 (fat) and 1,0 (carbohydrates) 
[1,2]. The RQ is about 0,8 at rest with a mixed diet. But also amino acid or protein oxidation is 
considered to have a RQ value between 0,8 and 0,9. Such measurements are used to calculate 
the basal metabolic rate which is the rate of energy expenditure at rest. Metabolic flexibility can 
also be assessed by using the change in RQ which should drop in healthy individuals when 
switching to lipid oxidation during fasting conditions [5]. At the state of rest the RQ corresponds to 
the respiratory exchange ratio (RER). The determination of the RQ is limited since it accounts for 
the heat production at the cellular level. On the contrary, the RER is easily measured at the nose 
or mouth, but this also means that the RER only serves as an estimate of the RQ. 
Short-term variations in energy intake or energy expenditure lead to either slightly positive or 
negative energy balances which are mostly buffered by an adjustment of oxidation to intake. 
During long-term energy balance however, energy expenditure eventually has to match energy 
intake, otherwise macronutrients are either stored or lost [6]. If this is not the case, metabolic 
homeostasis can no longer be maintained sometimes resulting in metabolic disorders, the bases 
of which are not fully understood. 
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1.2 Metabolic inflexibility – when metabolic control goes awry 
1.2.1 Obesity 
According to the World Health (WHO) organisation, overweight and obesity are defined as 
abnormal or excessive fat accumulation that presents a risk to health. The Body mass index (BMI) 
is commonly used to classify overweight and obesity in adults. It is defined as a person's weight in 
kilograms divided by the square of his height in meters (kg/m2). Overweight is defined as a BMI 
greater or equal to 25. People with a BMI greater or equal to 30 are considered obese. The 
causes for obesity are a combination of genetic predisposition, an increase in physical inactivity, 
and an increased intake of energy-dense food [7]. Recent research also links changes in the 
composition of the gut microbiota to obesity [8,9], which is most likely due to altered dietary 
composition and caloric intake. 
                 
Figure 1: Obesity as a pandemic. Incidence of obesity defined by a body mass index (BMI) ≥ 30 in 1980 
(A) and 2008 (B). Legends indicate BMI. From: global database on body mass index WHO, 2011. 
 
Obesity is becoming a major health problem not only in developed countries, but increasingly so 
also in developing countries. According to recent reports from the WHO (fact sheet number 311, 
2014) worldwide obesity has nearly doubled since 1980 (Fig. 1). In 2008, more than 1,4 billion 
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adults older than 20 were overweight, with the tendency rising, demonstrating that overweight and 
obesity can be considered a global epidemic. Overweight and obesity are risk factors for a 
number of chronic diseases, including diabetes, cardiovascular diseases, sleeping-breathing 
disorders and cancer [10,11], and are nowadays linked to more deaths worldwide in comparison 
to those caused by malnutrition [7]. Around 3,4 million adults die each year as a result of being 
overweight or obese. In 2013, more than 42 million children under the age of five were 
overweight, emphasising the rising need for new approaches for prevention or treatment. 
1.2.2 The metabolic syndrome 
Increasing evidence points to metabolic inflexibility as a key dysfunction of the cluster of disease 
states called metabolic syndrome. The metabolic syndrome is a loosely defined condition first 
described in 1988 by G.M. Reaven who defined it as a constellation of metabolic derangements 
then known as syndrome X [12]. Several organisations have recommended clinical criteria for the 
diagnosis of the metabolic syndrome such as high blood pressure (hypertension), high blood 
sugar (hyperglycaemia), insulin resistance, high triglycerides, low HDL cholesterol, high LDL 
cholesterol, a low-grade pro-inflammatory state, excess abdominal fat accumulation, and 
microalbuminuria (high urinary albumin secretion or albumin:creatinine ratio) (Fig. 2) [13-15]. The 
exact causes and underlying mechanisms are very complex and still under debate. Among the 
contributing interacting factors are genetics [16], family history of type 2 diabetes (T2D), stress, 
sleeping disorder [17], advanced age and risk factors for obesity such as sedentary lifestyle [18] 
and diet (particularly sugar-sweetened beverage consumption). As a consequence, individuals 
with the metabolic syndrome are at increased risk for developing cardiovascular diseases (CVD) 
and T2D or further secondary disorders such as non-alcoholic fatty liver disease (NAFLD). 
However, it is not clear whether obesity or insulin resistance is the cause of the metabolic 
syndrome or if they are consequences of a more far-reaching metabolic derangement. 
   
 
 
 
 
 
 
 
 
Figure 2: The metabolic syndrome. 
Causes (green), complications 
(orange) and consequences (red) of 
the cluster of disorders called the 
metabolic syndrome. 
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Given the increasing prevalence of the metabolic syndrome worldwide, largely as a consequence 
of the ongoing obesity epidemic, it is of high importance to find new treatment strategies. Lifestyle 
modification with increased physical activity and weight loss are recommended to be at the core 
of treating or preventing obesity. In addition, there is a general consensus that the risk for CVD 
and T2D should be managed by personalised medication aiming at controlling blood sugar, 
cholesterol, lipids, and high blood pressure [19-21]. But due to the complexity of the metabolic 
syndrome current therapies have failed to cure the disorder as a whole. 
1.2.3 Non-alcoholic fatty liver disease 
Obesity is associated with a spectrum of liver abnormalities described as non-alcoholic fatty liver 
disease (NAFLD) [22]. Within NAFLD cases one can distinguish between a state of accumulated 
intrahepatic triglycerides without inflammation (steatosis) or with inflammation and fibrosis (non-
alcoholic steatohepatitis (NASH)) [23]. Steatosis has been defined as an intrahepatic triglyceride 
content of >5% of liver volume or liver weight [24], or when 5% or more of hepatocytes contain 
visible intracellular triglycerides (TG) [25]. Steatosis develops when the rate of fatty acid (FA) 
input (uptake of plasma free fatty acids (FFA) and de novo lipogenesis) is greater than the rate of 
FA output (fatty acid oxidation and FA export within very low-density lipoproteins (VLDL)).  
                                
Figure 3: Fatty acid metabolism and the development of non-alcoholic fatty liver disease in obese 
persons. TG, triglyceride; FFA, free fatty acid; VLDL, within very low-density lipoprotein; DNL, de novo 
lipogenesis. Adapted and modified from [23]. 
 
Obesity-associated NAFLD together with hepatic and systemic inflammation are key factors 
involved in the development of insulin resistance and T2D (Fig. 3) [26]. The rate of release of FFA 
from adipose tissue and delivery to the liver and skeletal muscle is augmented in obese persons 
resulting in increased FFA uptake by the muscle and the liver and together with a greater de novo 
lipogenesis ultimately leading to intracellular FA accumulation. On the other hand, the production 
and secretion of TG in VLDL as a mechanism to remove excess FA is increased. However, since 
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FA oxidation is inhibited and de novo lipogenesis is stimulated by increased plasma glucose and 
insulin, the rate of TG secretion is not able to compensate for the rate of TG production. As a 
result, FA taken up by the liver are not oxidized or exported but are converted into TG and stored 
within lipid droplets. Consequently, these persons demonstrate hypertriglyceridaemia as well as 
TG accumulation in liver and muscle. In addition, certain FA intermediates can impair insulin 
signalling and lead to insulin resistance [27]. However the cause-effect relationship is not entirely 
solved, and it is still under debate whether NAFLD causes the described metabolic alterations or 
whether these abnormalities cause NAFLD [23]. 
1.2.4 Insulin resistance and type 2 diabetes 
Insulin resistance is a physiological condition whereby the organs of the body fail to respond to 
the hormone. When organs of the body become resistant to insulin, hyperglycaemia results. 
Chronic elevations in blood glucose stimulates the pancreas to increases the production of 
insulin, resulting in hyperinsulinaemia. Insulin resistance can affect the skeletal muscle (impaired 
insulin-mediated glucose uptake), the liver (impaired insulin-mediated suppression of glucose 
production), or the adipose tissue (impaired insulin-mediated suppression of lipolysis) [23]. 
NAFLD is associated with insulin resistance independently of obesity [28,29], and, as stated in 
1.2.3, it is still unclear whether NAFLD is the cause or the effect of insulin resistance. The 
complexity is highlighted by the observation that steatosis is not always associated with insulin 
resistance [30-32]. It is rather speculated that the esterification of excess FA into TG may protect 
the hepatocytes by preventing the accumulation of potential toxic intracellular FA [33,34]. 
Similar to the metabolic syndrome, insulin resistance is a complex metabolic disorder which 
cannot be explained by a single etiological pathway. There three major mechanisms are proposed 
to play crucial roles in the pathogenesis of insulin resistance: (1) ectopic lipid accumulation, (2) 
endoplasmic reticulum stress and activation of the unfolded protein response, (3) systemic 
inflammation [35]. The development of insulin resistance from ectopic lipid accumulation and the 
role of the liver will be addressed in 1.3.  
The endoplasmic reticulum (ER) is an intracellular organelle responsible for the coordinated 
synthesis, folding and trafficking of proteins. Unfolded or misfolded proteins are detected and 
removed from the cell via degradation by the proteasome system. Hypoxia, toxins, viral infections, 
and alterations in energy and substrates can lead to cell stress and the accumulation of unfolded 
proteins within the ER initiating an adaptive response known as the unfolded protein response 
(UPR) in order to regain organelle function [36]. Activation of three ER transmembrane sensors, 
inositol requiring enzyme-1 (IRE1α), PKR-like ER kinase (PERK) and activating transcription 
factor 6 (ATF6), aims at reducing unfolded proteins by increasing membrane biogenesis, halting 
protein translation, increasing ER-associated degradation genes and enhancing expression of ER 
chaperons. Activation of the UPR is reported to be involved in the pathogenesis of insulin 
resistance [37-39] but the underlying mechanisms are still under investigation. ER stress 
response has been shown to be induced by saturated FA in rats by activation of c-Jun N-terminal 
INTRODUCTION 
 6 
kinase (JNK) which in turn can inhibit insulin signalling through serine phosphorylation and/or 
degradation of the insulin receptor substrate (IRS1) [37]. 
Several studies show the impact of adipose tissue and intrahepatic inflammation on the 
development of insulin resistance [40,41]. The adipose tissue macrophage content and secretion 
of adipose tissue inflammatory proteins (such as interleukin 6 (IL-6), tumour necrosis factor α 
(TNFα) and chemokine (C-C motif) ligand 2 (CCL2)) are greater in obese than lean subjects [42] 
and in subjects with NAFLD compared to BMI-matched subjects with normal intrahepatic TG 
content [43], but the relative contribution in comparison with other potential factors for insulin 
resistance is not known. Several studies have demonstrated that cytokines increase adipose 
lipolysis which in turn may contribute to insulin resistance [44-46]. Also, altered adipocyte biology 
in obesity leads to a shift in other adipocytokines released from these cells: while leptin and 
resistin are produced to a larger extent, adiponectin release is reduced, all together leading to 
worsened insulin sensitivity and the development of metabolic syndrome [47]. In addition, the 
activation of hepatocellular NF-ᴋB is reported to be involved in insulin resistance by upregulating 
the production of pro-inflammatory cytokines, such as IL-6, that often affect insulin action [48,49]. 
Insulin resistance is a feature of T2D, wherein patients demonstrate a relative lack of insulin 
despite primarily functional β-cells of the pancreas and thus have hyperglycaemia and are 
glucose intolerant. In contrast, patients with type 1 diabetes have an absolute lack of insulin due 
to the destruction of β-cells in the pancreas. The majority of patients with diabetes suffer from 
T2D (~90%), and its prevalence is drastically increasing in parallel with its main cause, obesity 
[50]. In 2010 there were approximately 285 million people diagnosed with the disease compared 
to around 30 million in 1985 [51]. Long-term complications from high blood glucose can include 
CVD, stroke, diabetic retinopathy where eyesight is affected, kidney failure, and poor blood flow in 
the limbs leading to amputations [52]. Since T2D is mainly associated with obesity and the 
metabolic syndrome, they share the same risks and the same strategies for treatment and 
prevention. 
1.2.5 Mouse models for metabolic disorders 
Due to ethical and practical limitations in regards to tissue collection and therapeutic interventions 
(e.g. testing of drugs) in humans, animal models have become an important tool for gaining 
insights into the underlying mechanisms of human diseases, their risks and progression profile as 
well as to study approaches for therapy.  About 99% of mouse genes have a homolog in human 
[53]. Metabolic, physiological and behavioural stresses can be tested in mice and in many cases 
mouse models mimic the situation in humans [54]. Thus, mouse models are an adequate animal 
model for studying the biology of metabolic disorders such as obesity, diabetes or altered lipid 
metabolism, and may help to identify novel genes contributing to the onset or prevention of 
diseases [55]. 
In order to translate results found in laboratory model systems to the clinical situation and 
subsequently to the development of therapeutic or prevention strategies of the disease, it is 
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important that the animals model used to study metabolic disorders incorporate the pathological 
patterns and histological alterations found in the course of the disease, such as weight gain, 
dyslipidaemia or insulin resistance [56]. 
Several mouse lines have been established that serve as experimental models for metabolic 
diseases. Among them are the most frequently used monogenic mouse models for obesity and 
diabetes (leptin receptor deficient db/db mice [57,58] and leptin deficient ob/ob mice  [59]) and a 
polygenic mouse model for obesity and pre-diabetes (NZO mice [60]). Similar to db/db mice, the 
Zucker rat has a loss of the leptin receptor and shows similar phenotypes [61,62]. In recent years, 
studies have revealed that melanocortin or the melanocortin receptor (MC4R) critically regulate 
food intake and body weight [63], and so MC4R deficient mice are more frequently being used to 
study the development of late-onset obesity [64]. Furthermore, metabolic dysfunction can be 
induced in healthy wild type mice by environmental interference. In some mouse strains, long-
term feeding a diet rich in fat (HFD) results in obesity, impaired glucose tolerance, dyslipidaemia, 
expression of pro-inflammatory cytokines, oxidative stress, increased sensitivity to endotoxins and 
an impaired function of the intestinal barrier [65,66] closely resembling the pathological and 
molecular alterations found in humans with NAFLD. The severity, progression and specific 
features of the disease depend not only on the amount of dietary fat (30-75% of total calories) but 
also on the quality of fat and fatty acid composition. In addition, not every mouse strain is similarly 
responsive to a HFD [67]. C57Bl6/J mice for example develop more severe diet –induced insulin 
resistance than A/J mice [68]. High fat diets are furthermore used to promote the development of 
NASH from steatosis in genetic animal models (e.g. ob/ob mice). A more severe degree of liver 
damage can be obtained by feeding a diet deficient in methionine and choline (MCD) [69,70]. 
Mice fed a MCD diet rapidly (with 2-3 weeks) develop steatosis and subsequently necrosis and 
liver injury due to enhanced hepatic uptake of fatty acids and impaired secretion of VLDL particles 
from the liver, processes for which methionine and choline are essential in human and mouse. 
Despite causing faster and more severe NASH, the MCD diet lacks some characteristics of 
NAFLD found in humans, such as insulin resistance and obesity. On the contrary, it is reported 
that mice on MCD diet lose up to 35% of their body weight within 4 weeks [70]. In addition to the 
diets mentioned, researchers emphasise that a shift in dietary pattern towards a sugar-rich diet 
may also be a risk factor for the development of NAFLD in humans, and hence, nowadays, also 
fructose-rich diets or “western style diets” (fast food diets) containing a combination of fat and 
sugar are used to study NAFLD [71-74]. Moreover, the prevalence of the metabolic syndrome and 
NASH are increased with aging since the onset of obesity and diabetes increases with age [75-
77], and natural physiological changes inherent to the process of aging may trigger or promote 
the development of the metabolic syndrome later in life. Therefore, aged mice can also be used to 
study the onset and progression of fatty liver diseases and metabolic disorders. 
For this work both genetic and diet-induced models of obesity models were used, namely db/db, 
ob/ob, NZO/NZB mice as well as HFD and MCD diet. Also, geriatric mice were used for analysis. 
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1.3 The liver and its role in health and disease 
As described in section 1.1, the balance of energy storage and breakdown is essential for the 
maintenance of whole body energy homeostasis. The discontinuity in supply and demand for 
energy therefore requires the adaptation and coordination of the organism at several, from cellular 
integration of nutrient/hormonal signals to inter-organ communication and assimilation. Each 
major metabolically active organ, such as liver, adipose tissue, muscle, pancreas, intestines and 
brain, senses and integrates nutritional, neural and endocrine signals and can thereby participate 
in carbohydrate, lipid and amino acid metabolism in a tissue-specific manner. 
It is commonly accepted that the liver, being the largest internal organ and gland of the human 
body, is a pivotal contributor to metabolic control. Nutrients, hormones or drugs are delivered to 
the liver principally by the portal vein which transports its content from the gastrointestinal tract 
and the spleen directly to the liver. Due to this central position, the liver has a wide range of 
functions, including uptake and digestion of nutrients, detoxification, protein synthesis and 
hormone production. The liver consists of different cell types: parenchymal and non-parenchymal 
cells. The liver parenchymal cells, also called hepatocytes, make up 80% of the liver volume. The 
remaining non-parenchymal cells are mainly endothelial cells, hepatic stellate cells, immune 
reactive Kupffer cells, and natural killer cells [78]. 
1.3.1 Liver carbohydrate and lipid metabolism 
One of the liver’s primary functions is the regulation of glucose, lipid and protein metabolism 
which is mainly controlled by insulin and glucagon, two hormones with opposing roles. Whereas 
glucagon triggers catabolism (break down of molecules into smaller units to release energy), 
insulin promotes anabolism (build-up of molecules from smaller units to store energy) (Fig. 4).   
 
 
 
Figure 4: The role of 
insulin and glucagon in 
adaptive metabolism. 
While insulin (left) 
promotes anabolism to 
store energy during times 
of food excess, glucagon 
and glucocorticoids (right) 
trigger catabolism to 
release energy during 
times of food deprivation. 
Adapted and modified 
from Dr. Roldan de Guia, 
PhD Thesis, Herzig Lab. 
 
After food intake, a first breakdown of macro-nutrients occurs in the gastrointestinal tract, where 
carbohydrate polysaccharides are converted into simple sugars, protein polypeptides into shorter 
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peptides and amino acids, and lipids hydrolysed and packed with apolipoproteins. The absorbed 
nutrients are then transported to the liver via the blood and lymphatic stream and enter 
hepatocytes via facilitated diffusion (glucose), active co-transport (amino acids) or with the help of 
transport proteins (FA) and receptor-mediated processes (cholesterol). During fasting, 
macronutrients are broken down in muscle and adipose tissue and then transported to the liver 
via the same route. 
The fate of the nutrients, either being metabolised for energy storage or energy production, 
depends on the substrate availability and the metabolic state of the cell and the organism. 
Glucose is metabolised via the glycolytic pathway into pyruvate (Fig. 5). From there it can be 
converted into acetyl-CoA and either serves as energy source in mitochondria via the Krebs cycle 
and electron transport chain, or it is used for fatty acid, triglyceride and cholesterol synthesis 
(lipogenesis). Alternatively, glucose molecules can be used for the synthesis of glycogen. If this 
reaction is saturated, conversion of glucose into fats takes place. On the other hand, glucose can 
be generated either from pyruvate after degradation of proteins into amino acids or of triglycerides 
into glycerol (gluconeogenesis), or from glucose-6-phosphate after glycogen breakdown 
(glycogenolysis). Glucose can also enter the pentose-phosphate pathway via glucose-6-
phosphate where it can generate metabolites needed for nucleotide synthesis and the reducing 
equivalent NADPH. 
The blood glucose concentration is balanced through mechanisms that either produce or 
consume glucose. Hepatic glucose production (HGP) is regulated by the hormone insulin which is 
released from the pancreas when blood glucose or fatty acid levels rise. Insulin can inhibit HGP 
via the direct and indirect actions [79,80]. The indirect influence of insulin on HGP is mediated by 
the tissues that respond to insulin levels. As such, glucagon secretion from the pancreas is 
reduced [81], non-esterified fatty acids (NEFA) release from adipose tissue is diminished [82], the 
supply of gluconeogenic precursors from fat and muscle are reduced [83], and the brain provides 
neural input to the liver when insulin levels rise [84,85], all leading to a decrease in HGP. In 
experiments on conscious overnight-fasted dogs it could be shown that insulin has also a direct 
effect on the liver to reduce HGP [86,87]. On the other hand, a manipulation of the hepatic insulin 
receptor in mice did not inhibit insulin’s ability to suppress HGP [88], and also a restauration of the 
insulin receptor in mice lacking this receptor could not restore insulin’s function to reduce HGP 
[89]. Thus, the indirect actions of insulin seem to be dominant. Apart from insulin, also adrenaline, 
glucagon and somatotropin are involved in the regulation of the blood glucose concentration. 
Adrenaline and glucagon promote the release of glucose from depots, whereas somatotropin 
inhibits glucose uptake by cells. Together they are released when blood glucose levels decrease. 
Glucocorticoids  [90] and T3/T4 hormones work by reinforcing the effects of adrenaline and 
glucagon [91]. 
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Hormone leads to via at 
Insulin Decrease Inhibition of glucose production Liver 
  Stimulation of glucose uptake Muscle, fat 
  Stimulation of glycogensynthesis Muscle, liver 
  Stimulation of glycolysis Muscle, liver 
Glucagon Increase Stimulation glycogenolysis Liver  
  Stimulation of gluconeogenesis Liver 
  Inhibition of glycogensynthesis Liver  
Catecholamine Increase Stimulation glycogenolysis Muscle, liver 
  Inhibition of glycogensynthesis Muscle, liver 
  Inhibition of insulin release pancreas 
Glucocorticoids Increase Inhibition of glucose utilisation Muscle, fat 
  Stimulation of gluconeogenesis Liver  
T3/T4 Increase Stimulation glycogenolysis Muscle, liver 
Somatotropin Increase Stimulation of gluconeogenesis Liver 
  Inhibition of glucose utilisation Muscle, fat 
Table 1: Hormonal regulation of the blood glucose concentration. Modified and adapted from Mutschler, 
Schaible, Vaupel: Anatomie, Physiologie, Pathophysiologie des Menschen, 6. Auflage 2007 
 
Apart from playing a central role in the regulation of glucose homeostasis, the liver is also a key 
organ in the control of lipid metabolism [92]. The term lipid encompasses molecules such as 
triglycerides, fatty acids, phospholipids, sterol-containing metabolites such as cholesterol and 
others. NEFA can be taken up by the cell with the help of transport proteins such as fatty acid 
transport protein (FATP), fatty acid translocase (CD36), caveolin-1 and fatty acid binding protein 
(FABP). Once inside the cell, fatty acids can be used to generate energy during a process called 
β-oxidation. Therein, fatty acids are transported across the mitochondria or peroxisome 
membrane with the help of carnitine palmitoyltransferase-I (CPT-I) where they are broken down to 
acetyl-CoA which then enters the Krebs cycle to form NADH and ATP or is used to generate 
cholesterol or ketone bodies (ketogenesis).. Alternatively, acetyl-CoA can be used for the 
generation of TG which in turn are either stored in the liver or released into the circulation as very 
low density lipoprotein (VLDL) particles. Instead of being used as energy source, FA can also be 
converted into other lipid species such as sphingolipids and glycerophospholipids. Taken 
together, TG and FA within the liver come from four different sources: (1) from the diet, (2) de 
novo lipogenesis (DNL), (3) from lipolysis in adipocytes, and (4) cytoplasmic TG stores. 
Cholesterol, which is either taken up by the liver from the diet or synthesized from acetyl-CoA, is 
used as a component of biomembranes and for the synthesis of bile acids, steroid hormones (e.g. 
androgens, oestrogens, and glucocorticoids) and vitamin D. 
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Figure 5: Metabolism of carbohydrates, lipids and proteins in hepatocytes. ETC, Electron transport 
chain. Adapted and modified from Dr. Roldan de Guia, PhD Thesis, Herzig Lab.  
 
1.3.2 The lipoprotein pathway 
Due to their hydrophobic nature, TG and cholesterol have to be transported through the blood 
circulation in lipoproteins. Lipoproteins are composed of an outer shell containing amphipathic 
phospholipids, non-esterified cholesterol and apolipoproteins, and an inner core containing the 
TG and cholesterol esters. They can be classified according to their sizes and densities which are 
the result of their composition (Table 1). Furthermore, the composition of each lipoprotein particle 
determines where it will be metabolised.  
Lipoprotein 
Density 
[g/dL] 
Diameter 
[nm] 
Apolipoproteins Lipid composition [%] 
    TG C P 
Chylomicrons < 0,930 75-1200 
B48, E, A1, A2, 
A4, C2, C3 
80-95 2-7 3-9 
VLDL 0,930-1,006 30-80 B100, E, C2, C3 55-80 5-15 10-20 
IDL 1,006-1,019 25-35 B100, E 20-50 20-40 15-25 
LDL 1,019-1063 18-25 B100 5-15 40-50 20-25 
HDL 1,063-1,21 5-12 A1, A2, A5 5-10 15-25 20-30 
Table 2: Characteristics of lipoprotein particles. VLDL, very low density lipoprotein; IDL, intermediate 
density lipoprotein; LDL, low density lipoprotein; HDL, high density lipoprotein; % lipid content indicates 
percentages of triglycerides (TG), cholesterol ester (C) and phospholipids (PL) within the respective 
lipoprotein class, the remaining part consists of apolipoproteins. The density was determined by 
ultracentrifugation and the diameter by gel electrophoresis. Adapted from [93].  
 
The formation and degradation of lipoproteins can be summarised in the lipoprotein pathway (Fig. 
6). This pathway can be divided in to three arms: (1) the transport of TG and cholesterol from the 
diet (exogenous pathway), (2) the transport of hepatic lipids (endogenous pathway), and (3) the 
reverse cholesterol transport (RCT). TG from the diet cannot be absorbed by the duodenum and 
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are first hydrolysed into monoacylglycerol and free fatty acids and subsequently moved to 
absorptive enterocytes in the intestines. There TG are rebuilt from their fragments and packaged 
with apolipoproteins and cholesterol to form chylomicrons which are collected by the lymph 
system and transported to the large vessels near the heart before entering the blood circulation. 
The chylomicrons serve first muscle and adipose tissue with energy. TG in lipoproteins cannot be 
taken up by the cell directly and have to be first converted into NEFA and monoacylglycerol by 
lipoprotein lipases (LPL) which is on the wall of the capillaries in the peripheral tissues [94]. The 
TG-depleted chylomicron remnants containing cholesterol esters are then recognized by the liver 
[95], where the cholesterol esters are taken up by the cell via receptor-mediated processes 
involving the low-density lipoprotein receptor (LDLR), lipolysis-stimulated lipoprotein receptor 
(LSR), LDLR-related protein (LRP), and the scavenger receptor 1 (SRB1). 
      
Figure 6: The lipoprotein pathway. Shown are the exogenous (red arrows) and the endogenous lipoprotein 
pathway (blue arrows), as well as the reverse cholesterol transport (green arrows). For details, see text. TG, 
triglyceride; CM, chylomicrons; LPL, lipoprotein lipase; FA, fatty acid; HDL, high density lipoprotein; VLDL, 
very low density lipoprotein; IDL, intermediate density lipoprotein; LDL, low density lipoprotein; ABCA1, ATP-
binding cassette protein 1; CETP, cholesteryl ester transfer protein; CE, cholesteryl ester; LRP1, LDLR-
related protein 1; LDLR, low-density lipoprotein receptor; SRB1, scavenger receptor 1; HL, hepatic lipase; E, 
A1, A2, C2, C3, B48 and B100 refer to apolipoproteins. Adapted and modified from [96,97].  
 
VLDL particles, together with IDL and LDL, are the major transport vehicles of the endogenous 
lipoprotein pathway. VLDL particles are assembled in the endoplasmic reticulum (ER) which is 
strictly regulated by TG availability and regulatory proteins such as microsomal TG transport 
protein (MTP). The structure of VLDL particles resembles that of chylomicrons [98]. VLDL 
particles are hydrolysed in peripheral tissues by LPL, thereby providing adipose tissue and 
muscle with energy in the form of fatty acids. IDL particles result from VLDL breakdown and can 
be taken up by the liver via LDL receptors. IDL is further hydrolysed by hepatic lipase to low 
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density lipoprotein (LDL) with cholesterol-esters as main cargo. LDL can be cleared by the liver 
but in humans, the major amount of cholesterol is transported in the LDL fraction into the 
periphery. There they can be oxidized and taken up by macrophages leading to the formation of 
so called lipid filled foam cells. Foam cells can aggregate within the arterial wall and subsequently 
form atherosclerotic plaques which are associated with myocardial infarction and stroke [97]. 
Whereas cholesterol is transported to the periphery via LDL particles, it is carried back to the liver 
via HDL particles in a mechanism called the reverse cholesterol transport (RCT) [99-101]. It is 
due to these functions of LDL and HDL that they are called “Bad and good cholesterol” by the 
general public. Whereas an increase in LDL particles is associated with increased risk for 
atherosclerosis and heart disease, an increase of HDL is reported to have beneficial effects on 
health [102]. HDL is synthesized by the liver or intestine together with ATP-binding cassette 
protein 1 (ABCA1) of the peripheral tissues. The liver can take up these HDL particles via SRB1. 
Alternatively, some cholesterol-esters are transferred from HDL to VLDL particles in exchange for 
TG with the help of cholesteryl ester transfer protein (CETP). VLDL particles are then hydrolysed 
to IDL and LDL and either taken up by the liver or peripheral tissues. Either way, cholesterol 
transported to the liver can now be excreted in the form of bile salts. 
1.3.3 Dyslipidaemia and insulin resistance 
As already mentioned in 1.2.3, obese and diabetic individuals suffer from failure to suppress 
hepatic glucose production and FA efflux from adipose tissue, as well as defective fasting-induced 
skeletal muscle lipids utilisation. Furthermore, the transition from FA efflux to storage in response 
to a meal is also compromised in these disease states. The rate of release of FA from adipose 
tissue and delivery to the liver and muscle is increased in obese persons with NAFLD, which 
results in an increase in hepatic and muscle FFA uptake. As a consequence intracellular FAs 
accumulate within hepatocytes without further oxidisation. Instead, they are esterified to TG and 
stored within lipid droplets. Predominantly due to increased VLDL secretion by the liver as a 
compensatory reaction to the increased FA esterification, lipoprotein metabolism is disturbed in 
these individuals, a state called dyslipidaemia [103,104]. Once in the serum, cholesterol-ester 
transfer protein (CETP) transfers TG and cholesterol between VLDL and HDL or LDL leading to a 
reduction HDL and an accumulation of LDL particles. In addition, VLDL and LDL clearance are 
impaired with insulin resistance. Thus, the characteristics of this pathologic state are increased 
plasma TG and LDL-cholesterol levels, while HDL-cholesterol is decreased [105].  
There are different approaches to treat dyslipidaemia. One of them is a change of lifestyle as it 
has been also proposed for the treatment of the metabolic syndrome (see. 1.2.2). Other strategies 
aim at personalised medicine in form of pharmaceutical intervention. In that regard it had been 
suggested to administer drugs such as statins or fibrates which can help to reduce risk for 
developing atherosclerosis [106,107]. However, statin treatment can have adverse effects such 
as hepatotoxicity [108] and myopathy [109]. Other pharmacologic agents for the treatment of 
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dyslipidaemia are the cholesterol-absorption inhibitor ezetimibe, the lipolysis inhibitor niacin, bile 
acid sequestrants and omega-3 fatty acids [110,111]. 
Hepatic accumulation and increased hepatic release of TG observed in obese and diabetic 
patients is associated with insulin resistance [27,112]. Genetic rodent models that have altered 
expression of lipid transport proteins, such as LPL, LSR or CD36, provide evidence for the role of 
ectopic lipid accumulation in the pathogenesis of insulin resistance [95,113,114]. Moreover, it has 
been shown that in humans, the ectopic storage of fat in the liver, more so than skeletal muscle or 
adipose tissue, is associated with impaired metabolism [115,116]. The mechanisms of action 
might involve hepatokines, proteins released from the steatotic liver [117,118]. Furthermore, the 
incomplete oxidation of FA generates ketone bodies and acylcarnitines, which might also have 
adverse effects on insulin action, potentially linking mitochondrial dysfunction to insulin resistance 
[119]. However, the interaction between mitochondria and insulin sensitivity is very complex and 
controversial, and might not only be tissue-specific, but also dependent on the site of the 
impairment [120,121].  
The cellular mechanisms responsible for FA-induced insulin resistance in muscle and liver are not 
completely clear (Fig. 7). It is suggested that excessive intracellular lipid intermediates generated 
by FA metabolism, in particular, diacylglycerol (DAG), long-chain fatty acyl-CoA, ceramide, 
lysophosphatidic acid (LPA), and phosphatidic acid (PA), can have adverse effects on insulin 
action [35,122-124]. They might interfere with insulin action by activating protein kinase C (PKC), 
mammalian target of rapamycin (mTOR) and nuclear factor ᴋB (NF-ᴋB), and inhibiting AKT. But in 
current literature, it is questioned whether a defect in insulin signalling is obligatory for causing 
insulin resistance [125]. Some investigators have proposed that insulin’s ability to suppress 
hepatic glucose output does not require the canonical insulin signalling pathway [88,89,126] nor 
AKT as an obligate intermediate for proper insulin signalling [127]. It is speculated that within the 
liver not only a linear (canonical) insulin signalling pathway exists (via insulin receptorinsulin 
receptor substrate (IRS) phosphatidylinositol-3-kinase (PI3K) 3-phosphoinositide dependent 
protein kinase-1  (PDPK1)AKT) to activate or suppress forkhead box protein O1 (FOXO1), but 
also a non-canonical pathway independent of AKT which has yet to be identified. The divergent 
point of the non-canonical pathway from the canonical pathway could reside between IRS and 
AKT, specifically downstream of PDPK1 which affects not only AKT but also an atypical protein 
kinase C (aPKCλ), thereby controlling gluconeogenesis [128]. Alternatively, it is postulated that a 
non-autonomous pathway exists which includes adipose signalling to hepatocytes via free fatty 
acids. In this model the insulin resistance of adipose tissue, particularly visceral adipose, to 
suppress NEFA production leads to hepatic NEFA oversupply and thus impaired insulin 
suppression of HGP through an as yet undefined mechanism [129-131]. The discrepancy about 
the major underlying mechanism responsible for insulin resistance and the metabolic syndrome 
shows how much more investigation is needed in order to define the responsible players and 
thus, for the development of treatment strategies. 
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Figure 7: Fatty acid metabolism and insulin resistance. Potential cellular mechanism that might link the 
accumulation of fatty acids (FA) and their lipid intermediates to the development of insulin resistance. TG, 
triglyceride; FA, fatty acid; LPA, lysophosphatidic acid; PA, phosphatidic acid; DAG, diacylglycerol; NF-ᴋB, 
nuclear factor ᴋB; PKC, protein kinase C; mTOR, mammalian target of rapamycin; AKT, protein kinase B. 
Adapted and modified from [23]. 
 
1.4 Growth arrest and DNA damage-inducible 45 (GADD45) gene family 
Starvation as well as an oversupply of nutrients, both severe stresses for the organism, requires 
adaptation to these situations on many levels, from the single cell to the communication between 
organs, in order to maintain homeostasis. As for every environmental or physiological stress, the 
cellular response is very complex, involving countless interconnected and associated pathways, 
with an abundance of regulators and effectors. 
The metabolic challenges described so far lead to adaptive changes in cell signalling, ultimately 
leading to ER stress, mitochondrial dysfunction or inflammation. As soon as the cells cannot cope 
anymore with the stress situation they are confronted with, they go into programmed cell death 
(apoptosis). Indeed, it is described that apoptosis is associated with insulin resistance and 
different degrees of NAFLD [132-135], and is often linked to an excess of unoxidised long-chain 
fatty acids (lipoapoptosis) [136]. 
Apoptosis is often also triggered by other environmental agents, such as ionizing radiation (X-
rays) or nonionizing radiation (UV light), physiological processes which produce activated oxygen 
species and other reactive molecules, or alkylating agents, such as methyl methanesulfonate 
(MMS). They all have in common that they induce DNA damage. Genotoxic stress which leads to 
DNA damage is unavoidable, and cells have developed mechanisms to deal with its 
consequences and to maintain their integrity. DNA damage can be repaired during cell cycle 
arrest by various base-excision repair mechanisms [137]. However it will induce apoptosis if 
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damage is extensive and repair efforts fail. Whether a cell is getting repaired from DNA damage 
or undergoes apoptosis depends on the severity of the damage and the cell-type, but how the 
underlying pathways, such as the ATM/p53 tumour suppressor pathway [138,139] or the p38/JNK 
kinase pathway [140-142], interact to decide whether it comes to cell cycle arrest or cell death is 
not fully understood. Key players in the perception and coordination of cellular stress are the 
members of the Growth arrest and DNA damage-inducible (GADD) 45 family. 
GADD45 genes were first cloned in the late 1980s and early 1990s [143-146]. There are three 
family members: GADD45α (former GADD45), GADD45β (former MyD118), and GADD45γ 
(former CR6) which are located on three different chromosomes (chromosome 1, 19, and 9 for 
GADD45α, GADD45β and GADD45γ, respectively). The best described member of the GADD45 
family is GADD45α. Distinct isoforms for GADD45α and GADD45γ are produced through 
alternative splicing [147], but it has not been established yet whether there is a functional 
difference between these isoforms. They are evolutionary conserved and share 55-57% overall 
identity at the amino acid level. They are small (18kDa), highly acidic (pI=4,0-4,2) and are 
localised primarily within the cell nucleus [148,149]. GADD45 proteins are able to form homo- and 
hetero-dimers [150-152], and are differentially expressed in several tissues including heart, brain, 
spleen lungs, liver, skeletal muscles, kidneys, and testes [144]. GADD45 proteins are non-
enzymatic. Their actions are executed through interactions with protein partners or the modulation 
of DNA/RNA accessibility to other proteins. The interaction of GADD45 proteins with their partner 
protein is regulated at the level of expression, cellular localisation and posttranslational 
modification of both interaction partners. Indeed, GADD45 proteins were observed to harbour 
several threonine and tyrosine phosphorylation as well as acetylation sites [153]. 
1.4.1 GADD45 proteins in stress responses: the dual role in apoptosis and survival 
It has been shown that GADD45 proteins function as stress sensors and are implicated in the 
control of cell cycle arrest [154], DNA repair, cell survival [155,156], tumour development, 
senescence and apoptosis where they act in a synergistic manner [157-159]. Therefore they 
physically interact with other cellular proteins that are involved in cell cycle regulation and stress 
response, such as proliferating cell nuclear antigen PCNA [148,160-162], p21 (p21/WAF1/CIP1 
also known as cyclin-dependent kinase inhibitor 1) [148,149,162], Cdc2/cyclinBI [159,163,164], or 
MEKK4 (also MAP3K or MTK1) [165] (Fig. 9). Furthermore, GADD45α was the first stress-
induced protein discovered that was transcriptionally regulated by p53 [166,167] with the p53 
binding site being in the third intron of GADD45 [168]. Whether GADD45 proteins exert a pro- or 
anti-apoptotic function depends on the severity of DNA damage. For example, in the case of 
irreparable damage, increased expression of GADD45β triggers apoptosis via 
TGFβMEKK4p38/JNK and blockage of GADD45β suppresses apoptosis induced by TGFβ 
[169,170]. In the case of moderate DNA damage, GADD45β acts as anti-apoptotic agents via 
inhibition of the MKK7JNK pro-apoptotic pathway [152,171,172] (Fig. 8). 
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Figure 8: The dual role of GADD45β in apoptosis and survival. GADD45β induction can either lead to 
apoptosis via MEKK4p38/JNK, or prevent apoptosis by inhibition of the MKK7JNK pro-apoptotic 
pathway, depending on the severity of the DNA-damage. GADD45, growth arrest and DNA damage-
inducible 45; MEKK4, MAP kinase kinase kinase 4; p38, p38 mitogen-activated protein kinases; JNK, c-Jun 
N-terminal kinase; ASK1, Apoptosis signal-regulating kinase 1; MKK3/6/4/7, MAP kinase kinase 3/6/4/7. 
 
The implication of GADD45 proteins in DNA repair links them to their role in epigenetics. They are 
able to facilitate the physical approach of several proteins to DNA through active DNA 
demethylation [173-176], chromatin remodelling [177] and post-transcriptional RNA regulation 
[178]. 
GADD45 proteins have similar, but not identical functions along different stress response 
pathways. Each protein has a different pattern of cell-specific [144,179] and stimulus-induced 
expression, regulation and interaction partners, presumably reflecting different signaling 
pathways. For example, whereas Gadd45a expression is simulated by physical or chemical stress 
(UV radiation, X-rays, γ-radiation, low-frequency electromagnetic fields, hypoxia, hyperosmosis, 
low pH, arsenic, cisplatinum, methyl methanesulfonate, ethanol, cigarette smoke condensate and 
others), different inducers of oxidative stress including sodium arsenite as well as inflammatory 
(IL-6, IL-12 and IL-18) and pro-apoptotic cytokines (TGFβ and TNFα) stimulate the expression of 
Gadd45b and Gadd45g (see suppl. table 1 for references).  
              
Figure 9: GADD45 proteins in stress response. GADD45 proteins physically interact with other proteins 
during stress response. GADD45, growth arrest and DNA damage-inducible 45; MEKK4, MAP kinase kinase 
kinase 4; JNK, c-Jun N-terminal kinase; PCNA, proliferating cell nuclear antigen; cdc2, cell division cycle 2. 
Adapted and modified from [180]. 
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1.4.2 GADD45 proteins in cell differentiation, the immune response and neuronal 
function 
Apart from playing a role in the cell’s fate by controlling the balance between DNA repair, 
apoptosis or senescence, GADD45 proteins are also implicated in other cellular processes. It was 
shown that GADD45 family members play an important role in cell differentiation, both during 
embryogenesis and throughout adulthood. For example, GADD45γ is involved in neuronal 
differentiation [181,182] and development of male gonads [183], and GADD45β is required for 
somite segmentation [184], differentiation of chondrocytes [185] and neural development [186]. 
Furthermore, all three GADD45 proteins are important players in myeloid differentiation and thus 
haematopoiesis [143,187]. Apart from influencing differentiation, GADD45 proteins are crucial for 
maintaining a stem cell pool [188]. Moreover, GADD45 proteins contribute to survival not only at 
the cellular level but also by modulating the immune response on the organismal level. Especially 
GADD45β and GADD45γ stimulate proliferation of T helper 1 (Th1) cells and activation of the 
immune system [189,190], thereby contributing to enhanced immune surveillance [191] and 
elimination of cells that might display autoimmune behaviour [192]. Through the involvement of 
GADD45 family members in neuronal differentiation [193] and demethylation, they are also 
implicated in other neuronal functions [194]. As such, it has been shown that GADD45β is crucial 
for axonal plasticity [195], brain recovery and long-term memory [196].  
1.4.3 GADD45 proteins in stress signalling 
The common basis of all actions of all three GADD45 family members lies in the connection of 
upstream sensors and downstream effectors. Thus, their effect is stimulus- and cell type-
dependent, as well as variable due to different (downstream) interaction partners. In most cases, 
in response to stress, the GADD45 proteins stimulate the p38/JNK MAPK signalling pathway, 
thus increasing the sensitivity of cells to growth arrest, apoptosis or survival 
[165,169,190,197,198] (Fig. 11). For example, GADD45 proteins bind to an N-terminal domain of 
MEKK4 (MTK1) (amino acids 147 – 250) thereby inducing a conformational change of MEKK4 
which leads to a dimerization, auto-phosphorylation and activation of MEKK4 [165], which results 
in JNK and p38 activation. GADD45β is also an interaction partner of MKK4 [155] and MKK7 
[199] (Fig. 10), thereby functioning as an inhibitor of both proteins and preventing hereby the 
activation of JNK, as well as of apoptosis signal-regulating kinase 1 (ASK1) [199] which also 
activates JNK and p38 [200] (Fig. 8).  
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Figure 10: The GADD45β peptide and its functional domains. GADD45β, as all GADD45 family 
members, is described to bind several upstream sensors, such as the constitutive androstane receptor 
(CAR), as well as downstream effectors, such as MAP kinase kinase 7 (MKK7), cyclin-dependent kinase 
inhibitor 1 (p21) and proliferating cell nuclear antigen (PCNA). Furthermore, it is reported that GADD45 
proteins can form dimers and have hence a dimerization domain. Moreover, the GADD45β peptide shows a 
LXXL motif (a sequence of 5 amino acids where L = leucine and X = any amino acid) and a RNA binding 
domain. 
 
Importantly, GADD45 proteins and stress kinases seem to form a feedback loop with GADD45 
proteins not only modulating the activity of stress kinases, but also being under the control of p38 
and JNK kinases [201]. In addition to their described role in MAPK stress signalling, GADD45 
family members are also important regulators in several other pathways. For example, GADD45β 
mediates TGF-β-induced cell death [169,170], but CAR-induced cell survival [202-204] (Fig. 11). It 
is noteworthy, that GADD45β confers a transcriptional function upon CAR-stimulation and –
binding, hence also having a role as transcriptional coactivator beside its impact on protein 
activity (Fig. 10). In accordance to this finding, GADD45 also possesses a domain homologues to 
several other RNA binding proteins and a so-called LXXL motif (a contiguous sequence of 5 
amino acids where L = leucine and X = any amino acid) characteristic for transcriptional co-
regulators [205]. 
           
Figure 11: GADD45β in stress signalling. GADD45β has pro- and anti-apoptotic functions, dependent on 
the stimulus and interaction partners. It can prevent tumour necrosis factor α (TNF-α)-induced apoptosis by 
inhibiting MKK7JNK (A). Alternatively, it mediates transforming growth factor β (TGF-β)-induced apoptosis 
(B), or constitutive androstane receptor (CAR)-stimulated cell survival (C). GADD45β, growth arrest and 
DNA damage-inducible 45 β; p38, p38 mitogen-activated protein kinases; JNK2, c-Jun N-terminal kinase 2; 
MKK7, MAP kinase kinase 7; NF-ᴋB, nuclear factor ᴋB; STAT3, signal transducer and activator of 
transcription 3; Smad3/4, Mothers against decapentaplegic homolog 3/4. 
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1.4.4 GADD45 proteins in aging and age-related diseases 
The basic processes described so far, where GADD45 proteins are implicated in (DNA repair, 
cellular survival, senescence and apoptosis), are linked to aging and age-related diseases. In 
general, the ability to cope with stress situation is important for animal survival and longevity 
[206], and the overexpression of stress-related proteins (such as sirtuins, heat shock proteins, 
superoxide dismutase, or catalase) in certain tissues leads to longer life span of model organisms 
[207]. As such, the stress-associated GADD45 proteins are also involved in aging, longevity and 
age-related diseases [208]. An orthologue of GADD45α in Drosophila, D-GADD45, has been 
described to be a longevity regulator [209] by conferring stress-resistance [210] and delaying 
neurodegeneration [211] without compromising life quality factors such as physical activity and 
female fertility. 
Aging is a major risk factor for cancer. The anti-tumour activity of GADD45 proteins was shown 
both in vitro and in vivo studies. Whereas ectopic expression of GADD45 members induced 
apoptosis in several tumour cell lines [148,157,198,212-215], deletion of GADD45 members 
resulted in genomic instability [216], increased sensitivity to carcinogenesis [217], and lower 
immune response against implanted tumour cells [191,218]. Furthermore, GADD45 genes are 
deleted or silenced in several tumour identities by hypermethylation [215,219]. Such epigenetic 
changes typically occur with advanced age [220]. In contrast to this anti-cancer role (e.g. in Ras-
driven breast cancer) are reports that GADD45 proteins promote cancer growth (e.g. Myc-driven 
breast cancer). This opposing function may depend on the type of oncogenic stimuli [221]. 
GADD45 proteins are also involved in other age-related diseases. For example, GADD45α is 
highly expressed in neurons of Alzheimer’s disease patients where it is thought to protect the 
neurons from apoptosis induced by extracellular accumulation of β-amyloid [222,223]. GADD45α 
is also upregulated in an in vitro model for dopamine-induced neurotoxicity which is related to the 
pathogenesis of Parkinson’s disease [224]. Thus, increased expression of GADD45α in age-
related neurodegeneration might be a protective mechanism against neuro-toxic stress. The 
same could also be the case for atherosclerosis [225].  
1.4.5 GADD45 proteins in metabolism 
Taken together, GADD45 proteins are characterised by a plenitude of actions. A decreased 
induction of GADD45 members may have large-scale consequences, such as accumulation of 
DNA damage, genomic instability, and disrupted cellular homeostasis, which are hallmarks of 
aging and aging-related disorders such as tumorigenesis, reduced responsiveness to stress, and 
immunological and metabolic disorders [208]. In contrast, even though they are interesting 
candidate genes, there are only few studies describing a role for GADD45 members in metabolic 
function. Specifically, GADD45β has been described to be involved in hyperplasia of hepatocytes 
[203,204] and to promote survival in liver regeneration [226] which is known to have a metabolic 
requirement [227]. Moreover, GADD45β plays a role in the phosphorylation of the autophagy 
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regulator autophagy protein 5 (ATG5) through MEKKp38α and thereby inhibiting starvation-
induced autophagosome-lysosome fusion and, thus, autophagy [228,229]. Also, GADD45γ has 
been reported to have regulatory functions in metabolism, being induced by cold and playing a 
role in adaptive thermogenesis by activating uncoupling protein a (UCP1) via p38oestrogen-
related receptors γ (ERRγ) [230]. Furthermore, GADD45α was implicated in promoting muscle 
atrophy upon fasting, muscle immobilization, and muscle denervation by causing reprogramming 
of muscle gene expression. It was shown to be a downstream effector of activating transcription 
factor 4 (ATF4) during fasting-induced muscle atrophy [231], but is induced by histone 
deacetylase 4 (HDAC4) in denervated muscle where ATF4 is not involved [232]. 
It is also suggested that GADD45 proteins have anti-diabetic potential. GADD45α is potently 
induced by the peroxisome proliferator-activated receptor γ (PPARγ) agonist and anti-diabetic 
drug Troglitazone [233,234], and GADD45β expression is increased by insulin by activating the 
mammalian target of rapamycin (mTOR) pathway [235]. It is speculated that the underlying 
mechanism might involve the GADD45β-mediated inhibition of the TNFα-induced JNK pathway 
which is implicated in the development of insulin resistance [236,237]. 
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2. Aim of the study 
The aim of my PhD studies was to identify novel regulatory functions of GADD45 proteins for 
systemic metabolism, with special emphasis on GADD45β. Therefore, hepatic GADD45β was 
characterised in various mouse models of metabolic diseases as well as under the stress of 
nutrient depletion. GADD45β knock down and overexpression tools were generated in order to 
investigate its potential relevance in in vivo loss- and gain-of-function experiments. My final goal 
was to define a novel control level of hepatic energy homeostasis and to describe a novel role for 
GADD45β in the transition of pre-diabetic obesity to malign obesity and type 2 diabetes. 
            
Figure 12: Aim of the study. GADD45 proteins are known to be involved in many biological contexts, for 
example DNA damage repair, haematopoiesis and immunity, aging and longevity, thermogenesis, 
autophagy, epigenetics, differentiation and sex determination, as well as in cell survival and cell death. But 
which role they play in systemic and hepatic metabolism upon nutrient deprivation or overload is not known. 
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3. RESULTS 
3.1 Gadd45g is a candidate inflexible gene in metabolic disorder 
3.1.1 Discovery of Gadd45g by transcriptome analysis in db/db mice 
It is commonly accepted that the liver is a pivotal organ contributing to metabolic control. It is the 
primary site of glucose production and can provide alternate substrates such as ketone bodies 
under fasting conditions. Previous studies in our laboratory (Herzig Lab) have demonstrated that 
hepatic gluconeogenic, fatty acid and bile acid metabolism are controlled on a hormonal and 
nutritional level via transcriptional complexes [238-242]. To extend our knowledge of such 
processes we need to further characterise novel pathways involved in the control of liver 
metabolic function and dysfunction. One strategy to uncover novel molecular mechanisms 
contributing to metabolic flexibility in the fasted to fed transition could be to dissect the liver 
transcriptome to uncover select genes which display certain ‘inflexibility’ in conditions of metabolic 
dysfunction. Therefore, diabetic db/db mice and corresponding wild type healthy mice were either 
fasted for 48 hours or fasted for 48 hours and refed for 24 hours. RNA was extracted and pooled 
and analysed by gene chip and principle component analyses to determine differentially regulated 
mRNA transcripts between the conditions. The Principle Component Analysis (PCA) a statistical 
procedure where a set of observations of possibly correlated variables are converted into a set of 
values of linearly uncorrelated variables called principal components. PCA is used to structure, 
facilitate and illustrate extensive data sets. In this coordinate system the greatest variance comes 
to lie on the first coordinate (called the first principal component), the second greatest variance on 
the second coordinate, and so on. In our case the “WT refed” and “WT fasted” conditions are 
separated along the X axis, whereas “db/db refed” and “WT refed” conditions are separated along 
the Y axis. This means more genes were differentially regulated due to the nutritional state 
relative to the genotype condition as compared to “WT refed”. The “db/db fasted” condition was 
separated along both components. This work was done by a former PhD student of the lab, 
Prachiti Narvekar, and remains unpublished. Further details can be found in her PhD thesis which 
is available in our institute. Several candidates were found (Fig. 13A) one of which was a member 
of the GADD45 gene family, Gadd45g (Fig.13B). In particular, there was a strong upregulation of 
liver Gadd45g expression upon starvation which was absent in livers of db/db mice.  
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Figure 13: Transcriptome profiling of 48h fasted and 24h refed wild-type and db/db mice. (A) PCA with 
four clusters representing the four conditions (“WT refed”, “WT fasted”, “db refed” and “db fasted”). “WT 
refed” and “WT fasted” conditions are separated along the X axis, whereas “db/db refed” and “WT refed” 
conditions are separated along the Y axis. (B) Bar graph of relative mRNA levels of one of the differentially 
expressed genes, Gadd45g. Black bars represent the refed and grey bars represent the fasted animals used 
as in (A). n=4-6 per group. Adapted from Dr. Prachiti Narvekar, PhD Thesis, Herzig Lab. 
 
These data were further validated by real-time quantitative PCR (Fig. 14). 
 
 
 
Figure 14: Validation of the microarray result from figure 
13. Gadd45g expression in db/db and healthy control (WT) 
mice which were sacrificed after being fasted for 48h hours 
(fasted) or refed for 24h (refed) before sacrifice. Liver mRNA 
was analysed by RT-qPCR. Values are fold induction relative 
to “WT refed”. n=4-6 per group. Adapted from Dr. Prachiti 
Narvekar, PhD Thesis, Herzig Lab. 
 
 
3.2 GADD45β is induced upon nutrient depletion and dysregulated in 
disease and ageing 
GADD45 family members are known to be rapidly induced by a wide variety of genotoxic stress 
stimuli such as methyl methanesulfonate (MMS), sorbitol and ultra violet (UV) light [159,243]. 
Each protein has a different pattern of cell-specific and stimulus-induced expression, presumably 
reflecting different signaling pathways. In most publications this induction is described in the 
context of DNA repair, cell cycle regulation and apoptosis [159,244] and little is known about their 
role in metabolic stress situations. Consequently, it was of interest to follow up on the results from 
the transcriptome analysis (see figure 13) and to examine all three members of the GADD45 
family in the livers of mice with metabolic disorders. 
3.2.1 Hepatic Gadd45b expression pattern is constant between various mouse 
models of obesity and diabetes 
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Gadd45a, Gadd45b and Gadd45g expression levels were measured in livers of db/db, ob/ob and 
NZO mice to compare with levels observed in wild type counterparts. In all three studies, healthy 
and diabetic mice were sacrificed either in the 24 hour fasted or ad libitum (fed) state (Figure 15). 
We could confirm the upregulation of liver Gadd45g expression upon starvation, an effect absent 
in livers of db/db mice (Fig. 15A, panel 3). However this induction pattern could not be observed 
in the other two mouse models (Fig.15B and C, panel 3). Gadd45a expression was only mildly 
affected by fasting in all three models (Fig. 15A, B and C, panel 1). In contrast, the third member 
of the GADD45 family, Gadd45b, was potently affected in wild type mice upon nutrient depletion 
(Fig. 15A, panel 2). There was a strong induction of liver Gadd45b after food withdrawal which 
was markedly less pronounced in db/db mice. Importantly, this induction pattern was consistent 
between the models and could also be seen in ob/ob versus wild type and NZO versus NZB mice 
(Fig. 15 and C, panel 2). 
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Figure 15: Liver Gadd45a, Gadd45b and Gadd45g mRNA expression in different mouse models of 
obesity. Male wild-type (WT) and db/db (A) or ob/ob (B), as well as  New Zealand Black (NZB) and New 
Zealand Obese (NZO) (C) mice were fed ad libitum (fed) or fasted for 24h (fasted) where indicated and 
mRNA levels were analysed by RT-qPCR. Values are fold induction relative to “WT/NZB fed”. Mean ± SEM; 
n=4 per group; * genotype effect, # effect of fast time; (*) p ≤ 0.05, (**) p ≤ 0.01, (***) p ≤ 0.001. 
 
3.2.2 The induction of GADD45β also occurs at the protein level 
To investigate whether the fasting-induced upregulation of Gadd45b is restricted to mRNA levels, 
proteins from liver samples of db/db and wild type mice were extracted and analysed by 
immunoblotting. As seen in figure 16, GADD45β protein levels are potently increased upon food 
deprivation in wild type but not in diabetic animals. 
 
 
 
 
 
 
 
 
Figure 16: Protein expression of liver GADD45β. Protein 
lysates were obtained from male obese/type 2 diabetic (db/db) 
and corresponding wild type (WT) healthy mice being either 
fasted for 24h (fasted) or fed ad libitum (fed). Antibodies 
against GADD45β and the loading control (VCP) were used. 
Mean ± SEM; n=4 per group. 
 
3.2.3 The fasting-induced upregulation of Gadd45b is reversible after re-feeding 
It is reported that Gadd45 expression is increased within minutes upon certain stimuli [245] and 
that Gadd45b induction is regulated by distinct mechanisms in a stress-specific manner (either at 
the level of mRNA transcription or mRNA stability) [243]. We were now interested to determine 
how long Gadd45b expression is augmented and whether it is reversible after refeeding. 
Therefore C57Bl6/J mice were fasted for different durations or refed for fixed amounts of time 
before sacrifice. We could show that the hepatic Gadd45b expression followed a time course, 
having the highest peak after 48 hour starvation, diminishing after the return of food and reducing 
beyond basal levels after 24 hours of refeeding (Fig. 17).  
    
 
 
Figure 17: Liver Gadd45b mRNA expression during 
different times of fasting and refeeding. Male C57Bl6/J 
mice were fasted for various durations with subsequent 
various durations of refeeding as indicated. mRNA levels 
were analysed by RT-qPCR. Values are fold induction 
relative to the 24h refed group. Mean ± SEM; n=4 per group; 
(*) p ≤ 0.05, (**) p ≤ 0.01, (***) p ≤ 0.001. 
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3.2.4 The fasting-induced upregulation of Gadd45b is liver-specific 
Since the fasting-induced upregulation of Gadd45b was first discovered in the liver of healthy wild 
type animals compared to diabetic mice, we next examined the expression levels in other tissues 
of this study. A comparison of the Gadd45b expression levels in other metabolic organs such as 
brown adipose tissue (BAT), abdominal white adipose tissue (aWAT), the gastrocnemius muscle 
(GC) and the liver showed that the effect of nutrient starvation on Gadd45b expression was most 
pronounced in the liver, wherein the largest difference between wt and db/db mice in the fasted 
state was observed (Fig. 18). 
 
Figure 18: Gadd45b expression in different mouse organs. Male wild-type (WT) and db/db mice were fed 
ad libitum (fed) or fasted for 24h (fasted) where indicated and Gadd45b mRNA levels were subsequently 
analysed by RT-qPCR in liver (A), abdominal white tissue (aWAT; B), brown adipose tissue (BAT; C) and 
gastrocnemius muscle (GC, D). Values are fold induction relative to “WT fed”. Mean ± SEM; n=4 per group; * 
genotype effect, # effect of fast time; (*) p ≤ 0.05, (**) p ≤ 0.01, (***) p ≤ 0.001. 
 
3.2.5 Analysis of other GADD45 family members in different tissues of db/db mice 
Since also Gadd45g showed a mild induction upon fasting in liver of healthy mice which was 
absent in livers of db/db mice (Fig. 15A, panel 3), we next compared the expression levels of both 
Gadd45a and Gadd45g in aWAT, BAT and GCM in the same study (Fig. 19). Similar to Gadd45b, 
neither Gadd45a nor Gadd45g showed an augmentation in their mRNA levels in aWAT or BAT. 
The expression levels in general were very low for both genes in all tissues. Only Gadd45a was 
differently expressed in GCM of db/db mice in the fasted state compared to wild type mice (Fig. 
19C, panel 1). This is in accordance to recent reports showing that Gadd45a is induced upon 
fasting in skeletal muscle and required for muscle atrophy [231], a condition also found in db/db 
mice [246].  
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Figure 19: Gadd45a, Gadd45b and Gadd45g mRNA expression in different mouse organs. Male wild-
type (WT) and db/db mice were fed ad libitum (fed) or fasted for 24h (fasted) where indicated and mRNA 
levels were analysed by RT-qPCR in abdominal white tissue (aWAT; A), brown adipose tissue (BAT; B) and 
gastrocnemius muscle (GC, C). Values are fold induction relative to “WT fed”. Mean ± SEM; n=4 per group; * 
genotype effect, # effect of fast time; (*) p ≤ 0.05, (**) p ≤ 0.01, (***) p ≤ 0.001. 
 
3.2.6 The fasting-induced upregulation of hepatic Gadd45b occurs in hepatocytes 
Since the fasting-induced increase of Gadd45b in the liver was very potent (~ 12x), we 
hypothesised that this induction is intrinsic to hepatocytes since they represent the majority of 
cells in the liver [78] and are known to be affected by nutritional status [247]. To test whether the 
induction of Gadd45b is hepatocyte-specific, C57Bl6/J mice were sacrificed ad libitum or after 
being fasted for 24 hours. The liver was collagenase-perfused and liver cell populations were 
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isolated by differential centrifugation into hepatocyte and non-parenchymal fractions (NP). The 
mRNA expression of Gadd45b, as well as cell-type specific markers including Hnf4a 
(hepatocytes), Cd31 (endothelial cells), Des (Stellate cells) and Emr1 (Kupffer cells) from the 
fractions were subsequently quantified. As shown in figure 20, the expression level of Cd31 (Fig. 
20A), Des (Fig. 20B), and Emr1 (Fig. 20C) were exclusively present in the NP fraction, which 
shows that there are no NP cells in the hepatocyte fraction and the separation was successful. 
The expression level of Hnf4a (Fig. 20D, was significantly lower in the NP fraction, even though 
not to the same extent as for Cd31, Desmin and Emr1. This indicates that the separation of 
hepatocytes from the NP fraction was incomplete. Nevertheless, there was a significant fasting-
induced increase of Gadd45b expression in the hepatocyte fraction (Fig. 20E). The large 
variability might be due to a suboptimal experimental setup and isolation protocol. 
              
Figure 20: Gene expression analysis in hepatocytes and non-parenchymal cells. Male C57Bl6/J mice 
were fed ad libitum (fed) or fasted for 24h (fasted) after which the liver was collagenase-perfused and liver 
cell populations were isolated by differential centrifugation into hepatocyte (Hepas) and non-parenchymal 
(NP) fractions. The mRNA levels of cell-type specific markers including Cd31 (endothelial cells; A), Des 
(Stellate cells; B), Emr1 (Kupffer cells; C), and Hnf4a (hepatocytes; D), as well as from Gadd45b (E) from the 
fractions, were subsequently analysed by RT-qPCR. Values are fold induction relative to “NP fed” (A-C) or 
“Hepas fed” (D-E). Mean ± SEM; n=3 per group; * cell type effect, # effect of fasting; (*) p ≤ 0.05, (**) p ≤ 
0.01, (***) p ≤ 0.001. 
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3.2.7 Gadd45b is also induced upon nutrient depletion in vitro 
To investigate which nutrient, when deprived, is responsible for the elevation of Gadd45b, a 
differentiated, nontransformed hepatocyte cell line (AML12) was used [248]. For this purpose, 
cells were incubated with a series of specified cell culture media where certain nutrients were 
missing. In a first experiment the self-made medium (called “PBS full”) was compared to the 
regular growth-medium DMEM/F-12 to exclude the possibility of an induction of Gadd45b (Fig. 
21A left and right panel). Afterwards the self-made medium was composed of two media, the 
“base medium” and the “supplement medium” which were mixed to different degrees in order to 
reduce the nutrients. The “base medium” contained all the components crucial for cell survival 
and was always used at a fixed concentration. The “supplement medium” contained all the 
nutrients in question and its concentration varied between conditions (Fig. 21B). In a third 
experimental setup, specific nutrients were removed from the “supplement medium” while all the 
other components were kept at standard concentrations. This specific nutrient was added back to 
the medium as 1% of its usual concentration (Fig. 21C). In a last experiment, nutrients were 
removed in groups of two from the “supplement medium” and added subsequently to the cells 
(Fig. 21D). The compositions of all media are listed in the methods section 5.2.9.  
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Figure 21: Gadd45b expression in AML12 cells under different nutritional conditions. (A) AML12 cells 
were cultivated in standard DMEM/F-12 or self-made “PBS full” for either 6h or 24h before harvest. The left 
panel shows values as fold induction relative to DMEM/F-12, the right panel shows values as fold induction 
relative to 6h treatment. * effect of medium, # effect of time. (B) AML12 cells were cultivated for 24h either in 
“PBS full” or a medium consisting of “supplement medium” at 100%, 50%, 10%, 5% or 1% of “base medium”. 
Values are fold induction relative to “PBS full”. * relative to “PBS full”, # relative to “100%”. (C) AML12 cells 
were cultivated for 24h either in a medium consisting of “supplement medium” and “base medium” in a 1:1 
ration (“100% full”), in a medium consisting of “supplement medium” and “base medium” in a 1:0,01 ration 
(“1% full”), or in full medium with either 1% pyruvate (Pyr), glutamine (Gln), glucose (Glc), purine/pyrimidine 
(Purine), essential amino acids (EAA), non-essential amino acids (NEAA), or lipids. Values are fold induction 
relative to “100% full”. * relative to “100% full”. (D) Same as in (C) but two components reduced to 1%. 
AML12 mRNA was always analysed by RT-qPCR. Mean ± SEM; n= 3 per group; (*) p ≤ 0.05, (**) p ≤ 0.01, 
(***) p ≤ 0.001. 
 
As shown in Fig. 21A, there was no induction of Gadd45b in the self-made medium “PBS full”. 
The mRNA levels were rather reduced after 6 hours and after 24 hours of incubation (left panel). 
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Gadd45b levels were slightly but significantly increased after 24 hours incubation in both media 
compared to 6 hours incubation (right panel). Therefore, cells were harvested after 24 hours 
incubation in the following experiments. The mixture of “base medium” with “supplement medium” 
led to a slight induction of Gadd45b when mixed 1:2, 1:10 or 1:20 (Fig. 21B). However, a 
reduction of all variable nutrients to 1% of the original concentration led to a strong increase of 
Gadd45b levels. Reducing one (Fig. 21C) or pairwise combinations of nutrients (Fig 21D) did not 
lead to an increase in Gadd45b levels. Only the restriction of all components caused the induction 
as seen before These results lead us to believe that the combined restriction of all nutrients 
during starvation is responsible for and induction of Gadd45b and not a single candidate or a 
specific type of nutrient. 
3.2.8 Gadd45b is mildly upregulated by AMPK pathway in primary hepatocytes 
Next, we were interested to test if a non-nutrient component is responsible for the induction of 
hepatic Gadd45b. It is known that Gadd45b expression is induced by certain cytokines such as 
TNF-α [156]. It is also postulated that Gadd45b expression might be induced by insulin [235]. 
Therefore we isolated primary hepatocytes from C57Bl6/J and treated them with different 
compounds such as TNF-α or insulin for 8 or 24 hours at different concentrations (Fig. 22). 
Furthermore, we included AICAR (an analogue of AMP that is capable of stimulating AMP-
dependent protein kinase (AMPK) activity), forskolin (activates the enzyme adenylyl cyclase and 
increases intracellular levels of cAMP resulting in activation of cAMP-sensitive pathways such as 
protein kinase A (PKA)), IFNγ and a medium without FCS. As shown in figure 22 only the 
incubation with 200 µM of AICAR led to a mild increase in Gadd45b expression levels, whereas 
10 µM of Forskolin and 25 ng/ml IFNγ led to a decrease in mRNA expression levels. This is in 
accordance with AMPK being activated during nutrient deprivation leading to induction of energy-
producing, catabolic pathways [249]. 
Figure 22: Gadd45b 
expression in primary 
hepatocytes treated 
with different cell 
stimuli. Male C57Bl6/J 
mice were sacrificed ad 
libitum. The liver was 
collagenase-perfused 
and primary 
hepatocytes were 
isolated before being 
treated for 8h or 24h 
with different cell stimuli 
as indicated. mRNA 
levels were analysed by 
RT-qPCR. Values are 
fold induction relative to 
“10% serum”. Mean ± 
SEM; n=4 per group; * 
relative to “10% serum” 
at respective time point; 
(*) p ≤ 0.05, (**) p ≤ 0.01 
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3.2.9 Gadd45b is  not affected in a mouse model of type 1 diabetes 
To investigate if the observed absence of fasting-induced elevation in hepatic Gadd45b levels in 
db/db mice is a secondary effect of a disturbed β-cell function, we measured liver mRNA levels in 
healthy C57Bl6/J mice and in mice rendered insulin deficient and diabetic by treatment with the β-
cell toxin streptozotocin [250,251]. As shown in figure 23 Gadd45b was not induced in livers of 
mice suffering from experimental insulin-deficient diabetes. 
  
Figure 23: Liver Gadd45b expression of mice with type 1 diabetes 
or healthy mice. Male C57Bl6/J mice were injected with either 60 
mg/kg STZ intraperitoneally on 6 subsequent days (STZ) or with 
vehicle (sodium citrate, control). Mice were sacrificed 6 months after 
treatment was started. Liver Gadd45b mRNA levels were 
subsequently analysed by RT-qPCR. Values are fold induction relative 
to “control”. Mean ± SEM; n=10-13 per group. 
 
3.2.10 The fasting-induced upregulation of Gadd45b is blunted in aged mice 
Aging is characterized by an overall impairment of cellular function. Aged mice have altered 
glucose and fatty acid metabolism and whole body homeostasis compared to young mice 
resulting in common metabolic, inflammatory, cardiovascular and neurodegenerative diseases 
[252]. In the course of her own PhD studies, Dr. Katharina Niopek (Herzig Lab) performed a 
transcriptome analysis with liver samples from 22 month old and 12 week old mice, both groups 
either fasted for 16 hours or refed for 6 hours before sacrifice. One differentially expressed gene 
in those four groups was Gadd45b. Subsequently, we performed RT-qPCR analysis on those liver 
samples. We could confirm that Gadd45b expression was potently induced upon fasting young 
mice (Fig 24B). This induction was absent in fasted aged animals, resembling the mRNA 
expression pattern in db/db versus wild type mice (Fig. 15). Gadd45g showed a similar mRNA 
expression profile (Fig 24C). 
               
Figure 24: Liver Gadd45a, b and g expression in old and young mice. Male C57Bl6/J mice at the age of 
22 months (old) or 12 weeks (young) were sacrificed after being fasted for 16h hours (fasted) or refed for 6h 
(refed) before sacrifice. Liver mRNA levels were analysed by RT-qPCR. Values are fold induction relative to 
“young refed”. Mean ± SEM; n=5 per group; * age effect, # effect of fast time; (*) p ≤ 0.05, (**) p ≤ 0.01, (***) 
p ≤ 0.001. 
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3.2.11 Liver GADD45B is also dysregulated in men with type 2 diabetes 
Even though animal models are broadly used for the study of human biology and diseases, one 
might still question whether this is an accurate approach considering some stark differences 
between the two species resulting from adaptation to their respective environments during 
evolution [253]. Hence, for true translational validity, observations made in animals have to be 
confirmed in humans. We examined the liver GADD45B mRNA levels of lean and obese patients 
with or without type 2 diabetes. As shown in figure 25 liver GADD45B expression (as ratio 
GADD45B/HPRT1) was lower in fasted diabetic men (T2D) than in men with normal glucose 
tolerance (NGT) independent of the degree of obesity (lean, subcutaneous fat (SC), visceral fat 
(VIS)). Due to the scatter in the NGT groups, only the difference between the SC groups was 
significant, but there was also a significant main effect of T2D between the three NGT and the 
three T2D groups (not shown).                                                  
 
 
Figure 25: Liver GADD45B expression of lean and obese 
patients with type 2 diabetes or healthy men. Liver tissue 
samples were obtained by open liver biopsy from men with 
type 2 diabetes (T2D) or normal glucose tolerance (NGT). 
The patients were divided according to their body 
composition into lean men or men with subcutaneous (SC) or 
visceral (VIS) fat. Liver GADD45B mRNA levels were 
subsequently analysed by RT-qPCR and normalized to 
Hypoxanthine-Phosphoribosyl-Transferase 1 (HPRT1). Mean 
± SEM; n=14-23 per group; * diabetes effect; (***) p ≤ 0.001. 
 
3.3 GADD45β plays a role in adaptive metabolism during the stress of 
nutrient deprivation 
To gain insights into the potential importance of GADD45β for healthy and pathophysiologic liver 
function, we examined mice with whole body deletion of GADD45β. In particular, because we 
observed stark regulation of GADD45β by fasting, we wanted to examine a possible functional 
role for GADD45β in adaptive metabolism of nutrient depletion. 
Under fasting conditions, there is a complex interplay between the tissues in order to supply the 
energy needs of the body. Falling blood sugar levels lead to an inhibition of insulin secretion by 
the β-cells of the pancreas and an increased production of glucagon by the α-cells of the 
pancreas. Together with glucocorticoids from the adrenal cortex of the adrenal gland, glucagon 
stimulates several processes that collectively serve to increase and maintain normal 
concentrations of glucose in the blood. They signal to a variety of tissues. In the liver they lead to 
glycogen breakdown (glycogenolysis) and glucose production (gluconeogenesis) followed by 
glucose release from the liver. Furthermore they inhibit glucose uptake by muscle and adipose 
tissue, mobilize amino acids from extrahepatic tissues as substrates for gluconeogenesis, and 
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stimulate fat breakdown (lipolysis) in adipose tissue. FA are released from adipose tissue and 
taken up by the liver to be oxidized via β-oxidation to provide energy. In prolonged fasting, free 
fatty acids are broken down for the generation of ketone bodies. After feeding, the rise in blood 
glucose level is reduced by insulin which promotes glucose uptake by various tissues. Moreover, 
insulin stimulates the liver for glycogenesis to restore glycogen depots as well as de novo 
lipogenesis. Overnutrition results in perturbation of these reciprocal control mechanisms with 
failure to suppress hepatic glucose production as well as impaired transition from FA efflux to 
storage in response to a meal. 
3.3.1 Whole body GADD45β KO affects systemic and liver lipid metabolism upon 
fasting 
For a first assessment of a possible functional role of GADD45β in adaptive metabolism, 
GADD45β KO and WT littermates were starved for 24 hours before sacrifice. A blood sample was 
taken before food withdrawal. As expected, food withdrawal led to a significant (14%) reduction in 
body weight after 24 hours with no difference between genotypes (Fig. 26A). At the time of 
sacrifice, the weights of liver, aWAT and GCM were noted and normalized to the body weight. 
There was no difference between GADD45β KO and WT with regards to any of the tissue masses 
(Fig. 26B). 
                                     
 
Figure 26: Body and tissue 
weights in GADD45β KO and WT 
mice. (A) Body weight of male 
GADD45β KO and WT littermates 
was measured before (0h) or after 
(24h) food withdrawal. (B) Tissue 
weights were measured after 24h 
fasting during preparation of the 
same mice as in (A) and normalized 
to body weight. Mean ± SEM; n=5-8 
per group; * genotype effect, # effect 
of fast time; (*) p ≤ 0.05, (**) p ≤ 
0.01, (***) p ≤ 0.001. 
 
After processing the blood, the serum was analysed for its concentrations in NEFA, TG, glycerol, 
cholesterol, ketone bodies, alanine and branched-chain amino acids (BCAA). Surprisingly, we 
could observe a difference in the serum NEFA concentration between GADD45β KO and WT 
mice. As expected, in both groups fasting led to an increase in serum NEFA, but the increase in 
GADD45β KO mice was significantly lower (15%) compared with GADD45β WT animals (Fig. 
27A). Also serum TG, glycerol and ketone body concentrations were elevated by fasting but with 
no difference between genotypes (Fig.27B, C and E). Due to the limited amount of serum from 
fed animals, cholesterol, alanine and BCAA levels could only be measured in the serum of fasted 
mice (Fig. 27D). There was no difference between GADD45β KO and WT mice in their cholesterol 
concentration. Interestingly, GADD45β KO mice had a 50% reduction in both amino acids. As 
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expected, blood glucose concentrations were reduced upon fasting, with no difference between 
genotypes (Fig. 27F). 
                  
Figure 27: Serum metabolites in GADD45β KO and WT mice. Serum non-esterified fatty acids (NEFA, A), 
triglycerides (TG, B), glycerol (C), ketone bodies (KB, E) and blood glucose (F) of male GADD45β KO and 
WT littermates was measured before (0h) or after (24h) food withdrawal. Serum alanine, branched-chain 
amino acids (BCAA) and cholesterol from the same animals were measured only after 24h fasting (D). Mean 
± SEM; n=5-8 per group; * genotype effect, # effect of fast time; (*) p ≤ 0.05, (**) p ≤ 0.01, (***) p ≤ 0.001. 
 
With the hint that systemic metabolism might be affected by a deletion of GADD45β we next 
examined the livers of the GADD45β KO and WT mice. Even though there was no difference in 
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liver weight upon fasting (Fig. 26B), we could see a difference in the TG content of the liver (Fig. 
28A) with GADD45β KO mice having a 250% higher concentration than WT mice. Liver 
concentration of NEFA, cholesterol and glycogen were not significantly different. Interestingly, the 
reduced concentration of serum alanine and BCAA in GADD45β KO mice (Fig. 27D) was 
accompanied by a significant increase in liver protein concentration compared to WT mice (Fig. 
28B). Therefore, GADD45β seems to play a role in adaptive metabolism during the stress of 
nutrient deprivation, especially affecting lipid and amino acid homeostasis. 
Figure 28: Liver 
metabolites in 
GADD45β KO and WT 
mice. Liver non-esterified 
fatty acids (NEFA), 
cholesterol, triglycerides 
(TG) and glycogen (A) as 
well as liver protein 
concentration (B) of male 
GADD45β KO and WT 
littermates was measured 
after 24h fasting. Mean ± 
SEM; n=5-8 per group; * 
genotype effect; (*) p ≤ 
0.05, (**) p ≤ 0.01, (***) p 
≤ 0.001. 
 
3.3.2 Whole body GADD45β KO affects fasting hepatic amino acid and acyl carnitine 
metabolism only mildly 
During fasting, all cells in the body begin to break down protein resulting in a release of amino 
acids into the bloodstream, which can subsequently be converted into glucose by the liver and 
serve for energy production. The main amino acid substrate for gluconeogenesis in the liver is 
alanine [254] and glutamine for the gastrointestinal tract and the kidneys. The branched-chain 
amino acid carbon skeleton is oxidised in the muscle to generate energy [255] while the nitrogen 
moiety is transaminated to pyruvate, forming alanine, which is released into the blood. Since most 
of our muscle mass is protein, this phenomenon is responsible for the wasting away of muscle 
mass during starvation.  
We have observed a difference in the serum concentrations of NEFA, alanine and BCAA between 
GADD45β KO and WT mice with GADD45β KO mice having less NEFA and less of both amino 
acids. Also, GADD45β KO mice accumulate proteins together with TG in the liver upon starvation. 
We were hence interested if a deletion of GADD45β also affects the metabolism of other amino 
acids or acyl carnitines. Carnitines and their acyl esters (acylcarnitines) are essential compounds 
for the metabolism of fatty acids by assisting in the transport and metabolism of fatty acids into 
mitochondria. In addition, carnitine is required to remove any surplus of acyl groups from 
mitochondria and to export acetyl and other short chain acyl groups from peroxisomes. These 
activities influence in turn many aspects of carbohydrate and lipid metabolism, including the 
regulation of insulin secretion by pancreatic β-cells [256]. Amino acid and acylcartinine profiling 
was performed on liver samples from GADD45β KO and WT mice via electrospray-ionisation 
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mass spectrometry and the results normalised to the total amino acids or acylcarnitine 
concentration, respectively. As shown in figure 29, there was no difference between GADD45β 
KO and WT in any amino acid, expect for ornithine. Also, liver alanine and BCAA did not seem to 
be affected by whole body depletion of GADD45β. 
 
Figure 29: Liver amino acids in GADD45β KO and WT mice. Liver amino acids of male GADD45β KO 
and WT littermates were measured after 24h fasting and normalized to the total amino acid concentration 
(B). A list with full names can be found in suppl. table 6. Mean ± SEM; n=5-8 per group; * genotype effect; (*) 
p ≤ 0.05, (**) p ≤ 0.01, (***) p ≤ 0.001. 
 
Also for acylcarnitines, there was no striking effect of GADD45β KO (Fig. 30). Only the medium 
chain acylcarnitines C6 (hexanoylcarnitine) and C10 (decanoylcarnitine) as well as 
glutarylcarnitine (Glut) were reduced in livers of GADD45β KO mice. Total acylcarnitines, carnitine 
(C0) as well as acetyl carnitine (C2) were not changed either (Fig. 30B). 
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Figure 30: Liver acylcarnitines in GADD45β KO and WT mice. Liver acylcarnitines of male GADD45β KO 
and WT littermates were measured after 24h fasting and normalized to the total acylcarnitine concentration. 
Also free carnitine (C0) and acetylcarnitine (C2) were measured (B). A list with full names can be found in 
suppl. table 5. Mean ± SEM; n=5-8 per group; * genotype effect; (*) p ≤ 0.05, (**) p ≤ 0.01, (***) p ≤ 0.001. 
 
3.3.3 The loss of GADD45β is not compensated by an induction of the other GADD45 
family members 
Since also Gadd45g showed a mild induction upon fasting in livers of healthy but not of db/db 
mice (Fig. 15A, panel 3), we were interested if the effect we saw upon adaptive metabolism in 
GADD45β KO mice was accompanied by an increase of the other GADD45 family members. 
Therefore we measured the mRNA levels of Gadd45a and Gadd45g in the livers of fasted 
GADD45β KO and WT mice. There was no compensatory increase in expression of any of the 
two GADD45 family members (Fig 31). We could also confirm that all GADD45β KO animals used 
for the study had indeed a homozygous loss of the gene. 
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Figure 31. Liver Gadd45a, Gadd45b and Gadd45g 
expression in GADD45β KO and WT mice. Male 
GADD45β KO and WT littermates were sacrificed after 
being fasted for 24h hours. Liver mRNA levels were 
subsequently analysed by RT-qPCR. Values are fold 
induction relative to “WT”. Mean ± SEM; n=5-8 per group. 
 
3.3.4 Whole body GADD45β KO mice do not have altered systemic oxidative 
metabolism 
To measure indirect calorimetry, GADD45β KO and WT littermates were housed in an indirect 
open circuit calorimeter that provides measures of oxygen consumption (VO2) and carbon dioxide 
production (VCO2). We used the PhenoMaster system from TSE for that purpose. Apart from 
measuring energy intake and energy expenditure, as well as metabolic substrate selection, this 
system also concurrently monitors food and water consumption, and locomotor activity. The mice 
were acclimated to that system for 4 days before food withdrawal. 24 hours later food was given 
back and the mice were monitored for another period of 3 days before sacrifice. For the analysis, 
the mean values from the last 6 hours of the light phase or the dark phase were used, starting 
with the light phase in the pre-fast period and ending with the dark phase in the refed period. 
An overall analysis of the parameters from figure 32A (light phase) and 32B (dark phase) showed 
that, before food withdrawal, the WT mice were more active and consumed more food and water 
during the dark phase. Furthermore, pre-fasting RER levels were lower during the light phase 
(~0,9) relative to the dark phase (~1,0), showing that they switched from oxidation of more fat 
during their inactive time to the oxidation of more carbohydrates during their active time. Following 
food removal, parameters drastically changed. Water consumption and activity were reduced, 
although still comparatively higher in the dark phase. After an initial increase of body weight 
during the light phase, accounting for the first period after food withdrawal, the body weight 
dropped as expected. Also, since external food supply is gone, the mice have to rely on their 
internal energy storages and mobilise first their glycogen and then their fat reserves. This is also 
visible in figure 32. During the initial light phase after food withdrawal, the RER dropped to ~0,8 
(Fig. 32A), followed by a decrease further to 0,7 as fasting proceeds (Fig. 32B). This means that 
the mice switched from carbohydrate to completely fat oxidation and can consequently be 
considered metabolically flexible. After refeeding, the mice ate and drank more and were also 
more active relative to before food withdrawal. Also the RER increased drastically, overshooting 
its value in the light phase before reaching its steady state level during the dark phase. Most 
importantly, when comparing GADD45β KO and WT littermates, one did not observe any 
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difference in any of the parameters measured. GADD45β KO and WT littermates displayed 
similar metabolic flexibilities, and did not differ in their systemic oxidative metabolism. 
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Figure 32: Assessment of systemic oxidative metabolism by indirect calorimetry in GADD45β KO and 
WT mice. Male GADD45β KO and WT littermates were housed in the PhenoMaster system (TSE). After an 
acclimation period (pre-fast) , they were fasted for 24h before food was given back (refed). During this time, 
the respiratory exchange rate (RER), food and water intake, body weight and activity was monitored. The 
mean values from the last 6 hours of the light phase (A) or the dark phase (B) were calculated, starting with 
the light phase during the pre-fast period and ending with the dark phase during the refed period. Mean ± 
SEM; n=4-6 per group; $ effect of time; (*) p ≤ 0.05, (**) p ≤ 0.01, (***) p ≤ 0.001. 
 
3.3.5 GADD45γ plays no comparable role to GADD45β in adaptive metabolism during 
nutrient depletion  
The next question to be addressed was whether a deletion of GADD45γ would confer similar 
effects on lipid metabolism as did a knockout of GADD45β. Therefore we starved female 
GADD45γ WT and KO littermates for 24 hours before sacrifice. Male GADD45γ KO mice cannot 
develop gonads during embryogenesis and display a male-to-female sex switch, and thus, cannot 
be used for analysis [183,257]. Using RT-qPCR on liver samples we could confirm the total 
absence of Gadd45g (Fig. 33) in GADD45γ KO mice. Furthermore, we could not observe a 
compensatory induction of Gadd45b in GADD45γ KO and WT mice (Fig. 33). 
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Figure 33: Liver Gadd45b and Gadd45g expression in GADD45γ 
KO and WT mice. Female GADD45γ KO and WT littermates were 
fasted for 24h before sacrifice. Liver mRNA levels were 
subsequently analysed by RT-qPCR. Values are fold induction 
relative to “WT”. Mean ± SEM; n=5 per group. 
 
As expected, fasting of the mice for 24 hours resulted in a significant decrease in body weight 
with no difference between genotypes (Fig. 34A). Also the tissue weights of liver, aWAT, BAT and 
GCM did not show any distinction between the two groups (Fig. 34B).  
 
Figure 34: Body and tissue 
weights in GADD45γ KO 
and WT mice. (A) Body 
weight of female GADD45γ 
KO and WT littermates was 
measured before (0h) or 
after (24h) food withdrawal. 
(B) Tissue weights were 
measured after 24h fasting 
during preparation of the 
same mice as in (A) and 
normalized to body weight. 
Mean ± SEM; n=5 per group; 
* genotype effect, # effect of 
fast time; (*) p ≤ 0.05, (**) p ≤ 
0.01, (***) p ≤ 0.001. 
 
Analysis of the serum metabolites did also not reveal any difference between GADD45γ KO and 
WT littermates (Fig. 35). Fasting blood glucose did not differ (Fig. 35A), neither did any of the 
metabolites (NEFA, TG, glycerol and cholesterol). 
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Figure 35: Serum metabolites in GADD45γ KO and WT mice. Blood glucose (A) and serum metabolites 
(non-esterified fatty acids (NEFA), triglycerides (TG), glycerol, and cholesterol; B) of female GADD45γ KO 
and WT littermates were measured 24h after food withdrawal. Mean ± SEM; n=5 per group. 
 
As for the GADD45β WT and KO mice, the lipid profile of the liver was assessed (Fig. 36). Again, 
there was no difference in hepatic NEFA, TG or cholesterol content between the two groups. 
                                              
 
 
 
 
 
 
 
Figure 36: Liver metabolites in GADD45γ KO and 
WT mice. Liver metabolites (non-esterified fatty acids 
(NEFA), triglycerides (TG) and cholesterol) of female 
GADD45γ KO and WT littermates were measured 
24h after food withdrawal. Mean ± SEM; n=5 per 
group. 
 
3.3.6  Whole body GADD45β KO impairs liver lipid metabolism on a methionine and 
choline deficient diet 
Given the observation that TG accumulated in the liver of fasted mice with loss of GADD45β it 
was our aim to better understand this phenotype by challenging mice with a methionine and 
choline deficient (MCD) diet or a matching control (Con) diet for 3 weeks. Through a series of 
mechanisms, the MCD diet causes an accumulation of triglyceride and fatty acids in the liver as 
the liver cannot form new lipoprotein particles for secretion, ultimately resulting in liver injury [70].  
The MCD diet can also be considered nutrient deprivation since this diet lacks methionine and 
choline. We first measured the mRNA expression of Gadd45b in the liver of GADD45β KO and 
RESULTS 
 47 
WT littermates fed either the MCD or control diet. At the same time, we tested for the 
homozygous depletion of GADD45β and checked for a compensatory increase of its two family 
members. Gadd45b was induced upon MCD diet feeding with no concomitant increase in 
Gadd45a or Gadd45g expression (Fig. 37). Furthermore, we could not detect any Gadd45b 
mRNA in the GADD45β KO mice. 
              
Figure 37: Liver Gadd45a, Gadd45b and Gadd45g expression in GADD45β KO and WT mice on MCD 
or control diet. Male GADD45β KO and WT littermates were either fed a diet deficient in methionine and 
choline (MCD) or a matching control diet (Con) for three weeks before sacrifice. Liver mRNA levels were 
subsequently analysed by RT-qPCR. Values are fold induction relative to “WT Con”. Mean ± SEM; n=2-6 per 
group; * genotype effect, # diet effect; (*) p ≤ 0.05, (**) p ≤ 0.01, (***) p ≤ 0.001. 
 
Feeding GADD45β KO and WT littermates the MCD or control diet revealed no difference in 
genotype for most of the measured phenotypic parameters. All mice had a significantly lower 
blood glucose level at the day of sacrifice (30%, Fig. 38D), with no difference seen between 
genotype. All animals on the MCD diet lost weight during the three weeks of treatment (Fig. 38A), 
with a higher weight difference induced by MCD in WT mice relative to that observed in KO mice. 
The decrease in blood glucose and body weight is in accordance with current literature [69]. The 
tissue weights, normalised to body weight, did not change by feeding a MCD diet, nor was there a 
difference between GADD45β KO and WT mice (Fig. 38B, C, E and F). This is surprising given 
that the MCD diet is used to induce steatosis with severe accumulation of lipids in the liver. Liver 
weights were not significantly changed between the groups. 
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Figure 38: Body and tissue weights as well as blood glucose in GADD45β KO and WT mice on MCD 
or control diet. Male GADD45β KO and WT littermates were either fed a diet deficient in methionine and 
choline (MCD) or a matching control diet (Con) for three weeks before sacrifice. Body weight (A), liver weight 
(B), abdominal weight adipose tissue weight (aWAT, C), blood glucose (D), brown adipose tissue weight 
(BAT, E) and gastrocnemius muscle weight (GCM, F) was measured during preparation of the mice. Tissue 
weights (B, C, E, F) were normalized to body weight. Mean ± SEM; n=2-6 per group; * genotype effect, # diet 
effect; (*) p ≤ 0.05, (**) p ≤ 0.01, (***) p ≤ 0.001. 
 
The loss in body weight was also visible by analysing the body composition by magnetic 
resonance imaging (MRI). Body composition was measured before the start and at the end of the 
treatment. As shown in figure 39, mice on control diet gained weight during the three weeks 
mainly through an increase in fat mass (Fig. 39B) rather than lean mass (Fig 39A). Interestingly, 
GADD45β KO mice gained less fat mass on control diet. In contrast, mice on MCD diet lost 
weight through a loss in both lean and fat mass. There was no effect of genotype on the change 
in lean mass (Fig. 39A), but GADD45β WT mice lost less fat mass than their KO littermates. 
Paradoxically, GADD45β KO mice on MCD diet appeared to have more aWAT than WT mice at 
the end of the study (Fig.38C), hence the aggravated loss in fat mass observed by MRI in 
GADD45β KO mice might be due to a loss of other fat pads such as inguinal fat. 
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Figure 39: Body composition in GADD45β KO and WT mice on MCD or control diet. Male GADD45β 
KO and WT littermates were either fed a diet deficient in methionine and choline (MCD) or a matching 
control diet (Con) for three weeks before sacrifice. Body composition was measured at the beginning and at 
the end of the study and analysed as the change in lean mass (A) and fat mass (B) between the two time 
points. Mean ± SEM; n=2-6 per group; * genotype effect, # diet effect; (*) p ≤ 0.05, (**) p ≤ 0.01, (***) p ≤ 
0.001. 
 
The loss of body weight when fed a MCD diet (Fig. 38A) could be due to decreased feed 
efficiency, as assessed by the amount of weight gain per food energy intake, or less energy 
intake. Indeed, feed efficiency was reduced in GADD45β KO and WT mice with no difference 
between genotypes (Fig. 40B). In contrast, total energy intake was not different between the four 
groups (Fig. 40D). Interestingly, GADD45β KO mice on MCD diet tended to drink more water than 
mice of any other group (Fig. 40C). 
                           
 
 
Figure 40: Energy usability in 
GADD45β KO and WT mice on 
MCD or control diet. Male 
GADD45β KO and WT littermates 
were either fed a diet deficient in 
methionine and choline (MCD) or a 
matching control diet (Con) for 
three weeks before sacrifice. Body 
mass (A) was measured at the 
beginning and at the end of the 
study and analysed as the change 
between the two time points. Feed 
efficiency (B) and total caloric 
intake (D) were determined by 
measuring the food consumption 
within one day. Water consumption 
(C) was also measured within 24h. 
Mean ± SEM; n=2-6 per group; * 
genotype effect, # diet effect; (*) p 
≤ 0.05, (**) p ≤ 0.01, (***) p ≤ 
0.001. 
 
At the termination of the experiment, mice were sacrificed in the ad libitum fed state and 
comprehensive analyses of blood serum and liver metabolite levels were carried out. Analysis of 
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the serum metabolites revealed a significant decrease of TG (Fig. 41B) and cholesterol (Fig. 41C) 
with no change in other lipid metabolites (Fig. 41A and D). ). Accumulation of lipids in the liver 
following MCD feeding results from impaired formation of TG-containing VLDL particles and 
increased uptake of FA. Therefore, it is not surprising that serum TG levels were reduced on a 
MCD diet. Also, this lipid accumulation is accompanied with increased liver injury. We could 
measure an elevation of alanine aminotransferase (ALT) levels in mice fed the MCD diet (Fig. 
41E), a cytosolic enzyme of the hepatocyte commonly measured clinically as a part of a 
diagnostic evaluation of hepatocellular health. Healthy individuals show an activity of less than 50 
U/L. This was the case for mice fed the control diet. It is noteworthy that GADD45β depletion 
exacerbated liver injury. 
   
Figure 41: Serum metabolites in GADD45β KO and WT mice on MCD or control diet. Male GADD45β 
KO and WT littermates were either fed a diet deficient in methionine and choline (MCD) or a matching 
control diet (Con) for three weeks before sacrifice. Serum non-esterified fatty acids (NEFA, A), triglycerides 
(TG, B), cholesterol (C), glycerol (D) and alanine aminotransferase (ALT, E) were measured after processing 
the blood. Mean ± SEM; n=2-6 per group; * genotype effect, # diet effect; (*) p ≤ 0.05, (**) p ≤ 0.01, (***) p ≤ 
0.001. 
 
As seen in figure 42, GADD45β KO mice showed an accumulation of liver triglycerides (Fig. 42B), 
glycerol (Fig. 42C) and cholesterol (Fig. 42D). This is in agreement with the reduced serum TG 
and cholesterol seen in GADD45β KO mice on MCD diet (Fig. 41B and C). Also, there was a 
slight increase in liver NEFA content in GADD45β KO mice on MCD diet (Fig. 42A). Surprisingly, 
GADD45β WT mice did not show the expected accumulation of lipids in the liver when maintained 
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on the MCD diet. Interestingly, GADD45β KO mice showed a decrease in the glycogen content of 
the liver when fed a MCD diet (Fig. 42E). 
           
Figure 42: Liver metabolites in GADD45β KO and WT mice on MCD or control diet. Male GADD45β KO 
and WT littermates were either fed a diet deficient in methionine and choline (MCD) or a matching control 
diet (Con) for three weeks before sacrifice after which liver non-esterified fatty acids (NEFA, A), triglycerides 
(TG, B), glycerol (C), cholesterol (D) and glycogen (E) were measured. Mean ± SEM; n=2-6 per group; * 
genotype effect, # diet effect; (*) p ≤ 0.05, (**) p ≤ 0.01, (***) p ≤ 0.001. 
 
3.3.7 The impact of GADD45β KO on systemic amino acid and acyl carnitine 
metabolism during methionine and choline deficient diet is only mild 
Since mice fed a MCD diet do not take up dietary methionine, they have to find other internal 
sources for this amino acid. As an essential amino acid, methionine is not synthesized de novo in 
humans and other animals. Although mammals cannot synthesize methionine, they can still 
regenerate it from homocysteine via methionine synthase in a reaction that requires vitamin B12 
as a cofactor. Alternatively they have to break down proteins to increase their pool of methionine. 
Hence we were interested whether mice fed a MCD diet showed differences in serum amino 
acids and whether there was an influence of the GADD45β allele. Also, since MCD diet has a 
strong effect on lipid handling and influences serum TG levels, we also performed a profiling of 
serum acylcarnitines. As shown in figure 43, feeding the mice a MCD diet did not have a striking 
effect on serum amino acids. Only a few amino acids were reduced in their content relative to 
total amino acids which were increased overall on MCD diet (Fig. 43B). Those amino acids were 
methionine, as expected, valine, tyrosine and arginine (Fig. 43A). 
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Figure 43: Serum amino acids in GADD45β KO and WT mice on MCD or control diet. Serum amino 
acids of male GADD45β KO and WT littermates were measured after being fed either a diet deficient in 
methionine and choline (MCD) or a matching control diet (Con) for three weeks before sacrifice (A). 
Concentrations are normalised to the total amino acid concentration (B). A list with full names can be found 
in suppl. table 6. Mean ± SEM; n=2-6 per group; * genotype effect, # diet effect; (*) p ≤ 0.05, (**) p ≤ 0.01, 
(***) p ≤ 0.001. 
 
In a similar manner, the concentrations individual acylcarnitine species were generally not altered 
upon MCD diet consumption (Fig.44). Only acylcarnitines C10:1 (decenoylcarnitine), C18:2 
(linoleylcarnitine) and MeGlut (α-methylglutarylcarnitine) were increased on MCD diet (Fig. 44A). 
Total acylcarnitines, carnitine (C0) as well as acetyl carnitine (C2) were not changed either (Fig. 
44B). None of the measured acylcarnitines differed between genotypes. 
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Figure 44: Serum acylcarnitines in GADD45β KO and WT mice on MCD or control diet. Serum 
acylcarnitines of male GADD45β KO and WT littermates were measured after being fed either a diet 
deficient in methionine and choline (MCD) or a matching control diet (Con) for three weeks before sacrifice 
(A). Concentrations are normalised to the total acylcarnitine concentration (B). Also free carnitine (C0) and 
acetylcarnitine (C2) were measured (B). A list with full names can be found in suppl. table 5. Mean ± SEM; 
n=2-6 per group; * genotype effect, # diet effect; (*) p ≤ 0.05, (**) p ≤ 0.01, (***) p ≤ 0.001. 
 
3.3.8 db/db mice show similar fasting effects on some serum parameters as seen in 
GADD45β KO mice  
Since hepatic Gadd45b and Gadd45g were first discovered to be upregulated under the metabolic 
stress of fasting in healthy but not in diabetic db/db animals, we now characterised db/db mice 
further in terms of their metabolic reaction towards fasting. In the course of his PhD studies, Dr. 
Roldan de Guia (Herzig Lab) could already confirm that db/db mice are obese and diabetic having 
significant higher body weight, body fat and blood glucose levels, less lean mass, but almost 
twice as big livers at WT mice (see Fig. 3.2 of his PhD thesis). Most importantly, many 
abnormalities in serum parameters in db/db mice resembled what we have observed in GADD45β 
KO mice. Specifically, in db/db mice the increase of serum NEFA levels upon fasting was not as 
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striking as in WT mice, showing that they are metabolic inflexible in times of food deprivation. 
Also, whereas db/db mice had higher serum TG levels in the fed state, they did not respond with 
an increase of serum TG levels upon fasting as do the WT mice. We next quantified the hepatic 
NEFA and TG from these db/db and WT mice (Fig. 45). Liver NEFA levels did not change upon 
fasting in either group (Fig. 45A). We could confirm that db/db mice had dyslipidaemia through the 
massive accumulation of liver TGs in the fed state. Interestingly, only WT mice showed an 
increase in liver TG content upon fasting, reaching the same level as db/db mice (Fig. 45B).  
 
 
Figure 45: Liver metabolites in 
db/db and WT mice. Male wild-type 
(WT) and db/db mice were fed ad 
libitum (fed) or fasted for 24h (fasted) 
where indicated and liver non-
esterified fatty acids (NEFA, A) and 
triglycerides (TG, B) were measured. 
Mean ± SEM; n=4 per group; * 
genotype effect, # effect of fasting; (*) 
p ≤ 0.05, (**) p ≤ 0.01, (***) p ≤ 0.001. 
 
3.3.9 Systemic lipid metabolism is also disturbed in aged mice 
Based on the observation that the induction of liver Gadd45b upon fasting is blunted in aged 
mice, as it is in diabetic mice, we were interested if we would also see age-dependent differences 
in lipid handling. While the transcriptome analysis with liver samples from 22 months old and 12 
weeks young mice was performed by Dr. Katharina Niopek (Herzig Lab), the analysis of serum 
and the liver was done by her intern Astrid Wendler. Serum and liver parameters in aged mice 
resembled those seen in GADD45β KO and db/db mice. Specifically, there was a blunted fasting-
induced increase in serum NEFA concentrations in aged mice compared to young mice. Also, 
while both groups had the same blood glucose levels in the fed state, upon fasting old mice did 
not reduce their blood glucose levels to the same extent as young mice. Additionally, only young 
mice showed an increase in liver TG content upon fasting, while old mice did not show any 
difference between the fed and fasted state, showing that old mice are in a state of metabolic 
inflexibility. 
3.3.10 The reduction in liver GADD45B also correlates with altered systemic lipid 
metabolism in humans 
To test whether changes in GADD45β plays a role in the adaptive metabolism during the stress of 
nutrient deprivation in humans, we performed correlation analysis of serum parameters from lean 
and obese patients with and without T2D. Since GADD45B expression levels did not depend on 
the obese status but showed a significant reduction in all diabetic men (see Fig. 25), we grouped 
lean and obese patients for correlation analysis. In the Appendix, one can find a table with the 
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results of the dissected analysis (Suppl. table 4). As shown in figure 46, the concentrations of 
serum TG (Fig. 46A), fasting plasma glucose (Fig.46B), homeostatic model assessment for 
insulin resistance (Fig.46C) (HOMA-IR, a medical formula for quantifying insulin resistance [258]) 
and serum NEFA (Fig. 46D) correlated negatively with liver GADD45B levels (but HOMA-IR and 
NEFA showed a tendency towards significance). This means that men with lower liver GADD45B 
expression levels had increased serum NEFA and TG concentrations, a higher blood glucose 
level and were more insulin resistant.  
                   
Figure 46: Serum metabolites, fasting plasma glucose and HOMA-IR in correlation to liver GADD45B 
expression levels in human. 37 Caucasian lean and obese men were fasted overnight and underwent 
abdominal surgery between 8 and 10 am during which liver biopsies were taken. Liver GADD45B mRNA 
levels were subsequently analysed by RT-qPCR and normalized to Hypoxanthine-Phosphoribosyl-
Transferase 1 (HPRT1). Serum triglycerides (TG, A), fasting plasma glucose levels (FPG, B) and non-
esterified fatty acids (NEFA, D) were measured and homeostatic model assessment for insulin resistance 
(HOMA-IR, C) was calculated. Correlation was determined using Shearman’s correlation coefficient. Mean ± 
SEM; n=37. 
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3.4 GADD45β plays a role in regulating insulin sensitivity in chronic 
stress of nutrient overload  
Since it is postulated that increased flux of hepatic lipids may be linked to insulin resistance 
[124,259], the next step was to induce fatty liver and insulin resistance in GADD45β WT and KO 
mice and determine if GADD45β plays also a role in the chronic supply of nutrients and 
adaptation of the organism to changes in metabolism. 
3.4.1 GADD45β KO mice are more insulin resistant after 4 months on a high fat diet 
Feeding mice diet rich in fat (HFD, 60% of total energy) is a more physiological alternative to 
induce obesity, diabetes and fat accumulation in the liver, than the MCD diet. Over the course of 
several weeks, feeding a HFD results in weight gain, development of hyperglycaemia, 
hyperinsulinaemia, hypertension and an increased TG content in adipose tissue, serum and liver 
[66]. For our purpose, GADD45β KO and WT mice were kept on a HFD or a matching control diet 
(NFD, 10% of total energy) for four months. The first analysis to be done was to confirm the 
complete depletion of GADD45β in GADD45β KO mice and to see if there was a compensatory 
induction of other GADD45 family members. As shown in Fig. 47, the genotype could be 
confirmed and there was no increase in Gadd45a or Gadd45g expression level when GADD45β 
was absent. 
           
Figure 47: Liver Gadd45a, Gadd45b and Gadd45g expression in GADD45β KO and WT mice on HFD 
or control diet. Male GADD45β KO and WT littermates were either fed a diet high in fat (HFD) or a 
matching control diet (NFD) for 16 weeks before sacrifice. Liver mRNA levels were subsequently analysed 
by RT-qPCR. Values are fold induction relative to “WT NFD”. Mean ± SEM; n=6-9 per group. 
 
Next, we investigated if the presence or absence of GADD45β would make a difference in in body 
composition when fed a HFD. As expected, at the end of 4 months mice on HFD gained over 100 
% of the weight of mice on NFD (Fig. 48A). Interestingly, GADD45β KO mice on NFD gained 
more weight than WT animals, but there was no effect of genotype when fed a HFD. The fat and 
lean mass before, during and at the end of the study was assessed by magnetic resonance 
imaging (MRI) (Fig. 48B and C). GADD45β KO and WT mice showed similar changes in fat and 
lean mass, both parameters increased on HFD. It seems as if the difference in body weight on 
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NFD between GADD45β KO and WT mice was a result of gaining more fat mass while having the 
same amount of lean mass. 
                        
Figure 48: Body composition in GADD45β KO and WT mice on HFD or control diet. Male GADD45β 
KO and WT littermates were either fed a diet high in fat (HFD) or a matching control diet (NFD) for 16 weeks 
before sacrifice. Body weight was measured every three weeks (A, right) and the difference between the 
beginning and the end of the study was calculated (A, left). Body composition was measured at the 
beginning, in the middle and at the end of the study and analysed as the change in body fat (BF, B) and lean 
mass (LM, C) between day 0 and day 112 Mean ± SEM; n=6-9 per group; * genotype effect, # diet effect; (*) 
p ≤ 0.05, (**) p ≤ 0.01, (***) p ≤ 0.001. 
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The body composition was further analysed during the preparation of the mice. The change in 
body weight was also reflected in total body weight gain (Fig. 49B). Animals on HFD had 
significantly higher body weight, but there was no difference between genotypes. Also, GADD45β 
KO mice on NFD were heavier than their WT littermates. This difference was due to a higher 
percentage of abdominal fat in GADD45β KO mice (Fig. 49D). On HFD, however, there was no 
difference between GADD45β KO and WT mice. Liver weights were the same between the 
groups on NFD and HFD, but GADD45β WT mice on HFD had slightly heavier livers than their 
KO littermates (Fig. 49C). Together with the body and tissue weights, we also measured blood 
glucose levels (Fig. 49A). As expected, mice on HFD were hyperglycaemic, with GADD45β KO 
mice having even slightly higher glucose levels. 
                           
Figure 49: Body and tissue weights as well as blood glucose in GADD45β KO and WT mice on HFD 
or control diet. Male GADD45β KO and WT littermates were either fed a diet high in fat (HFD) or a 
matching control diet (NFD) for 16 weeks before sacrifice. Blood glucose (A), body weight (B), liver weight 
(C) and abdominal weight adipose tissue weight (aWAT, D) were measured during preparation of the mice. 
Tissue weights (C and D) were normalized to body weight. Mean ± SEM; n=6-9 per group; * genotype effect, 
# diet effect; (*) p ≤ 0.05, (**) p ≤ 0.01, (***) p ≤ 0.001. 
 
Next we were interested if a knockout of GADD45β would influence the systemic and hepatic 
metabolism during an oversupply of fat and nutrients. In general there was no or if at all only a 
mild effect of genotype on serum metabolites. Circulating NEFAs were reduced on HFD in both 
groups (Fig. 50A), whereas there was no effect on serum TG (Fig. 50B). Serum glycerol and 
cholesterol were higher in GADD45β KO mice on NFD compared to their WT littermates (Fig. 50C 
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and D). On HFD however, there was no effect of genotype. Serum cholesterol levels were 
increased on HFD in both groups. 
         
Figure 50: Serum metabolites in GADD45β KO and WT mice on HFD or control diet. Male GADD45β 
KO and WT littermates were either fed a diet high in fat (HFD) or a matching control diet (NFD) for 16 weeks 
before sacrifice. Serum non-esterified fatty acids (NEFA, A), triglycerides (TG, B), glycerol (C) and 
cholesterol (D) were measured after processing the blood. Mean ± SEM; n=6-9 per group; * genotype effect, 
# diet effect; (*) p ≤ 0.05, (**) p ≤ 0.01, (***) p ≤ 0.001. 
 
Analysis of liver metabolites revealed no difference between GADD45β KO and WT, neither on 
NFD nor on HFD. We could confirm that feeding a HDF increased the levels of TG in the liver 
over 100% (Fig. 51B), and also liver cholesterol was 100% increased (Fig. 51C), but no 
metabolite showed an effect of genotype. The same holds true for liver NEFA levels (Fig. 51A). 
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Figure 51: Liver metabolites in GADD45β KO and WT mice on HFD or control diet. Male GADD45β KO 
and WT littermates were either fed a diet high in fat (HFD) or a matching control diet (NFD) for 16 weeks 
before sacrifice. Liver non-esterified fatty acids (NEFA, A), triglycerides (TG, B), and cholesterol (C) were 
measured after processing the blood. Mean ± SEM; n=6-9 per group; * genotype effect, # diet effect; (*) p ≤ 
0.05, (**) p ≤ 0.01, (***) p ≤ 0.001. 
 
After completing the metabolic profiling of GADD45β KO and WT fed a HFD or control diet, which 
did not reveal a striking phenotype effect, we went back to the original question if GADD45β might 
be involved in the response of the organism to overnutrition on the level of glucose/insulin 
homeostasis.  
The first measurements were performed after 4 weeks on HFD or NFD, when for a glucose 
tolerance test (GTT) 5 μl/g body weight of a 20% glucose solution was injected into the 
peritoneum of fasted mice and blood samples were taken to determine how quickly the sugar 
could be cleared from the blood (Fig. 52). Already after one month on HFD, mice had higher 
fasting glucose levels than mice fed a NFD (Fig. 52A). After glucose administration glucose levels 
were increased in all mice. Although the total blood concentration was higher in mice on HFD 
(Fig. 52A), their rise in glucose levels relative to their basal level was not higher than in mice on 
NFD (Fig. 52B). Taking the total glucose levels into account (Fig. 52A), the area under the curve 
was higher for mice on HFD, with no difference between GADD45β KO and WT mice (Fig. 52C). 
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Figure 52: GTT in GADD45β KO and WT mice on HFD or control diet. Male GADD45β KO and WT 
littermates were either fed a diet high in fat (HFD) or a matching control diet (NFD) for 4 weeks when an 
intraperitoneal glucose tolerance test (ipGTT) was performed as described in the methods section. Blood 
glucose levels were measured after 20, 60 and 120 minutes and shown as total concentrations (A) and as 
percentage from basal levels (B). From (A) the area under the curve mas calculated (AUC, C). Mean ± SEM; 
n=6-9 per group; * genotype effect, # diet effect; (*) p ≤ 0.05, (**) p ≤ 0.01, (***) p ≤ 0.001. 
 
After 4 months on HFD or NFD an insulin tolerance test (ITT) was performed. As such, 1 U 
insulin/kg body weight was injected intraperitoneally into the mice and blood glucose levels were 
monitored for 120 minutes. As shown in figure 53, all mice on HFD had higher blood glucose 
concentrations (Fig. 53A) and were not responsive to exogenously administered insulin during the 
ITT despite being administered double the absolute dose owing to their higher body mass. In 
contrast, mice fed a NFD showed a drop in their blood glucose concentration (Fig. 53B). Since the 
basal level of blood glucose was higher when fed a HFD, and also the drop in glucose 
concentration was lower than in NFD fed animals (Fig. 53D), the resulting area under the curve 
(AUC) was bigger on HFD compared to NFD fed animals (Fig. 53C). Most interestingly, 
GADD45β KO mice fed a HFD had an even higher AUC than their WT littermates on the same 
diet. 
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Figure 53: ITT in GADD45β KO and WT mice on HFD or control diet. Male GADD45β KO and WT 
littermates were either fed a diet high in fat (HFD) or a matching control diet (NFD) for 16 weeks before 
sacrifice. One week before, an intraperitoneal insulin tolerance test (ipITT) was performed as described in 
the methods section. Blood glucose levels were measured every 20 minutes and shown as total 
concentrations (A) and as percentage from basal levels (B). From (A) the area under the curve mas 
calculated (AUC, C) and the highest drop in glucose concentration relative to time point 0 was determined 
(D). Mean ± SEM; n=6-9 per group; * genotype effect, # diet effect; (*) p ≤ 0.05, (**) p ≤ 0.01, (***) p ≤ 0.001. 
 
From blood taken during fasting sampling in the GTT and ITT glucose and insulin concentrations 
were measured to calculate the HOMA-IR (Fig. 54). Blood glucose levels were always lower in 
mice on NFD than in mice on HFD, both after 4 and 16 weeks on the diet (Fig. 54A). Blood 
glucose concentrations did not change over time and did not show an effect of genotype at either 
time point. Unlike blood glucose levels, serum insulin levels changed over time (Fig. 54B). 
Already after 1 month on HFD, mice had augmented serum insulin levels which increased 
strikingly within the following three months. Whereas there was no difference between GADD45β 
KO and WT mice on HFD after 1 month, GADD45β KO had a significantly higher insulin 
concentration when fed a HFD for 4 months. Insulin resistance can be assessed by the use of the 
HOMA-IR, which takes the fasting glucose and insulin concentrations into account. As shown in 
figure 54C, all mice on HFD had a higher HOMA-IR than mice fed a NFD, but GADD45β KO mice 
on HFD for 4 months had a significant higher HOMA-IR value than their WT littermates on the 
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same diet. Taken together, these data show that GADD45β KO mice were more insulin resistant 
after 4 months on HFD. 
                               
Figure 54: Fasting blood glucose, serum insulin and HOMA-IR of GADD45β KO and WT mice on HFD 
or control diet. Male GADD45β KO and WT littermates were either fed a diet high in fat (HFD) or a 
matching control diet (NFD) for 16 weeks before sacrifice. After 1 and 4 months fasting blood glucose (A) 
and serum insulin (B) were measured and the homeostatic model assessment for insulin resistance (HOMA-
IR, C) was calculated. Mean ± SEM; n=6-9 per group; * genotype effect, # diet effect; (*) p ≤ 0.05, (**) p ≤ 
0.01, (***) p ≤ 0.001. 
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3.4.2 The impact of GADD45β KO on systemic amino acid and acyl carnitine 
metabolism during high fat diet is only mild 
Even though we did not observe a difference between GADD45β KO and WT in their lipid profiling 
under HFD conditions, we could see a difference in regard to their insulin sensitivity with 
GADD45β KO mice being more insulin resistant than their WT littermates. This result prompted us 
us to examine the serum amino acid and acylcarnitine concentrations. It is reported, that 
circulating BCAA in the background of a HFD are involved in the induction of obesity-associated 
insulin resistance [260-262], and also certain acylcarnitine species are increased in T2D [263-
266] due to an increased BCAA catabolic flux, dysregulated mitochondrial function or incomplete 
long-chain fatty acid oxidation [267].  
As shown in figure 55, there was a tendency for total amino acid levels to be increased on HFD, 
but when normalizing to the total amino acid concentration, there was no difference in BCAA or 
any other amino acids between GADD45β KO and WT mice. 
 
Figure 55: Serum amino acids in GADD45β KO and WT mice on HFD or control diet. Serum amino 
acids of male GADD45β KO and WT littermates were measured after being fed either a diet high in fat (HFD) 
or a matching control diet (NFD) for 4 months before sacrifice. Concentrations are normalised to the total 
amino acid concentration (small insert). A list with full names can be found in suppl. table 6. Mean ± SEM; 
n=6-9 per group; * genotype effect, # diet effect; (*) p ≤ 0.05, (**) p ≤ 0.01, (***) p ≤ 0.001. 
 
Also the effect of GADD45β deletion on acylcarnitine concentrations was only mild (Fig. 56A). 
There were only a few acylcarnitines whose concentration increased upon HFD feeding, which 
are all long-chained, namely C18 (stearoylcarnitine), C18:1OH (3-OH-octadecenoylcarnitine), 
C16OH (3-OH-palmitoylcarnitine) and Glut (glutarylcarnitine). This is in accordance with recent 
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literature, where in particular long chain acylcarnitines are reported to be involved in obesity-
related insulin resistance [263,264,266]. None of these showed a difference between the 
genotypes, however, C16:1OH (3-OH-hexadecenoylcarnitine) concentrations were increased in 
GADD45β KO mice compared to all other groups. Also, total acylcarnitines, free carnitine (C0) as 
well as acetyl carnitine (C2) were not changed either (Fig. 56B).  
 
Figure 56: Serum acylcarnitines in GADD45β KO and WT mice on HFD or control diet. Serum 
acylcarnitines of male GADD45β KO and WT littermates were measured after being fed either a diet high in 
fat (HFD) or a matching control diet (NFD) for 4 months before sacrifice (A). Concentrations are normalised 
to the total acylcarnitine concentration (B). Also free carnitine (C0) and acetyl carnitine (C2) were measured 
(B). A list with full names can be found in suppl. table 5. Mean ± SEM; n=6-9 per group; * genotype effect, # 
diet effect; (*) p ≤ 0.05, (**) p ≤ 0.01, (***) p ≤ 0.001. 
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3.5 Effect of hepatic GADD45β overexpression on the observed 
phenotypes 
To investigate if hepatic GADD5β plays a crucial role in mediating the observed effects on lipid 
handling and insulin resistance, gain-of-function experiments were performed. Adenoviruses (AD) 
are commonly used as vector systems to transport exogenous DNA to cells or organs, so 
recombinant adenoviruses were generated, which contained either a liver-specific vector for the 
expression of a flag-tagged Gadd45b cDNA or an empty vector as control. 1 x109 infectious units 
per recombinant virus were injected into mice via their tail vein. The viruses were thereafter 
transported through the vascular system and trapped liver while other tissues are barely affected. 
Since adenoviruses can be cleared from the system of the host after approximately 14 days, 
experiments were terminated at the ideal time point for phenotypic analysis which has been 
shown to be one week after virus application [241]. 
3.5.1 The designed GADD45β overexpression construct is functional in vitro 
Before adenovirus production could be started, it had to be verified that the generated GADD45β 
overexpression construct is able to generate an overexpression of GADD45β in vitro. Therefore, 
we transfected HEK293 cells with pENTR-Flag vectors either harboring the GADD45β sequence 
or a non-specific sequence as control together with a vehicle control, using PEI as a transfection 
reagent. Cells were harvested 48 hours later, and the protein levels of GADD45β were assessed 
by immunoblotting. As shown in figure 57, GADD45β could be detected only in cells transfected 
with the GADD45β-flag vector. Consequently, the vectors could be used to produce adenovirus 
particles (see methods section 5.3.1). 
                                   
Figure 57: Cloning of expression constructs for GADD45β overexpression. HEK293 cells were 
transfected with pENTRY vectors containing the GADD45β sequence (pENTRY-GADD45β OE) or a non-
specific sequence (pENTRY-NC) or vehicle (negative). 48 hours later the cells were harvested and the 
protein levels of GADD45β were assessed by immunoblotting using GADD45β- or flag-antibody, and VCP-
antibody as loading control. Results from 3 independent experiments are shown. 
 
3.5.2 Adenoviruses for the overexpression of GADD45β are functional in vitro 
Prior to in vivo use, the generated adenovirus for the overexpression of GADD45β was tested in 
HEK293 cells. For this purpose, cells were infected with different doses (MOI = cells in well/virus 
ifu per µl) of adenoviruses either carrying a vector for the expression of a flag-tagged Gadd45b 
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cDNA (AD-GADD45β OE) or an empty vector as control (AD-NC). The cells were incubated for 24 
hours and the protein levels of GADD45β were assessed by immunoblotting with an antibody 
against the flag tag. As shown in figure 58, only cells that received the AD-GADD45β OE showed 
a dose-dependent expression of GADD45β. Thus the generated viruses were functional and 
could be used for in vivo applications. 
                                  
Figure 58: Infection of HEK293 cells with adenovirus. HEK293 cells were infected with increasing doses 
(MOI = cells in well/virus ifu per µl) of adenoviruses containing a vector for the expression of a flag-tagged 
Gadd45b cDNA (AD-GADD45β OE) or an empty vector as control (AD-NC). Cells were harvested 24 hours 
later and the protein levels of GADD45β were assessed by immunoblotting using flag-antibody. 
 
3.5.3 Two pilot studies confirm the liver-specific overexpression of GADD45β via 
adenovirus administration in vivo 
To test if the generated adenoviruses confer a liver-specific overexpression of GADD45β, two 
pilot studies were conducted. For the first study, only GADD45β WT mice received the AD-
GADD45β OE, and one week later, half of these mice were fasted for 24 hours before sacrifice. 
For the second pilot study, AD-NC or AD-GADD45β OE viral particles were administered to 
GADD45β KO mice, which were sacrificed in the random fed state. For both studies genomic 
DNA and RNA was extracted to measure the hepatic viral load and Gadd45b mRNA levels, 
respectively. Here, liver samples from animals which did not receive adenoviruses were also 
included as controls. 
As shown in figure 59A, application of the adenoviruses via the tail vein resulted in successful 
sequestration of the virus in the liver, in agreement with the literature [268,269]. One animal from 
the fasted and one animal from the fed group showed less viral load, which correlated with levels 
of the Gadd45b mRNA (Fig. 59B) and GADD45β protein levels (Fig. 59C). Interestingly, virus-
mediated GADD45β overexpression seemed to overcome the fasting-mediated induction of 
Gadd45b (Fig. 59B); the fed group showed in average similar mRNA expression levels compared 
to the fasted group.  
In the second pilot study, adenovirus administration was not as successful as it was in the first 
pilot study. Viral load in livers from mice receiving the AD-GADD45β OE was bigger than in mice 
receiving the AD-NC (Fig. 59D). This may be due to inconsistent application of the virus via tail 
vein injection and hence the virus particles might not have reached the liver. Since the mice were 
sacrificed ad libitum, Gadd45b levels should be low. AD-GADD45β OE administration led to a 
strong induction of Gadd45b, whereas AD-NC injection resulted in similar expression levels as 
compared to the control animals (Fig. 59E). Even though the mRNA expression was strong, it 
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was hard to detect GADD45β at the protein level (Fig. 59F). But nevertheless a faint band could 
be detected in the animals with AD-GADD45β OE.  
Taken together, the generated adenoviruses harbouring a vector for the liver-specific 
overexpression of GADD45β were shown to be functional and were therefore used in 
subsequent gain-of-function experiments. 
 
Figure 59: Liver Gadd45b mRNA and GADD45β protein levels in GADD45β KO and WT mice after 
adenovirus administration. Five male GADD45β WT mice received the AD-GADD45β OE, and after one 
week three of them were fasted for 24 hours before sacrifice (fasted) whereas the other two mice were 
sacrificed ad libitum (fed) (A-C). Other six GADD45β KO mice received AD-NC or AD-GADD45β OE 
particles and were sacrificed ad libitum one week later (D-F). Viral DNA content (A, D) and Gadd45b mRNA 
levels (B, E) were analysed by RT-qPCR, GADD45β levels by immunoblotting (C, F) using antibodies 
against GADD45β, the flag tag or the loading control (VCP). 
 
3.5.4 GADD45β overexpression in GADD45β KO mice can partially reverse their 
dysregulated fasting lipid metabolism 
In a first attempt to rescue the phenotype observed with GADD45β KO mice under the stress of 
nutrient deprivation by liver-specific GADD45β overexpression, GADD45β KO and WT mice 
received 1 x109 infectious units per recombinant virus (AD-NC or AD-GADD45β OE), and one 
week later were fasted for 24 hours before sacrifice. As shown in figure 60, the injection of AD-
GADD45β OE into the tail vein led to a strong increase of Gadd45b levels in the liver in GADD45β 
KO and WT animals compared to those animals which received the AD-NC (Fig. 60A). 
Interestingly, GADD45β KO animals with AD-GADD45β OE had almost the same expression 
levels as their WT littermates, although variation was bigger in this group (Fig. 60B). 
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Figure 60: Liver Gadd45b mRNA expression in GADD45β KO and WT mice after adenovirus 
administration and 24 hours fasting. Male GADD45β KO and WT mice received the AD-GADD45β OE or 
AD-NC, and after one week they were fasted for 24 hours before sacrifice. Liver Gadd45b mRNA levels 
were analysed by RT-qPCR and are shown as a fold induction relative to WT mice with AD-NC (A). The 
exact expression values are shown in (B). 
 
After having confirmed that AD-GADD45β OE administration led to an overexpression of 
GADD45β, the next step was to examine if the blood glucose levels as well as the body and 
tissue weights were altered upon virus treatment. The body weight one week after virus 
application did not differ from the body weight before injection, and fasting reduced, this variable 
to the same extent in both genotypes (Fig. 61A-C). Glucose levels were significantly lower in WT 
mice with GADD45β overexpression, whereas KO littermates did not show a change in blood 
glucose values upon AD-GADD45β OE administration (Fig. 61D). This difference was abolished 
after 24 hour fasting (Fig. 61E). Blood glucose levels dropped with fasting in all groups. As a 
consequence, only GADD45β WT mice showed a change in blood glucose levels between the fed 
and fasted state (Fig. 61F). Interestingly, GADD45β overexpression resulted in a heavier liver in 
GADD45β WT but not in KO mice (Fig. 61G). The weight of abdominal fat was not significantly 
affected upon GADD45β overexpression (Fig. 61H). 
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Figure 61: Body and tissue weights as well as blood glucose in GADD45β KO and WT mice after 
adenovirus administration. Male GADD45β KO and WT mice received the AD-GADD45β OE or AD-NC, 
and after one week they were fasted for 24 hours before sacrifice. Body weight was measured before virus 
injection (A), one week after virus injection but before fasting (B) and after 24 hours fasting (C). Blood 
glucose was measured one week after virus injection but before fasting (D) and after being fasted for 24 
hours (E). The change in blood glucose levels between those two time points was determined (F). Liver (G) 
and adipose tissue weight (aWAT, H) were measured during preparation of the mice and normalized to body 
weight. Mean ± SEM; n=7-8 per group; * genotype effect, # effect of GADD45β overexpression; (*) p ≤ 0.05, 
(**) p ≤ 0.01, (***) p ≤ 0.001. 
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Except for the liver weights, there was no observed differences caused by the genotypes or the 
administered viruses, and the results seem to mimic what has been shown in the starvation 
experiment with GADD45β KO and WT mice (see chapter 3.3.1).Next we examined the serum 
and liver metabolites to see if liver-specific rescue of GADD45β would influence the previously 
observed disturbances in systemic and liver lipid handling in GADD45β KO mice 
Before fasting, serum NEFA levels were the same in all groups (Fig. 62A). Likewise, fasting led to 
a 160% increase in serum NEFA concentrations in all groups. Remarkably, the blunted increase 
in serum NEFA which we could observe after 24 hour starvation in GADD45β KO mice was gone 
after GADD45β overexpression. There was rather a tendency of higher serum NEFA levels in 
GADD45β KO mice compared to their WT littermates with GADD45β overexpression. 
Unexpectedly, we could not observe the blunted effect of serum NEFA in the AD-NC control 
group. There was only a mild blunted effect. Serum TG concentrations were the same in all 
groups before fasting and did not increase upon fasting (Fig. 62B). Only in GADD45β KO mice 
with GADD45β overexpression serum TG levels were almost 100% augmented compared to all 
other groups. Serum glycerol levels were increased upon GADD45β overexpression before food 
withdrawal but this difference relative to the AD-NC group was abolished after 24 hours of fasting 
(Fig 62C). Serum glycerol levels increased in the AD-NC group, with no difference between 
genotypes, whereas serum glycerol concentrations did not change in the AD- GADD45β OE 
group. 
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Figure 62: Serum metabolites in GADD45β KO and WT mice after adenovirus administration. Male 
GADD45β KO and WT mice received the AD-GADD45β OE or AD-NC, and after one week they were fasted 
for 24 hours before sacrifice. Serum non-esterified fatty acids (NEFA, A), triglycerides (TG, B) and glycerol 
(C), were measured before (0h) and after (24h) food withdrawal. Mean ± SEM; n=7-8 per group; * genotype 
effect, # effect of GADD45β overexpression; (*) p ≤ 0.05, (**) p ≤ 0.01, (***) p ≤ 0.001. 
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GADD45β overexpression had a striking effect on liver metabolites (Fig. 63). Administration of 
AD-GADD45β OE resulted in a reduction of liver NEFA levels in both GADD45β WT and KO mice 
(Fig. 63A). The formerly described increase of liver TG in GADD45β KO mice was still 
measurable after AD-NC application but abolished upon GADD45β overexpression (Fig. 63B). 
GADD45β overexpression had no effect on liver cholesterol concentrations; they were the same 
in all four groups (Fig. 63C). 
   
Figure 63: Liver metabolites in GADD45β KO and WT mice after adenovirus administration. Male 
GADD45β KO and WT mice received the AD-GADD45β OE or AD-NC, and after one week they were fasted 
for 24 hours before sacrifice. Liver non-esterified fatty acids (NEFA, A), triglycerides (TG, B) and cholesterol 
(C) were measured after food withdrawal. Mean ± SEM; n=7-8 per group; * genotype effect, # effect of 
GADD45β overexpression; (*) p ≤ 0.05, (**) p ≤ 0.01, (***) p ≤ 0.001. 
 
Taken together we could partially rescue the observed fasting-induced metabolic derangement in 
GADD45β KO mice and alleviate lipid accumulation in the liver by overexpressing GADD45β. 
3.5.5 GADD45β overexpression in db/db mice can partially reverse their diabetic 
phenotype 
In order to verify that the observed fasting-induced effects on serum and liver parameters as well 
as on insulin sensitivity in db/db mice compared to healthy mice are due a reduced expression of 
GADD45β in the liver, we injected the AD-GADD45β OE or AD-NC into db/db and healthy control 
animals and sacrificed them one week later in the fasted state. As for the rescue experiment with 
GADD45β KO and WT mice, we first assessed the status of overexpression in the different 
groups. Two animals had anatomical abnormalities and were excluded from any analysis (animal 
2.3 and 3.5). Analysis of mRNA expression levels revealed almost 100fold higher Gadd45b 
expression levels in db/db and WT mice with GADD45β overexpression (Fig. 64C). The scatter in 
WT mice receiving the AD-GADD45β OE was higher than in other groups, and two animals had to 
be excluded from subsequent analysis due to absent overexpression (Fig. 64B, red). Surprisingly, 
Gadd45b expression levels were the same between WT and db/db mice after AD-NC 
administration. This should not be the case considering that db/db mice were not able to induce 
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GADD45β upon fasting (see initial screen 3.2.1). Surprisingly it was not possible to detect 
GADD45β at the protein level (Fig. 64A), although positive control lysates indicated that the 
antibody was clearly functional. Only in liver samples with the highest mRNA expression values 
(e.g. 2.5, 4.3 and 4.6) was a band for GADD45β visible. Remarkably, almost all of the WT animals 
did not show a signal on protein level, despite the fact that an induction of GADD45β should have 
been observed due to fasting. This is in accordance with endogenous GADD45β being generally 
hard to detect. Nothing is known about the stability and half-life of GADD45β but at least for 
GADD45γ it is assumed that its stability is very weak and half-life very short (personal 
communication with Dr. Anastasia Kralli [230]). 
 
Figure 64: Liver Gadd45b mRNA and GADD45β protein levels in db/db and control mice after 
adenovirus administration. Male db/db or healthy control mice (WT) received the AD-GADD45β OE or AD-
NC, and after one week they were fasted for 24 hours before sacrifice. GADD45β levels were determined by 
immunoblotting (A) using antibodies against GADD45β, the flag tag or the loading control (VCP). Gadd45b 
mRNA levels were analysed by RT-qPCR and shown as a fold induction relative to WT mice with AD-NC 
(C). The exact expression values are shown in (B). Animals that were excluded in further analysis are 
marked in red. 
 
After having confirmed the overexpression of GADD45β in db/db and WT mice, we next examined 
the mRNA expression levels of the other two GADD45 family members GADD45α and GADD45γ 
(Fig. 65). Gadd45a expression was 4-6 times higher in db/db mice than in WT mice independently 
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of GADD45β overexpression. Gadd45g expression was higher in db/db mice with AD-NC injection 
and was reduced upon GADD45β overexpression. Overall, both gene expression patterns 
differed from what we could observe in the initial screen (see. Fig. 15) where fasting resulted in 2-
fold higher Gadd45a expression in db/db mice, and Gadd45g expression was 5 times higher in 
WT mice than in db/db. It is also surprising, as mentioned before, that Gadd45b expression in WT 
with AD-NC is not induced but on the same level as in db/db mice. 
           
Figure 65: Liver Gadd45a, Gadd45b and Gadd45g expression in db/db and control mice after 
adenovirus administration. Male db/db or healthy control mice (WT) received the AD-GADD45β OE or AD-
NC, and after one week they were fasted for 24 hours before sacrifice. mRNA levels were analysed by RT-
qPCR and shown as a fold induction relative to WT mice with AD-NC. Mean ± SEM; n=4-6 per group; * 
genotype effect, # effect of GADD45β overexpression; (*) p ≤ 0.05, (**) p ≤ 0.01, (***) p ≤ 0.001. 
 
Next, we examined body and tissue weights of the four groups (Fig 66). As expected db/db mice 
were much heavier than control animals both in the fasted and in the fed state and with both 
recombinant viruses (Fig. 66A). Interestingly, GADD45β overexpression resulted in a slight but 
significant decrease in body weight in both before and after fasting. Independently of virus, db/db 
mice had much heavier livers and much more aWAT than healthy WT mice (Fig. 66B). WT mice 
seemed to have a slightly bigger liver and a bit less aWAT with GADD45β overexpression than 
with AD-NC. Even though the liver weight was higher in db/db mice, the percentage relative to 
body mass was only 2% more than in WT mice (Fig. 66C). This difference was gone after 
GADD45β overexpression; WT mice with GADD45β overexpression had a higher percentage of 
liver to total body weight which is comparable to that of db/db mice. The opposite was true for 
aWAT; hepatic GADD45β overexpression resulted in less relative aWAT in WT mice, but not in 
db/db mice. 
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Figure 66: Body and tissue weights in db/db and WT mice after adenovirus administration. Male db/db 
and healthy control mice (WT) received the AD-GADD45β OE or AD-NC, and after one week they were 
fasted for 24 hours before sacrifice. Body weight was measured before and after fasting (A). Liver and 
adipose tissue weight (aWAT) were measured during preparation of the mice and shown as total weight (B) 
and normalized to body weight (C). Mean ± SEM; n=4-6 per group; * genotype effect, # effect of GADD45β 
overexpression; (*) p ≤ 0.05, (**) p ≤ 0.01, (***) p ≤ 0.001. 
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Apart from having an increase in body, liver and fat weight we could confirm that db/db are in a 
state of hyperglycaemia (Fig. 67). Their blood glucose levels were always higher than that of 
healthy WT mice, independent of virus application (Fig. 67A) or fasting (Fig. 67B). But most 
importantly, we could observe a 40% reduction in blood glucose levels in db/db with GADD45β 
overexpression after 6 hour fasting (Fig. 67A) and after 24 hour fasting (Fig. 67B). Also in the 
random fed state, blood glucose levels were 30% lower in db/db mice with GADD45β 
overexpression (Fig. 67B). 
               
Figure 67: Blood glucose levels in db/db and WT mice after adenovirus administration. Male db/db 
and healthy control mice (WT) received the AD-GADD45β OE or AD-NC, and after one week they were 
fasted for 24 hours before sacrifice. Blood glucose (BG) concentrations were measured before and one 
week after virus injection after 6 hours of fasting (A), and in the ad libitum state and after 24 hours of fasting 
both one week after virus injection (B). Also the change in blood glucose is shown for both cases. Mean ± 
SEM; n=4-6 per group; * genotype effect, # effect of GADD45β overexpression; (*) p ≤ 0.05, (**) p ≤ 0.01, 
(***) p ≤ 0.001. 
 
With the hint that glucose homeostasis might be affected by GADD45β overexpression, we also 
measured the fasting serum insulin levels before and one week after virus administration, and 
calculated the HOMA-IR to determine insulin resistance. Similar to their blood glucose levels, 
fasting insulin concentrations of db/db mice were always higher than that of healthy WT mice, 
independent of virus application (Fig. 68A). But also here we could measure a 45% reduction in 
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serum insulin levels with GADD45β overexpression. Since serum insulin and glucose are 
parameters for the calculation of HOMA-IR, it is plausible that the HOMA-IR value was reduced 
with diminished insulin and glucose levels. This means that db/db mice were less insulin resistant 
with GADD45β overexpression (Fig. 68B). 
         
Figure 68: Serum insulin levels and HOMA-IR in db/db and WT mice after adenovirus administration. 
Male db/db and healthy control mice (WT) received the AD-GADD45β OE or AD-NC, and after one week 
they were fasted for 24 hours before sacrifice. Serum insulin concentrations were measured before and one 
week after virus injection after 6 hours of fasting (A), and homeostatic model assessment for insulin 
resistance (HOMA-IR) was calculated (B). Also the change in serum insulin levels and HOMA-IR is shown 
for both cases. Mean ± SEM; n=4-6 per group; * genotype effect, # effect of GADD45β overexpression; (*) p 
≤ 0.05, (**) p ≤ 0.01, (***) p ≤ 0.001. 
 
Since overexpression of GADD45β on one hand led to a reduction in blood glucose, insulin and 
HOMA-IR in db/db mice, and on the other hand resulted in a partial rescue of the dysregulated 
fasting lipid metabolism in GADD5β KO mice (see section 3.5.2), we next were interested if 
GADD45β overexpression could also reverse the effects seen in db/db mice on their serum and 
liver lipid handling (see section 3.3.8). 
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As shown in figure 69A, db/db mice with AD-NC had higher circulating NEFA levels in the fed 
state compared to WT control mice. This difference was abolished upon GADD45β 
overexpression. Fasting increased serum NEFA concentrations in all groups with no difference in 
genotype or virus. Importantly, the blunted increase in serum NEFA that we could observe before 
was abolished after GADD45β overexpression. Unexpectedly, serum TG levels were always 
lower in db/db mice in the fed and fasted state (Fig.69B). Upon fasting, TG levels increased 
independently of GADD45β overexpression in all four groups, with a bigger change in WT mice 
than db/db mice. Most importantly, during fasting serum TG concentrations in db/db mice 
increased more with GADD45β overexpression than with AD-NC. Thus, GADD45β 
overexpression did not only have an impact on insulin sensitivity of db/db mice, it could also 
reverse the dysregulated systemic lipid metabolism in db/db mice and confer higher metabolic 
flexibility upon nutrient deprivation. 
               
Figure 69: Serum metabolites in db/db and WT mice after adenovirus administration. Male db/db and 
healthy control mice (WT) received the AD-GADD45β OE or AD-NC, and after one week they were fasted for 
24 hours before sacrifice. Serum non-esterified fatty acids (NEFA, A), and triglycerides (TG, B) were 
measured before (random fed) and after food withdrawal (24h fast). Also the change in NEFA and TG levels 
is shown for both cases. Mean ± SEM; n=4-6 per group; * genotype effect, # effect of GADD45β 
overexpression; (*) p ≤ 0.05, (**) p ≤ 0.01, (***) p ≤ 0.001. 
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Last, we wanted to investigate if GADD45β overexpression can also lead to a reduction of fasting 
liver lipids as we have observed in GADD45β KO and WT mice (see in section 3.5.2). As shown 
in figure 70A, GADD45β overexpression resulted in only a mild reduction of liver NEFA 
concentrations in WT but not in db/db mice. Similarly, GADD45β overexpression only reduced 
liver TG levels in WT animals, with no effect in TG-laden livers from db/db mice (Fig. 70B). 
     
                                  
Figure 70: Liver metabolites in 
db/db and WT mice after 
adenovirus administration. 
Male db/db and healthy control 
mice (WT) received the AD-
GADD45β OE or AD-NC. After 
one week they were fasted for 24 
hours before sacrifice and liver 
non-esterified fatty acids (NEFA, 
A), and triglycerides (TG, B) were 
measured. Mean ± SEM; n=4-6 
per group; * genotype effect, # 
effect of GADD45β 
overexpression; (*) p ≤ 0.05, (**) 
p ≤ 0.01, (***) p ≤ 0.001. 
 
Thus, despite only having a mild effect on systemic and hepatic lipid handling, GADD45β 
overexpression could increase the insulin sensitivity in obese mice by lowering fasting blood 
glucose and serum insulin levels and hence can partially reverse their obese and diabetic 
phenotype. 
3.6 Analysis of the underlying mechanisms of GADD45β action 
In the course of these studies it became more and more evident that GADD45β might have a role 
in two stress scenarios: 1) nutrient depletion where it might play a role in lipid homeostasis, and 2) 
nutrient overload where it may confer an effect on insulin sensitivity. The final questions that have 
arisen concern the mechanism. How can GADD45β play a role in both situations? Where is the 
missing link? There a several approaches to answer these questions. We addressed the two most 
obvious ones. (1) Does GADD45β have an influence on the transcription of certain genes? (2) 
Does GADD45β have an impact on signalling pathways within the cell by modulating protein 
activity? 
3.6.1 The effect of GADD45β may not be mediated via transcriptional regulation 
In a first attempt to unravel the mechanisms of GADD45β action, we examined the expression 
levels of crucial genes involved in detoxification, drug transport and fatty acid metabolism. We 
could show that some of those genes were indeed slightly altered in GADD45β KO animals (Fig. 
71). Specifically GADD45β KO livers had a reduced expression of CD36 (fatty acid translocase), 
Acly (ATP citrate lyase) and Cyp2b10 (a CAR target) and an increased expression of Slco1a1 (an 
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organic anion transporting polypeptide). In contrast, genes involved in glucose metabolism such 
as Pck1 (involved in glycolysis) and Pdk4 (involved in gluconeogenesis) were unaffected. It is 
noteworthy that not all examined genes involved in fatty acid metabolism were dysregulated upon 
GADD45β depletion. Even though the expression of Acly, which is involved in FA synthesis, 
seems to be reduced, there was no effect on other lipogenic markers such as Cyp4a14 (fatty acid 
hydroxylase), Fasn (fatty acid synthase), or Acc1 (acetyl-Coa carboxylase). An exemplary gene 
involved in the breakdown of FA, Mcad (medium-chain acetyl-CoA dehydrogenase), was not 
affected by the absence of GADD45β. Interestingly, the expression of Slco1a1, which is involved 
in bile acid and drug transport, was increased in GADD45β KO, whereas the expression of 
Cyp2b10, which is involved in detoxification, was decreased. Overall, only modest and 
inconsistent effects were observed of GADD45β KO on the expression of genes involved in FA 
metabolism, drug transport and detoxification.  
 
Figure 71: Liver gene 
expression analysis 
in GADD45β KO and 
WT mice. Male 
GADD45β KO and WT 
littermates were 
sacrificed after being 
fasted for 24h hours. 
Liver mRNA levels 
were subsequently 
analysed by RT-qPCR. 
Values are fold 
induction relative to 
“WT”. Mean ± SEM; 
n=5-8 per group. * 
genotype effect; (*) p ≤ 
0.05, (**) p ≤ 0.01, (***) 
p ≤ 0.001. 
 
If the effect of GADD45β depletion on the observed gene expression profile was causal, 
overexpression of GADD45β in turn should change the expression of the affected genes. Hence, 
we examined the mRNA levels of some of the genes in livers of GADD45β KO and WT mice 
which received the AD-GADD45β OE or AD-NC. Unexpectedly, gene expression patterns 
observed in our initial experiment were not faithfully reproduced in our control virus-treated cohort. 
For example, CD36 (Fig. 72A), Acly (Fig. 72B), Slco1a1 (Fig. 72C), and Cyp2b10 (Fig. 72D) 
expressions were not altered in GADD45β KO mice with AD-NC. But whereas there was no effect 
of genotype in any of the genes, there was indeed a general effect of GADD45β overexpression. 
CD36, Acly and Cyp2b10 mRNA levels, which were reduced with GADD45β KO, were increased 
with GADD45β overexpression, and Slco1a1 mRNA levels, which were increased with GADD45β 
KO, were reduced. But since there was no effect of genotype in this experimental mouse cohort, 
overexpression of GADD45β did in fact not rescue the effects on gene expression observed 
previously. 
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Figure 72: Liver gene expression analysis in GADD45β KO and WT mice after adenovirus 
administration. Male GADD45β KO and WT mice received the AD-GADD45β OE or AD-NC, and after one 
week they were fasted for 24 hours before sacrifice. Liver mRNA levels of CD36 (A), Acly (B), Slco1a1 (C) 
and Cyp2b10 (D) were subsequently analysed by RT-qPCR. Values are fold induction relative to “WT AD-
NC”. Mean ± SEM; n=7-8 per group. * genotype effect, # effect of GADD45β overexpression; (*) p ≤ 0.05, 
(**) p ≤ 0.01, (***) p ≤ 0.001. 
 
To get a broader idea on the influence of GADD45β on gene expression, we submitted liver RNA 
samples from starved GADD45β KO and WT littermates to the Genomics and Proteomics Core 
Facility of the DKFZ where they performed a single read, 50 bp multiplexed run on 3 HiSeq lanes 
without reading direction with subsequent poly-A purification. The subsequent analysis on 
differential expression, visualisation and pathway/network of differentially expressed transcripts 
was performed by Dr. Emil Karaulanov from the Institute of Molecular Biology, Mainz (see 
Methods section for further details). He filtered robust (consensus) hits by performing several 
parallel workflows using TopHat and Genomatix GMS for read mapping and CuffDiff (v1.0.3, 
Galaxy) and DESeq (v1.10.1, Genomatix) for differential expression analysis. In general, there 
were a few hundred apparently KO-dysregulated transcripts, most of them moderately affected 
(~2x). Some genes showed differential expression of some transcript isoforms only. Also some 
genes showed low levels of expression. Generally, there were more down-regulated than up-
regulated transcripts. Transcripts belonging to the following genes showed robust up-regulation 
(>2x): Ces4a, Cgref1, Cidec, Cntnap1, Derl3, Lad1, Nudt7, Onecut1, Peg10, Pfkfb3, Pitx3, 
Serpina12, Serpina4-ps1, Slc35f1. Transcripts belonging to the following genes show robust 
down-regulation (>2x): Atp6v0d2, Bmpr2, Cbl, Cdk6, Gprin3, Klf12, Klhl11, Lcn2, Lcor, Lmbrd2, 
Lnpep, Mib1, N4bp2, Ptar1, Ptpn4, Rel, Sesn3, Themis, Uhmk1, Xpo4, Xrn1, Zbed6, Zfp369, 
Zfp433. A complete table with robust hits can be found in the Appendix section. Some 
differentially expressed genes showed strong 5' -> 3' gradient of differential read enrichment, 
which was either a peculiar biological phenomenon or a technical artefact from the sample 
isolation or library preparation (e.g. RNA degradation, batch effects etc.). Functional annotation 
analysis (DAVID) for down regulated genes was mostly weak which could be due to the low 
number of affected genes. Supplementary figure 1 shows that most genes affected were 
clustered as phosphoproteins or were involved in phosphate metabolic processes, 
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phosphorylation and cell cycle. Latter grouping is not surprising since GADD45β is reported to 
play a role in senescence and cell cycle control. No significant enrichments could be seen for 
upregulated genes which could also be due to the low number of genes.  
Some of the results of the RNAseq screen with moderate or high gene expression levels were 
subsequently validated by RT-qPCR. Some hits could be nicely validated (Lnpep, Onecut1, 
Nudt7, Lcn2, Tsc22d1, Atp6v0d2, Ces4a), others did not change (Vps13b, N4bp2, Zfp, Lcor, 
Abca1, Serpina4-p1), and some changed in the expected direction, but with low statistical 
significance due to high intra-group variability (Derl3, Saa2, Cidec, Cyp2b9). 
 
Figure 73: RNAseq validation in GADD45β KO and WT mice. Male GADD45β KO and WT littermates 
were sacrificed after being fasted for 24h hours. Differentially expressed genes from the RNAseq analysis 
were subsequently validated by RT-qPCR. Values are fold induction relative to “WT”. Mean ± SEM; n=5-8 
per group. * genotype effect; (*) p ≤ 0.05, (**) p ≤ 0.01, (***) p ≤ 0.001. 
 
It is surprising that some of the apparently differentially expressed genes could not be validated 
even though they seem to be clearly affected. Some possible explanations could be: (a) selective 
mRNA degradation before or during HiSeq library preparation or (b) unspecific (cross-reacting) 
RT-qPCR primers that report also other paralogs or transcript variants. 
The next step was to determine if the rescue of GADD45β could also change the expression of 
the affected genes. As before, we examined the mRNA levels of some of the RNAseq hits in 
livers of GADD45β KO and WT mice which received the AD- GADD45β OE or AD-NC. The 
expression pattern of GADD45β KO and WT should be similar to what has been observed after 
RNAseq analysis. This was only partially the case (Fig. 74). For Onecut1 (Fig. 74A) and Tsc22d1 
(Fig. 74C) we could see increased mRNA expression levels in GADD45β KO mice compared to 
WT littermates, as we also could see it after RNAseq analysis and subsequent validation (Fig. 
73). In contrast, there was no effect of genotype for Nudt7 (Fig. 74B), Atp6v0d2 (Fig. 74D) or 
Ces4a (Fig. 74E), even though RNAseq analysis revealed Ces4a to be the gene with the highest 
fold change between GADD45β KO and WT. However, we could not observe a compensatory 
change in gene expression with GADD45β overexpression in any of the genes. 
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Figure 74: RNAseq validation in GADD45β KO and WT mice after adenovirus administration. Male 
GADD45β KO and WT mice received the AD-GADD45β OE or AD-NC, and after one week they were fasted 
for 24 hours before sacrifice. Liver mRNA levels of Onecut1 (A), Nudt7 (B), TSC22D1 (C), Atp6v0d2 (D) and 
Ces4a (E) were subsequently analysed by RT-qPCR. Values are fold induction relative to “WT AD-NC”. 
Mean ± SEM; n=7-8 per group. * genotype effect, # effect of GADD45β overexpression; (*) p ≤ 0.05, (**) p ≤ 
0.01, (***) p ≤ 0.001. 
 
Since the influence of GADD45β KO on differentially expressed genes was only mild and we 
could not confirm every hit by RT-qPCR, together with the fact that the affected genes involved in 
fatty acid metabolism and detoxification could not be rescued with GADD45β overexpression, we 
believe that the effect of GADD45β is not via transcriptional regulation even though GADD45β is 
reported to be a potential transcriptional co-regulator of nuclear receptor transcription factors 
[203, 205]. 
3.6.2 The GADD45β-mediated effects on lipid and glucose metabolism are 
independent of the JNK and p38 pathways 
Further investigations to unravel the underlying mechanism of GADD45β action were focused on 
its potential impact on protein activity and cell signalling pathways. Therefore, protein levels in 
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GADD45β KO and WT mice fed a HFD or NFD as well as in db/db and WT mice with GADD45β 
overexpression were assessed by immunoblotting. First, we examined if GADD45β mediates its 
effect on lipid metabolism and insulin sensitivity by its known downstream effectors JNK and p38. 
JNK has been reported to be activated in diabetic conditions and is implicated in the development 
of insulin resistance for over one decade [237,270]. There are also studies describing a role for 
p38 MAPK in the pathogenesis of T2D, although the underlying mechanisms are still under 
debate [271]. 
Since we could show that GADD45β KO mice were more insulin resistant after 4 months on a 
high fat diet, we investigated if this effect was due to altered activities of JNK or p38 activity. 
Hence, liver proteins from whole tissue extracts were separated by SDS-PAGE and total and 
phosphorylated p38 and JNK levels were measured by immunoblotting with antibodies against 
the T180/182 phosphorylation site of p38 and the S265 phosphorylation site of JNK. As shown in 
figure 75A, the phosphorylation status and thus the activity of p38 was not altered between the 
groups. Therefore we did not examine the total protein levels. The signal for phospho-JNK was 
very weak, but it seems as if GADD45β KO mice had a slightly stronger signal when fed a HFD. 
Therefore we also assessed the levels of total proteins. After normalizing the phospho-JNK levels 
to the levels of total JNK, we could not see a significant difference between the groups (Fig.75B). 
Most importantly, the KO of GADD45β did not lead to an increase or decrease of phospho-JNK, 
neither on NFD nor on HFD. 
                  
Figure 75: Protein expression of p38 and JNK and their phospho-proteins in GADD45β KO and WT 
mice on HFD or control diet. Male GADD45β KO and WT littermates were either fed a diet high in fat 
(HFD) or a matching control diet (NFD) for 16 weeks before sacrifice. Phospho-p38, phospho-JNK and JNK 
levels were determined by immunoblotting using antibodies against the respective protein or the loading 
control (VCP). Shown are representative blots (A). The signal intensity was assessed by normalising the 
optical density (OD) first to VCP and then to total normalised protein (B). Mean ± SEM; n=6 per group. 
 
Next we performed the same analysis with db/db and WT mice with AD-GADD45β OE or AD-NC 
administration where the overexpression of GADD45β in db/db mice ameliorated their diabetic 
phenotype. As shown in figure 76, phospho-JNK levels were always higher in db/db than in WT 
mice. This was expected after AD-NC injection where GADD45β levels should be lower in db/db 
mice (according to the first screen, see section 3.2.2) and consequently should have higher 
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phospho-JNK levels assuming that GADD45β inhibits MKK4/7 and therefore also JNK activity. In 
addition, obesity and insulin resistance are characterised by increased JNK activity [272]. With the 
overexpression of GADD45β one might have expected a reduction of JNK activity in db/db and 
WT animals, although this was not the case. 
                  
Figure 76: Protein expression of JNK and its phospho-proteins in db/db and WT mice after 
adenovirus administration. Male db/db and healthy control mice (WT) received the AD-GADD45β OE or 
AD-NC, and after one week they were fasted for 24 hours before sacrifice. Phospho-JNK and JNK levels 
were determined by immunoblotting using antibodies against the respective protein or the loading control 
(VCP). Shown are representative blots (A). The signal intensity was assessed by normalising the optical 
density (OD) first to VCP and then to total normalised protein (B). Mean ± SEM; n=3 per group; * genotype 
effect, # effect of GADD45β overexpression; (*) p ≤ 0.05, (**) p ≤ 0.01, (***) p ≤ 0.001. 
 
Taken together, we conclude that the impact of GADD45β on the insulin sensitivity might be 
independent of the JNK and p38 pathway. 
3.6.3 The impact of GADD45β on the hepatic insulin signalling pathway remains 
elusive 
The further investigation was focused on the insulin signalling pathway. Since GADD45β did not 
seem to mediate its effect via the JNK or p38 pathway, we were interested if GADD45β would 
have an influence on the activity of any downstream effector of the insulin receptor and thereby 
modulate the organism’s reaction to nutrient overload. The insulin signalling pathway is a complex 
network of many proteins and several feedback loops. Thus we focused on the “main track” which 
is the IRS  PI3K  AKT axis. AKT itself has numerous targets, of which we examined those 
involved in gluconeogenesis (FOXO1), glycogenesis (GSK3β) and protein synthesis (S6K1). 
Since we saw a major effect of GADD45β overexpression on the glucose levels of db/db mice, we 
examined the phosphorylation status of those insulin targets which are involved in 
gluconeogenesis and glycogenesis, namely FOXO1 and GSK3β. As shown in figure 77A, db/db 
mice had an increased phosphorylation of AKT and its downstream target GSK3β compared to 
WT mice. Upon GADD45β overexpression phospho-AKT levels were even higher in both db/db 
and WT animals. The same tendency is true for phospho-GSK3β. Phosphorylation of GSK3β 
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resulted in its inactivation and consequently to a reduction in its inhibitory effect on glycogen 
synthase and hence in the end promoting glycogen synthesis. This is in accordance with our 
observation of a reduction in blood glucose in db/db mice with GADD45β overexpression. 
 
Figure 77: Protein expression of AKT, GSK3β and FOXO1 and their phospho-proteins in db/db and 
WT mice after adenovirus administration. Male db/db and healthy control mice (WT) received the AD-
GADD45β OE or AD-NC, and after one week they were fasted for 24 hours before sacrifice. Levels of AKT, 
GSK3β and FOXO1 and their phospho-proteins were determined by immunoblotting using antibodies against 
the respective protein or the loading control (VCP). Shown are representative blots (A). The signal intensity 
was assessed by normalising the optical density (OD) first to VCP and then to total normalised protein (B). 
Mean ± SEM; n=3 per group; * genotype effect, # effect of GADD45β overexpression; (*) p ≤ 0.05, (**) p ≤ 
0.01, (***) p ≤ 0.001. 
 
Another downstream target of AKT, FOXO1, was not altered in its phosphorylation status, but in 
the levels of total protein (Fig. 77A). When examining the ratio of phosphorylated FOXO1 to total 
FOXO1, it seems that db/db mice had a higher FOXO1 phosphorylation status (Fig. 77B). 
Phosphorylation of FOXO1 decreases hepatic glucose production through a decrease in 
transcription of glucose 6-phosphatase. Indeed we could measure a decrease in glucose 6-
phosphatase mRNA expression in db/db mice with GADD45β overexpression (Fig 78). 
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Figure 78: Liver glucose 6-phosphatase expression in db/db 
and control mice after adenovirus administration. Male db/db 
or healthy control mice (WT) received the AD-GADD45β OE or 
AD-NC, and after one week they were fasted for 24 hours before 
sacrifice. Glucose 6-phosphatase (G6Pase) mRNA levels were 
analysed by RT-qPCR and shown as a fold induction relative to 
WT mice with AD-NC. Mean ± SEM; n=4-6 per group; * genotype 
effect, # effect of GADD45β overexpression; (*) p ≤ 0.05, (**) p ≤ 
0.01, (***) p ≤ 0.001. 
 
With the hint that GADD45β might have an effect on insulin signalling via AKT, the same targets 
were investigated in the HFD study with GADD45β WT and KO mice. Here we could not see an 
effect on the phosphorylation status of GSK3β or FOXO1 (Fig. 79C and F). The reason for the 
discrepancy might be that the db/db mice were sacrificed in the fasted state, whereas signalling in 
the GADD45β KO mice was examined in the fed state. The results are also difficult to compare 
since both studies were conducted with animal models possessing different etiological causes for 
their for obesity and insulin resistance. 
Furthermore, we could see a decrease in the protein levels of total IRS-1 in mice fed a HFD with 
no effect of genotype and no change in the phosphorylation status of the protein at Ser1101 (Fig. 
79A, H and I). Unfortunately it was not possible to get a signal for other phosphorylation sites 
such as S307 or T895. Additionally, p85 (the regulatory subunit of PI3K), a downstream target of 
IRS-1, was reduced in mice on HFD with no effect of genotype (Fig. 79A and J). In contrast to 
these findings, there was a slight increase in phospho-AKT at both phosphorylation sites (T308 
and S473) in mice on HFD (Fig. 79B, D and E) and no effect on GSK3β-phosphorylation (Fig. 
79C and F). However, a striking (4x) increase in S6K1-phosphorylation could be observed in 
GADD45β KO mice fed a HFD compared to all other groups (Fig. 79C and G). This is in 
accordance with other reports, wherein S6K1 activity was elevated in ob/ob and db/db mice and 
negatively regulated insulin signalling under conditions of nutrient satiation [273-275]. 
Taken together, the impact of GADD45β on insulin signalling when fed a HFD remains 
controversial. Total IRS-1 seems to be reduced when fed a HFD which was reflected by its 
downstream target PI3K. This could be an effect of increased insulin resistance. In GADD45β KO 
mice the levels of both proteins seemed to be even more reduced than in WT mice, although not 
significantly, which would fit to the observation that GADD45β KO animals were more insulin 
resistant than their WT littermates. Why AKT phosphorylation would be increased in livers of 
these mice remains speculative. It might be activated by another (unknown) kinase and not signal 
via GSK3β but via mTORC1 and S6K1. 
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Figure 79: Protein expression of IRS-1, p85, AKT, GSK3β, S6K1 and FOXO1 and their phospho-
proteins in GADD45β KO and WT mice on HFD or control diet. Male GADD45β KO and WT littermates 
were either fed a diet high in fat (HFD) or a matching control diet (NFD) for 16 weeks before sacrifice. Levels 
of IRS-1, p85, AKT, GSK3β, S6K1 and FOXO1 and their phospho-proteins were determined by 
immunoblotting using antibodies against the respective protein or the loading control (VCP). Shown are 
representative blots (A-C). The signal intensity was assessed by normalising the optical density (OD) first to 
VCP and then to total normalised protein (D-J). Mean ± SEM; n=6 per group; * genotype effect, # diet effect; 
(*) p ≤ 0.05, (**) p ≤ 0.01, (***) p ≤ 0.001. 
 
3.7 Does a hepatocyte-specific loss of GADD45β mimic the effects seen 
on lipid handling and insulin sensitivity? 
In the future our aim is to test whether a hepatocyte-specific deficiency in GADD45β function 
mimics the phenotype observed in whole-body GADD45β KO mice. Therefore we want to 
administer recombinant adeno-associated viruses (AAV) into C57Bl6/J mice and keep them on a 
HFD or NFD to induce insulin resistance. Unlike adenoviruses, these virus particles are not 
cleared by the host’s immune system and, unlike adenovirus, can therefore be used for long term 
studies [276]. The AAV serotype that was used (AAV2/8) was designed to preferentially infect 
hepatocytes. The viruses express a specific GADD45β miRNA or non-specific miRNA under the 
control of a hepatocyte-specific LP1 promoter which is not active in other liver cells such as 
Kupffer cells [240]. Planned are analyses of fasting blood glucose and serum insulin as performed 
before, but this time we want to sacrifice the animals in the fasted state to compare the results 
better with db/db mice and to see if they have a dysregulated systemic and liver lipid metabolism. 
3.7.1 The designed miRNA against GADD45β is functional in vitro 
The functionality of the designed miRNA had to be tested in vitro before AAV production and 
administration into animals. Therefore, the plasmids containing the GADD45β miRNA sequence 
(pcDNA6.2GW/EmGFP-miR mGadd45b) or the empty vector (pcDNA6.2/GWEmGFPmiR-NC) 
were separately transfected into Hepa1c1 cells together with a vehicle control, using 
Lipofectamine 2000 transfection reagent. 12 hours later the medium was changed either to 
normal culture medium (DMEM with additives) or to starvation medium (Hank’s buffered saline 
solution (HBSS) with additives) to induce GADD45β expression. Cells were harvested 8 hours 
later and the protein levels of GADD45β were assessed by immunoblotting. As shown in figure 
80, the addition of starvation medium resulted in a potent increase in GADD45β protein levels in 
cells transfected with the scrambled control vector and vehicle. Importantly, transfection of the 
cells with the plasmid containing the GADD45β miRNA sequence resulted in an efficient 
suppression of GADD45β induction. Since the miRNA sequence was functional, it was 
subsequently sub-cloned into the pdsAAV-LP1-EGFPmut AAV. The plasmids encoding the 
miRNA constructs were cotransfected into HEK293T cells with the pDGΔVP helper plasmid [277] 
and a mutated p5E18-VD2/8 expression vector encoding AAV2 rep and a mutated AAV8 cap 
protein [278]. The generated virus particles were purified via iodixanol gradient and titred for in 
vivo application. 
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Figure 80: Cloning of AAV miRNA expression 
construct for long term GADD45β knockdown. 
Hepa1c1 cells were transfected with plasmids 
containing a GADD45β miRNA sequence or a 
scrambled miRNA sequence (NC) or vehicle. 12 hours 
later the medium was changed either to normal culture 
medium (DMEM with additives) or to starvation 
medium (Hank’s buffered saline solution (HBSS) with 
additives) to induce GADD45β expression. Cells were 
harvested 8 hours later and the protein levels of 
GADD45β were assessed by immunoblotting using 
GADD45β -antibody and VCP-antibody as loading 
control. Results from 3 independent experiments are 
shown. 
 
3.7.2 A pilot study confirms that administration of AAV harbouring a GADD45β 
specific miRNA leads to efficient knockdown in vivo 
Before the planned study can be conducted the functionality of the produced AAV had to be 
verified in a pilot study. To test for the miRNA-mediated hepatocyte-specific knockdown of 
GADD45β, 2 x1011 virus particles per recombinant AAV were administered via tail vein injection 
into male C57Bl6/J mice. After three weeks on control diet, fasting was conducted for 24 hours 
before sacrifice. As shown in figure 81, efficient GADD45β knockdown in the liver could be 
achieved in three out of five animals. Since the hepatocyte-specificity of this virus system was 
described previously [242,279], no other tissues were analysed for GADD45β expression. 
          
Figure 81: AAV mediated GADD45β knockdown. AAV harbouring a plasmid containing the GADD45β 
miRNA sequence (GADD45β KD) or a scrambled control sequence (NC) were administered via tail vein 
injection into male C57Bl6/J mice. After three weeks mice were fasted for 24 hours before sacrifice. 
GADD45β mRNA levels were analysed subsequently by RT-qPCR and shown as a fold induction relative to 
“AAV NC” (A). The exact expression values are shown in (B). 
 
Since these results validated sufficient hepatic GADD45B knockdown, we initiated the loss-of-
function experiment inmale C57Bl6/J mice. One week later half of the animals switched to HFD. 
This study was ongoing at the time of preparation of this work. 
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4. DISCUSSION 
Given the increasing prevalence of obesity, insulin resistance and the metabolic syndrome 
worldwide, accompanied with a lack of successful treatment of these disorders beyond life style 
and diet interventions, the elucidation and understanding of the underlying and dysregulated 
mechanisms has become more and more crucial in order to identify novel targets and to allow for 
more promising interventions. This intention is particularly challenging since the above mentioned 
metabolic disorders are not characterised by one single pathway gone awry, but by several 
intertwined and misoperating systems on the intracellular, intercellular or inter-organ level. In the 
present work we describe for the first time a role for hepatic GADD45β in adaptive metabolism 
under the stress of food deprivation and nutrient overload. We uncovered GADD45β as a fasting-
induced gene, which is inflexibly regulated in different mouse models of obesity, diabetes and 
aging, as well as in diabetic patients. We propose that this induction is not under hormonal 
control, but due to sensing lack of nutrients. GADD45β is crucial for systemic and lipid 
metabolism, and its depletion is accompanied by decreased serum FA but increased liver TG 
upon starvation. On the other hand, we have evidence that GADD45β is also important for 
glucose homeostasis. In particular, GADD45β KO mice on HFD are more insulin resistant, and 
exogenous overexpression can improve the diabetic phenotype in mice. We conclude that 
GADD45β might be a new link between lipotoxicity and development of insulin resistance through 
exerting a protective role during increased fatty acid supply either in fasting states or during 
obesity. However, the mechanism(s) through which GADD45β mediates its effects remains 
unclear. 
4.1 Fasting-induced hepatic GADD45β induction might be due to lack of 
nutrients 
GADD45 proteins are induced by several environmental and physiological stresses such as 
methyl methanesulfonate (MMS), γ-radiation, ultra violet light, and inflammatory cytokines (see 
suppl. table 1 for further information). Thus far only mouse GADD45α has been reported to be 
induced upon the stress of fasting leading to muscle atrophy [231]. In Drosophila, D-GADD45, an 
orthologue for mouse GADD45α, is slightly induced upon starvation, and overexpression in the 
nervous system led to an increased resistance to starvation [210]. In the present study we show a 
potent (> 10-fold) induction of liver GADD45β upon food withdrawal in C57Bl6/J mice (Fig.15). 
This increase in expression confirms other reports in which, using RNAseq and gene chip arrays, 
GADD45β was revealed to be one of the most heavily induced genes during starvation [280-282]. 
In the work at hand we showed this induction was blunted in diabetic and obese mice (Fig. 15). 
We could also demonstrate that the induction upon fasting followed a time course and was 
reversible after refeeding (Fig. 17). Furthermore, of the metabolic tissues examined, the induction 
was limited to the liver (Fig. 18) specifically to hepatocytes (Fig. 20), and was not accompanied by 
a compensatory increase of other GADD45 family members (Fig. 31). In order to examine which 
stimulus (e.g. hormone, cytokine, nutrient availability) was responsible for the increase in 
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GADD45β, several ex vivo and in vitro experiments were performed. Primary hepatocytes showed 
a slight (not even 1,5-fold, but significant) induction of Gadd45b only after treating them with 
AICAR, an analogue of AMP that is capable of stimulating AMP-dependent protein kinase 
(AMPK) activity (Fig. 22). AMPK is known to be activated during nutrient deprivation leading to 
induction of energy-producing, catabolic pathways [249]. Interestingly, Gadd45b expression was 
not stimulated upon insulin or TNFα treatment, which is in contrast to other reports [156,235]. 
However, in the study where insulin treatment caused an increase in Gadd45b mRNA levels, Rat 
H4-IIE hepatoma cells were used, and the induction of Gadd45b was relatively mild (2-3-fold). 
The observation that Gadd45b mRNA levels are stimulated upon nutrient deprivation could further 
be confirmed in a differentiated, non-transformed hepatocyte cell line (AML12; Fig. 21). 
Interestingly, Gadd45b was only induced when all nutrients were reduced to 1 % of their original 
concentration. Omission of a single nutrient, such as glucose or lipids, or two nutrients of a 
specific class, such as glucose and pyruvate, did not change the expression level. This is in 
contrast to another publication where microarray expression profiling of amino acid deprived 
HepG2 human hepatoma cells displayed GADD45β among the upregulated genes [283]. 
However, this effect could also be attributed to the tumorigenic properties of this cell line. On the 
other hand, this report is confirming our hypothesis that GADD45β levels are driven by an 
upstream sensor of nutrient deprivation than a hormonal stimulus or cytokine. 
The experiments performed with AML12 cells bear several points for criticism. First of all, more 
experiments could have been done to confirm that it is the lack of a combination of nutrients, 
which is responsible for Gadd45b induction. For example, one could have used a medium with all 
nutrients being reduced to 1 % of their original concentration, and then each nutrient could have 
been added back individually. Also, different combinations of nutrients could have been left out of 
the medium, not only ones of a specific class. 
Furthermore, one has to question how meaningful and physiologically relevant the experiments 
with AML12 cells are. Even though the cells are not transformed and non-tumourigenic, they are 
derived from livers of transgenic mice overexpressing transforming growth factor α (TGFα) [248] 
which overcomes growth and replicating restrictions, so they do not stop replicating in contrast to 
primary hepatocytes. Thus, they are a more artificial system than primary hepatocytes, liver slices 
or the mouse per se. Hence, similar experiments should be repeated in those systems. In 
addition, the blood from fasted animals does not reflect the DMEM/F-12 with deprived nutrients 
we used in our experiment. Fasting blood has a different composition than fed blood, and also 
than AML12 medium. In our in vitro model we assumed that all nutrients are low or that only 
special compounds were missing which is not the case in fasting blood. In the end, to find the 
stimulus responsible for Gadd45b induction one should compare serum from fasted and fed mice 
and treat primary hepatocytes with those.  
Taken together, the conducted experiments gave a first indication that GADD45β induction upon 
fasting might not be mediated by a hormone or cytokine (at least not by those we tested) but 
rather by the lack of nutrients. However, it is noteworthy, that we did not address the involvement 
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of transcription factors as a potential mediator of GADD45β induction. It is reported that several 
transcription factors and coactivators are involved in the starvation response and energy 
metabolism, such as PPARα [284], FXR [285], CAR [286], PGC-1α [287] and Nrf2 [288] and 
potentially could be involved in the induction of GADD45β expression. On the other side, owing to 
their LXXL-motif, GADD45 proteins are described to interact with several nuclear hormone 
receptors including RXRα, ERα, PPARα/β/γ and act as nuclear receptor coactivators in vitro 
[202,205]. Thus, it would be interesting to test whether GADD45β activity can be modulated by 
binding to nuclear receptors and whether these interactions are increased during starvation (see 
outlook section for possible experiments to assess protein-protein interactions). 
4.2 GADD45β is required to maintain systemic and hepatic lipid 
metabolism 
One central player in metabolic diseases is nutritional fat, and many proposed causes for obesity 
and insulin resistance (e.g. chronic inflammation [289], endoplasmic reticulum stress [37], 
mitochondrial dysfunction [290,291], oxidative stress [292], dysregulated signalling pathways 
[35,124]) are themselves the cause or consequence of ectopic lipid accumulation [27]. Lipid 
accumulation leads to stress, wherein the cell or organ has to activate defence mechanisms in 
order to maintain its functionality. Starvation is the opposite extreme of obesity, but also here the 
liver and other metabolically active organs have to adapt to the situation by altering their anabolic 
and catabolic pathways. Similarly to the obese state, during fasting fatty acids are released from 
the adipose tissue and are taken up by the liver where they are used to generate energy. As a 
consequence serum NEFA and ketone bodies levels rise. On the other hand, prolonged fasting is 
accompanied with accumulation of TG in the liver.  
We could confirm these fasting phenotypes in C57Bl6/J mice. The mice lost weight (Fig. 26A), 
had reduced blood glucose levels, and showed an increase in serum ketone bodies and NEFA 
concentrations (Fig. 27). Also, serum TG and glycerol levels rose as expected due to lipid 
mobilisation from adipose tissues (Fig. 27). Most interestingly, whole-body GADD45β KO 
disturbed this adaption to starvation. GADD45β KO mice showed a blunted increase in serum 
NEFA levels (Fig. 27A), and, most strikingly, accumulated more TG in their livers than WT 
littermates (Fig. 28A) while their fat and liver weights did not show an effect of genotype (Fig. 
26B). In stressing this phenotype further by feeding mice a MCD diet, which leads to steatosis 
and liver damage, we could recapitulate the observed effect. GADD45β KO mice accumulated 
more fat (NEFA, TG, glycerol and cholesterol) in their livers (Fig. 42) and showed a higher degree 
of liver damage compared to WT mice (Fig. 41E), while serum parameters did not differ between 
genotypes (Fig. 41). In fasted diabetic humans and db/db mice a reduction in liver GADD45β 
expression was associated with an augmentation of serum TG levels in human (Fig. 46A) and a 
blunted increase of serum NEFA in db/db mice (like in GADD45β KO mice) (see Dr. Roldan de 
Guia’s PhD thesis for further detail). Furthermore, we could observe similar effects on some 
serum and liver parameters in aged mice as seen in GADD45β KO and db/db mice (see Astrid 
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Wendler’s Master’s report for further detail). On the other hand, we could show that an exogenous 
overexpression of hepatic GADD45β in whole-body GADD45β KO mice could partially reverse 
their dysregulated fasting phenotype; liver NEFA and TG concentrations could be reduced (Fig. 
63).  
The open question that needs to be answered is how GADD45β mediates its effect on lipid 
homeostasis. One possibility might be by influencing the transcription of downstream target 
genes, since GADD45β has been described to be a transcriptional coactivator [205]. To address 
this possibility we submitted liver RNA samples of fasted GADD45β KO and WT mice to the 
Genomics Core facility at the DKFZ for RNAseq analysis, and also measured the mRNA levels of 
different genes involved in detoxification (Cyp2b10), drug transport (Slco1a1), FA uptake (CD36) 
and FA metabolism (Acly, Cyp4a14, Fasn, Acc1). In both analyses the effect of GADD45β 
deletion on differentially expressed genes was inconsistent and only mild (Fig. 71 and 73), and 
could not be rescued by liver-specific overexpression of GADD45β (Fig. 72 and 74). As a 
consequence, we conclude that GADD45β might not mediate its influence on lipid metabolism by 
transcriptional regulation. As the tested genes involved in FA transport and synthesis were not 
commonly dysregulated upon GADD45β depletion, it seems that, at least on mRNA level, 
GADD45β has no impact on these aspects of lipid homeostasis. The RNAseq results also do not 
point to this direction; the DAVID enrichment analysis did not reveal an effect on FA metabolism 
pathways (Suppl. Figure 1). 
Lipid accumulation, as we observed it in GADD45β KO mice, occurs when the rate of FA uptake 
and de novo lipogenesis is greater than the rate of FA oxidation or FA export in form of TG in 
lipoproteins. This is happing not only in the obese state under nutrient over load, but also during 
prolonged fasting. Thus, GADD45β could in principle act on any of those aspects. In the fasted 
state, de novo lipogenesis of FA is suppressed, and indeed we could not see an effect of 
GADD45β KO on genes involved in FA synthesis (Acly, Cyp4a14, Fasn, Acc1) (Fig. 71). 
Additionally, as mentioned above, we doubt that FA uptake is affected by GADD45β deletion (at 
least on CD36 mRNA level which was initially reduced in GADD45β KO mice, but could not be 
recapitulated with GADD45β overexpression. Anyway, a reduction in hepatic CD36 would not 
have resulted in increased liver accumulation [293,294]). We could also show that FA oxidation is 
not altered in GADD45β KO mice as neither the RER (Fig. 32) nor the formation of ketone bodies 
(Fig. 27E) or acylcarnitines (Fig. 30) were different between the genotypes. Some possible 
explanations why GADD45β KO mice showed a blunted increase in serum NEFA levels (Fig. 
27A) and an accumulation of TG in the liver (Fig. 28A) could be that either the esterification of 
NEFA into TG (biosynthesis of TG) was affected, or that the export of FA in form of VLDL-
particles was impaired. The latter is true when mice are fed the MCD diet. Feeding GADD45β KO 
and WT mice a MCD diet for three weeks led to an expected accumulation of liver lipids (Fig. 42) 
and liver damage (Fig. 41E) together with a decrease in serum TG and cholesterol levels, with 
GADD45β KO mice showing a more severe phenotype (Fig. 41). However, this study does not 
exclude the possibly of a concurrent impact of GADD45β on the esterification of FA. Also, fasted 
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GADD45β KO and WT mice showed a slight increase in serum TG concentrations upon fasting 
(Fig. 27B) which is not in favour with the possibility of an impaired TG release. Thus, our 
experiments do not solve the question whether GADD45β KO influences FA conversion into TG 
or whether it affects FA export. One possibility to address this issue is to track FA in GADD45β 
KO and WT mice to determine their fate. More specifically, one could perfuse livers of fed and 
fasted GADD45β KO and WT littermates with radioactive labelled oleate (monounsaturated FA) or 
palmitate (saturated FA) and examine whether their carbons accumulate in the liver as 
intermediates of the esterification pathway (e.g. 1-acylglycerol phosphate, phosphatidate, 1,2-
diacylglycerol) or as triglycerides. Furthermore, one could inhibit β-oxidation in the fed and fasted 
state by (+)-decanoylcarnitine, an inhibitor of long chain acylcarnitine transferase [295], or by 
PPARα antogonists [296] such as GW6471 [297] or MK886 [298], and examine whether 
GADD45β WT mice have an advantage compared to their KO littermates in handling the 
increased flux through esterification. The same experiment could also be done combined with 
feeding a MCD diet. Furthermore, we were critical about an impact of GADD45β on FA uptake 
since we could not see an effect of GADD45β KO on CD36 mRNA level. However, it might also 
be that GADD45β interacts with CD36 on protein level to modulate its activity. Furthermore, CD36 
is not the only protein responsible for FA uptake. We did not assess whether fatty acid binding 
protein 4 (FABP4) or FA transport protein (FATP) are affected [299]. Also, acyl-CoA synthetase 
(ACS) enhances the uptake of FA by catalysing their activation to acyl-CoA esters. All proteins 
have been shown to positively relate to liver fat content [300,301]. Hence, an increase in the flux 
of peripherally derived FA to the liver might still occur and has to be considered as an underlying 
mechanism for GADD45β KO-mediated TG accumulation. Measuring the potential of FA uptake 
in isolated primary hepatocytes from GADD45β KO and WT animals, as well as ACS activity 
assays [301], might give insight of the impact of GADD45β on FA uptake. Moreover, an oral lipid 
tolerance test is a possibility to determine whether GADD45β KO and WT show difference in 
handling and clearance of excess lipids in the circulation through the liver, which is described to 
be the major site of TG removal under normal conditions [302,303]. Indeed, fasted GADD45β KO 
mice showed an enhanced clearance of either TG or NEFA after injecting a lipid mixture 
compared to WT littermates, which is reflected by lower serum TG levels throughout the test (data 
not shown). 
Triglycerides are stored in lipid droplets within hepatocytes. These lipid droplets are structurally 
similar to circulating lipoproteins. Lipid droplet-associated proteins are involved in the formation, 
maturation, secretion, and trafficking of lipid droplets and participate in both lipolysis and 
lipogenesis [304]. Growing evidence has shown that lipid droplet proteins play a role in the 
pathophysiology in the fatty liver disease [305,306]. As such, lipid storage droplet protein 5 
(LSDP5) has been shown to enhance lipid accumulation in AML12 cells and primary hepatocytes 
[307], and perilipin (PLIN) gene expression was positively correlated with liver fat content [300]. 
Hence, it would be interesting to examine whether GADD45β plays a role in assembling lipid 
droplet formation, thereby exerting its effect on lipid accumulation. For this purpose, lipid droplet-
associated proteins can be detected via Western Blotting or immunohistochemistry. 
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The endoplasmic reticulum (ER) plays not only an import role for the coordinated synthesis, 
folding and trafficking of proteins, but also for the biosynthesis of TG and cholesterol and the 
assembly of VLDL particles. It has been shown that ER stress leads to an increase of CCAAT-
enhancer-binding protein (C/EBP) [308] and sterol regulatory element-binding protein (SREBP-1) 
[309], which in turn is responsible for cholesterol and TG uptake and biosynthesis, and hence for 
lipid accumulation in the liver. It is reported, that this increase in lipid biosynthesis in 
hyperhomocysteinaemia-induced ER stress is not accompanied by a defect of VLDL release, but 
that TG and cholesterol export are rather increased [310]. This study suggests that hepatic 
steatosis is not due to impaired lipid export, but instead results from increased lipid biosynthesis 
and uptake. On the other hand, mice with hepatocyte-specific deletion of inositol-requiring 
enzyme 1 α (IRE1α), which has an important role in preventing ER stress, have enhanced hepatic 
steatosis and reduced plasma lipids due to suppressed apoB-containing lipoprotein secretion 
[311]. We could show a slight increase of serum TG upon fasting with no difference in genotype 
(Fig. 27B) suggesting that lipid export was not affected. To confirm that TG originates from the 
liver one can perform a TG secretion rate assay. Thereby, fasted mice are injected with Triton 
WR1339. Since Triton WR1339 blocks conversion of VLDL to LDL, the resulting increase in 
plasma triglyceride and cholesterol concentrations reflect hepatic secretion of VLDL in the 
absence of LDL uptake [312,313]. Importantly, it has been shown that GADD45β is induced upon 
ER stress [314], thereby providing a link to enhanced lipid accumulation in GADD45β KO mice. 
Thus, one might assess if ER stress is involved in the observed effect of our work. Therefore one 
might overexpress the ER chaperone GRP78/BiP and examine whether ER stress and GADD45β 
KO-mediated lipid accumulation is reduced. Overexpression of GRP78/BiP has been reported to 
protect cells from ER stress [315]. Also, ER ultrastructure in GADD45β KO and WT mice could be 
assessed by electron microscopy. 
Recently it has been described that GADD45β can inhibit autophagy [228,229]. Autophagy in turn 
can regulate lipid stores and metabolism in the liver by a mechanism called lipophagy [316]. 
Hereby TG and cholesterol are taken up by autophagosomes and delivered to lysosomes for 
degradation resulting in FA generation which can be used for energy production via β-oxidation 
[317]. Thus, lipophagy is crucial for maintaining lipid and energy homeostasis, and a decrease in 
lipophagy is involved in the development of steatosis. Furthermore, a function for autophagy in 
mediating hepatocyte resistance to death from oxidative stress [318] and in pro-survival pathways 
has been described [319,320]. Obesity is characterised by a decrease in hepatic autophagy. The 
underlying mechanism are not completely solved but might include a reduction of autophagy 
factors (ATF) or impaired fusion of autophagosomes and lysosomes, both leading to decreased 
autophagy. Furthermore, the accumulation of hepatic fat is accompanied by increased levels of 
saturated long-chain fatty acids, which can cause lipotoxicty [321] with the result that lipophagy 
and subsequent β-oxidation are reduced, levels of saturated long-chain fatty acids are increased 
and apoptosis is eventually triggered. GADD45β might be involved in those chains of events. 
Since GADD45β is a stress-induced gene and reported to be induced upon palmitic acid 
treatment in human hepatoma cells (HepG2) [322], it might be induced upon lipotoxicity. 
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GADD45β inhibits autophagy by preventing the fusion of autophagosomes with lysosomes [229]. 
Thus, the induction of GADD45β through obesity-mediated lipotoxicity might reduce lipophagy 
and in the end trigger apoptosis. In this regard apoptosis might be a protective mechanism 
against an excess of saturated long-chain fatty acids. On the other hand this hypothesis stands in 
contrast to the involvement of apoptosis in the development of insulin resistance [132-135] and 
our observation that liver-specific overexpression of GADD45β ameliorates the diabetic 
phenotype of db/db mice. It also does not explain why GADD45β KO mice accumulate more fat in 
the liver as autophagy should be increased with GADD45β KO, and why we can reduce liver 
NEFA and TG contents upon liver-specific GADD45β overexpression. Furthermore, detecting 
delipidated ATG5 [229] by immunoblotting in the fasted state did not reveal any change between 
the genotypes (data not shown), indicating unaltered regulation of autophagy during fasting in 
GADD45β KO mice. Taken together, the question is still open whether GADD45β-mediated 
inhibition of autophagy is involved in the observed effects of GADD45β on lipid metabolism. 
Staining for autophagosomes and assays to assess apoptosis (e.g. tunel staining [323], caspase 
activity assays) could help to clarify this issue. 
GADD45β might be involved in the adaptive handling of FA supply through another mechanism. 
GADD45 proteins are involved in p53-mediated apoptosis by being p53-regulated [166,167] and 
also by contributing to p53 activation via p38 [169]. P53 is activated under stress situations by 
p38 and other mitogen-activated protein kinases (MAPK) (e.g. JNK, ERK) through 
phosphorylation of p53 at its N-terminus, which decreases the binding of p53 to mouse double 
minute 2 homolog (MDM2), resulting in protein stabilisation and accumulation [324-326]. 
Evidence has accumulated that p53 is not only involved in apoptosis, cell cycle arrest and DNA 
repair, but also has essential functions of metabolic control by various metabolic pathways 
[327,328]. These functions are important in the context of preventing development of cancer, but 
also in responding to metabolic stresses, thereby having profound roles in the development of 
metabolic diseases. One of these functions is the adaptation to food deprivation. Recently, it has 
been shown that the MDM2-p53 pathway controls fatty acid oxidation during starvation. In this 
study, fasting-induced p53 activation led to increased malonyl CoA decarboxylase (MCD) 
expression, which stimulates malonyl-CoA breakdown and facilitates the transport of FA into the 
mitochondrial matrix for β-oxidation through enhanced carnitine palmitoyl transferase (CPT1α) 
activity [329]. These events would be attenuated in our GADD45β KO model due to a decreased 
activation of p53, consequently leading to reduced FA oxidation but biosynthesis of TG, thereby 
giving an explanation for the accumulation of TG in the livers of GADD45β KO mice under fasting 
conditions (Fig. 28A). Although we did not observe a difference in FA oxidation between 
GADD45β KO and WT mice, it might be worthy to test if the described events play a role in the 
context of GADD45β deletion. For this purpose, one might determine the activity 
(phosphorylation) status of p53 by immunoblotting, determine the location of p53 in the cell (it is 
described to be transported from the nucleus to the cytosol when inactive where it gets degraded 
[330]) and measure the activity of CPT1α as previously described elsewhere [331]. Furthermore, 
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one might assess the contribution of FA oxidation and TG synthesis in GADD45β KO and WT 
mice by determining the ratio of acetyl-CoA and malonyl CoA via enzymatic-colorimetric assays 
[332,333]. Of note, the mentioned study was performed after food withdrawal. However, it is not 
clear if the same chain of events play a role in FA oversupply during obesity, and the role of p53 
in the adaptive response to FA overload is controversial [331]. 
One alternative reason why serum NEFA are reduced in GADD45β KO mice upon fasting might 
be a decrease in lipolysis in adipose tissue and hence a reduced transport of FA to the liver. But 
since we did not observe a change in fat pat weight [334] (Fig. 26B), we are critical about this 
possibility. We emphasise that the action of GADD45β is intrinsic to hepatocytes since we could 
partially rescue the dysregulated lipid phenotype by overexpressing GADD45β in the liver (Fig. 
63). Also, we did not observe a drop in in oxygen consumption (Fig. 32), muscle mass (Fig. 26B) 
and ketone body production (Fig. 27E), or increase in RER (Fig. 32) which might indicate that the 
fasted mouse had to use other nutrient such as proteins for energy production [335]. To further 
confirm that TG lipolysis is not altered in GADD45β KO mice one could isolate fat pads from 
GADD45β KO and WT mice and measure the lipolysis rate (concentrations of NEFA and glycerol) 
in the presence or absence of the lipolysis stimulant forskolin or a synthetic catecholamine (e.g. 
isoproterenol). Since adipose triglyceride lipase (ATGL) and hormone-sensitive lipase (HSL) are 
the major enzymes in adipose tissue TG catabolism [336], measurement of their TG hydrolase 
activity with radioactive labelled substrates could additionally be performed. 
Taken together, we believe that GADD45β may not mediate its effect by transcriptional regulation. 
From our experiments we conclude, that GADD45β plays a crucial role in hepatic adaptation to 
changes in FA supply. This function is probably carried out on the site of FA conversion into TG 
rather than on FA synthesis, oxidation or export. Its involvement in FA uptake is still unclear. 
Further experiments should be performed to confirm these suggestions and to assess the role of 
the ER and/or apoptosis as link between GADD45β and lipid homeostasis. 
4.3 GADD45β is required to maintain glucose homeostasis 
The liver is a crucial organ for whole body energy homeostasis, not only in regulating the use and 
fate of lipid species, but also by regulating glucose turnover. In times of energy demand, the liver 
converts fat and polycarbohydrates into glucose, whereas in times of energy oversupply, it 
converts glucose into polycarbohydrates and fat. This reciprocal mechanism is disturbed in 
obesity and insulin resistance, which is characterised by a failure to suppress hepatic glucose 
production and FA efflux from adipose tissue, with the consequence that plasma FA and glucose 
levels are constantly high and lipids accumulate in the liver. 
We could confirm most of these obesity-induced phenotypes by feeding C57Bl6/J mice a diet rich 
in fat (HFD) for four months. Those mice were hyperglycaemic (Fig. 49A) and had a fatty liver 
(higher NEFA, TG and cholesterol) (Fig. 51). However, serum NEFA levels were reduced and TG 
levels did not change on HFD; only serum cholesterol was elevated as expected in a 
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dyslipidaemic state [103] (Fig. 50). Furthermore we could show that those mice were insulin 
resistant (Fig. 53). Most importantly, GADD45β KO mice were more insulin resistant after 4 
months on HFD than their WT littermates as reflected by a bigger area under the curve during an 
insulin tolerance test (Fig. 53C) and a higher HOMA-IR (Fig. 54C). Moreover, a reduction in liver 
GADD45B was negatively correlated with fasting plasma glucose levels in men (as well with a 
tendency for higher HOMA-IR, p=0,099) (Fig. 46). We could also confirm the diabetic phenotype 
of db/db mice. In the fed state they had a 2,5x higher blood glucose level than WT mice. During 
fasting their blood glucose levels fell, as they did in healthy control animals, but they stayed 
significant higher (~1,5x) (see Dr. Roldan de Guia’s PhD thesis for further detail). Furthermore, 
those diabetic animals have immense lipid accumulation in their livers (Fig. 45), and upon fasting 
there were similar effects on serum NEFA levels as seen in GADD45β KO mice (blunted 
increase) (see Dr. Roldan de Guia’s PhD thesis for further detail). Most importantly, we were able 
to reduce the diabetic phenotype of db/db mice by liver-specific overexpression of GADD45β (Fig. 
67 and 68). Thereby we could also partially restore the dysregulated systemic lipid metabolism in 
db/db mice and confer higher metabolic flexibility upon nutrient deprivation (Fig. 69). 
Of importance, we could not see a difference in glucose homeostasis between GADD45β KO and 
WT mice after being starved, a situation when the liver is also encountered with an increased flux 
of FA. Here, GADD45β KO mice accumulated more TG in the liver than WT mice (Fig. 28A), but 
they had equal fasting blood glucose values and were not hyperglycaemic (Fig. 27F). We could 
only observe an effect on glucose metabolism under the condition of long-lasting nutrient 
oversupply, and then only in the context of a loss of function (on HFD) or in the context of a gain 
of function of GADD45β (in db/db mice). GADD45β might not have a direct effect on glucose 
metabolism, but only confers its influence on lipid homeostasis on insulin resistance during times 
of nutrient spillover, thereby exerting an indirect influence on glucose homeostasis. 
The major metabolic tissues (brain, liver, muscle, fat, pancreas, intestine, kidneys) work together 
to maintain glucose homeostasis during the fasting-feeding cycle of healthy organisms [337]. 
Thereby, systemic glucose concentrations are a result of glucose uptake by the liver and other 
peripheral tissues and by glucose production by the liver and other gluconeogenic organs such as 
the kidney [338] and intestine [339]. In times of nutrient oversupply, when high glucose levels 
result in high insulin concentrations, glucose uptake by the muscle and liver is promoted leading 
to the biosynthesis of glycogen and fat. In the insulin resistant state, however, insulin-mediated 
skeletal muscle glucose uptake is impaired, which leads to a redirecting of glucose to the liver and 
a production of more liver fat [35]. These hepatic liver lipids also impair the ability of insulin to 
suppress glucose production, leading to a hyperglycaemic state. Similar to the regulation of 
hepatic lipid content, GADD45β can exert its effect on glucose homeostasis either on glucose 
production or/and on glucose clearance from the system. We propose that GADD45β mediates its 
advantageous effect through the liver, either by a direct intrinsic effect in the liver, or by indirect 
effects from the liver to other organs (for example via hepatokines [117,118]), since we could 
rescue the diabetic phenotype by liver-specific overexpression of GADD45β (Fig. 67 and 68). 
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However, we cannot confirm with certainty that either the improved glucose clearance or the 
reduced glucose production is the underlying mechanism. If clearance of blood glucose by the 
liver was augmented by GADD45β overexpression, then this would lead to a higher conversion 
rate into TG (after glycogen stores are full), but we did not see an accumulation of liver TG 
accompanied with reduction of blood glucose levels (Fig. 70). Conversely, in db/db mice 
GADD45β overexpression might improve insulin’s ability to suppress glucose production, thereby 
leading to lower blood glucose levels and as a consequence also lower insulin levels, which is all 
together reflected by a reduction in insulin resistance. In GADD45β KO animals, insulin’s ability to 
supress glucose is impaired resulting in more severe insulin resistance under HFD conditions. 
Thus, we think that an effect on glucose production is more likely to be the site of action by which 
GADD45β exerts its influence. However, more studies have to be conducted in order to confirm 
this presumption. One might perform glucose uptake assays on isolated muscle or liver tissues to 
assess the contribution of glucose uptake on our phenotype. In muscle, 2-deoxyglucose can be 
used for this purpose. Glucose hexokinase phosphorylates 2-deoxyglucose, thereby trapping the 
product, 2-deoxyglucose-6-phosphate, intracellular since it cannot be further used for glycolysis 
nor converted back to 2-deoxyglucose. In the liver however, this latter case can happen, since the 
liver expresses glucose-6-phosphatase (G6Pase), and glucose can be released from the cell 
again. Hence for the liver, one needs to perform more sophisticated tracer studies [340] in order 
to determine the affected sites of altered glucose metabolism. Furthermore, in the context of 
investigating the liver glucose production rate, it would be interesting to determine whether 
GADD45β KO mice show a different reaction following a pyruvate challenge in the course of a 
pyruvate tolerance test. Moreover, in a glucose output assay one might measure the ability of 
primary hepatocytes from fasted GADD45β KO and WT mice to convert lactate or pyruvate into 
glucose with or without insulin treatment. 
We could show that GADD45β overexpression in db/db mice lead to an increase in AKT 
phosphorylation and its downstream target GSK3β (Fig. 77), indicating a promotion of glycogen 
synthesis and increase in liver glucose uptake rate. Consistent with this result, also FOXO1 
phosphorylation status was increased (Fig. 77) leading to an inhibition of its downstream target 
G6Pase (Fig. 78), which is a key enzyme for gluconeogenesis. Unfortunately we could not see a 
similar suppression of another key gluconeogenic gene, phosphoenolpyruvate carboxykinase 1 
(PCK1, data not shown); its expression was lower in db/db mice independent of GADD45β 
overexpression. Hence, more experiments and analyses should be performed in order to confirm 
an impact of GADD45β on AKT downstream targets for glucose production and glycogen 
synthesis. First, glycogen contents in db/db and WT mice upon GADD45β overexpression should 
be assessed. Also, while we showed increased phosphorylation of GSK3β, we did not measure 
the phosphorylation status of its downstream target glycogen synthase, which should be 
increased. Also, one might test whether the activity of another AKT downstream target and 
important transcriptional coactivator involved in gluconeogenesis is inhibited, that of peroxisome 
proliferator-activated receptor-γ coactivator 1 (PGC-1) [287,341]. PGC-1 needs FOXO1 for its 
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gluconeogenic function [342], but FOXO1-phosphorylation status was increased and hence the 
protein degraded.  
Considering only the study where GADD45β overexpression in db/db mice led to an improvement 
of their diabetic phenotype, one might conclude that GADD45β has an impact on the insulin 
signalling pathway, thereby improving insulin‘s ability to supress glucose production. 
Unfortunately, we could not recapitulate this effect on the insulin signalling pathway with 
GADD45β KO mice on HFD. Here we could not see an effect on the phosphorylation status of 
GSK3β or FOXO1 (Fig. 79). On the contrary, AKT phosphorylation seems to be increased on 
HFD with no effect of genotype (Fig. 79), while its upstream effectors show reduced 
phosphorylation with no difference between GADD45β KO and WT mice (Fig. 79). This 
observation raises doubt about an impact of GADD45β on the insulin pathway to mediate its 
effect on glucose output. It rather goes in line with other theories that insulin’s ability to suppress 
hepatic glucose output does not require the canonical insulin signalling pathway [88,89] or AKT as 
an obligate intermediate for proper insulin signalling [262]. It is noteworthy, that those non-
canonical pathways might be only obvious in the hyperinsulinaemic or fed state, which was the 
case in our HFD study. The db/db experiment in contrast was analysed under fasted conditions. 
Surprisingly, we did not find the stress-activated c-Jun amino-terminal kinase (JNK) to be involved 
in GADD45β’s effect on glucose homeostasis (Fig. 75 and 76). However, JNK proteins play an 
important role in metabolism and are involved in the development of obesity, insulin resistance 
and T2D by having a direct effect on glucose metabolism and insulin sensitivity [237,272,343]. 
JNK is activated in signal transduction under conditions of obesity and insulin resistance by 
several effectors, among them TNFα inducing upstream MAP3K [344,345], reactive oxygen 
species (ROS) [346], IRE1 during UPR in the ER [37,347], and free FA [345], all leading to dual 
phosphorylation of JNK by MKK4 and MKK7, which results in phosphorylation of downstream 
transcription factors of JNK such as c-Jun or effector proteins such as insulin receptor substrate 
(IRS) [344]. Thus, many paths lead to one outcome: JNK activation and blockage of insulin 
signalling in a tissue specific-manner. As a consequence, we would have expected JNK levels in 
animals on HFD or db/db mice to be higher than in animals on control diet or WT mice. This was 
indeed the case for db/db mice (Fig. 76), but mice on HFD showed no significant difference 
compared to mice on NFD, if anything then the tendency was to have a lower phospho-JNK 
status (Fig. 75). But then we did not see an effect of genotype on HFD and no effect of GADD45β 
overexpression in db/db and WT mice. It has to be emphasised that GADD45β exerts its impact 
on JNK activity on two different routes: activation via MEKK4 [165] and inhibition via MKK4/7 
[152,199,348]. We cannot distinguish between the two pathways in our experiments. One might 
say HFD and obesity are severe conditions and therefore GADD45β would act via MEKK4JNK 
[169]. GADD45β KO would then lead to a reduction in JNK activity and overexpression to an 
increase in phospho-JNK. We could not see either of both outcomes. On the other hand one 
might argue that HFD and obesity are characterised by high TNFα levels (which we did not 
measure to confirm!) and hence JNK levels are high, which we could confirm in db/db mice but 
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not in mice on HFD. GADD45β can be induced by TNFα and acts in a feedback loop to inhibit 
JNK [171,172]. Thus, GADD45β KO should lead to higher and overexpression to lower JNK 
activity which we could not observe in either of or two studies. Thus, the inconsistency of our 
results with the literature and the unknown underlying pathways in our models to induce or inhibit 
JNK led us to the conclusion that the JNK pathway is not involved in the GADD45β-mediated 
effect on glucose homeostasis. 
One striking effect of GADD45β KO mice fed a HFD was the 4-fold increase in ribosomal protein 
S6 kinase 1 (S6K1) activity compared to all other groups, even to WT mice fed a HFD (Fig. 79G). 
S6K1 is an effector of mTOR and sensitive to both insulin and nutrients, including amino acids, 
and the activity of this protein leads to an increase in protein synthesis and cell proliferation. It is 
induced by insulin via a canonical pathway including class I PI3KAKTmTOR, as well as by 
amino acids via a non-canonical pathway including class III PI3KmTOR which might explain 
why it is induced even though total IRS-1 protein is reduced in GADD45β KO mice fed a HFD 
(Fig. 79H). It is reported that S6K1 activity negatively regulates insulin signalling under conditions 
of nutrient oversupply [273-275] through negatively regulating IRS1 function via phosphorylation 
at different residues such as Ser207, Ser1101 and Ser307 [349,350], whereas the physiological 
relevance of latter phosphorylation site is under debate [351,352]. So it is surprising that we could 
not see an increase of phospho(T389)-S6K1 in WT animals fed a HFD, but the deletion of 
GADD45β triggered some unknown event resulting in a strong upregulation of phospho(T389)-
S6K1. As mentioned it is induced upon amino acid overload, which naturally comes along with 
nutrient excess. There is increasing evidence that elevated dietary protein consumption also 
contributes to metabolic abnormalities [353-356], which may act through the mTORC1-S6K1 
pathway. However, our HFD does not differ in protein content to the control diet and we could not 
see an effect on the serum amino acid profile (Fig. 55). Moreover, IRS-1 phosphorylation on 
Ser1101 was not increased in GADD45β KO mice on HFD (Fig. 79I). Hence, more research has 
to be done to define the cause-effect relationship between GADD45β and S6K1 and which 
downstream effects are involved with this potent GADD45β KO-mediated upregulation. For that, 
other possible phosphorylation sites of IRS-1 other than Ser1101 have to be examined. In this 
context, it has been described that S6K1 mediates IRS1 serine phosphorylation, disrupting its 
interaction with the insulin receptor and leading to its degradation [357,358]. This would support 
our observations of a reduction of total IRS-1 in GADD45β KO mice fed a HFD and their 
increased state of insulin resistance. However, other researchers doubt the involvement of 
Ser307-phosphorylation in insulin resistance [351,352]. Along that line it would be interesting to 
know whether there is a connection to the involvement of GADD45β in lipid homeostasis. It has 
been reported that a liver-specific depletion of S6K1 can ameliorate insulin resistance and 
steatosis by having an influence on genes involved in lipogenesis [275]. Even though we think 
that de novo lipogenesis of FA might not be the underlying site for GADD45β’s action, GADD45β 
might as well influence S6K1 in modulating the expression of genes involved in FA uptake or 
esterification. This question might be addressed by liver specific knockdown of S6K1, for example 
with AAV bearing a miRNA against S6K1, in GADD45β KO and WT animals under food 
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deprivation and oversupply. However, it is noteworthy that we could not see a comparable 
increase of S6K1 in db/db mice with concomitant decrease upon GADD45β overexpression (not 
shown), which might be due to the nutrient status during sacrifice or the difference in mouse 
models. 
In general it is difficult to investigate the insulin signalling pathway or any other pathway in vivo 
due to the high variability of animals. It would be advisable to investigate the impact of GADD45β 
on the lipid or glucose homeostasis in the context of insulin signalling in an in vitro model. Here, 
variations between replicates are lower, the experiments are easily reproducible and results 
faster to obtain. For example, one might mimic insulin resistance in AML12 cells by oversupply of 
oleate or palmitate [306,359-361] and treat them with insulin or vehicle in the background of 
either GADD45β overexpression or knockdown. However, as mentioned in the beginning, in vitro 
experiments should only aim at confirming of in vivo results or giving the basis for subsequent in 
vivo studies. 
4.4 GADD45β – a link between lipotoxicity and insulin resistance? 
Even though the fasting-mediated induction of GADD45β in liver is striking, as is its blunted 
increase in diabetic mice and men, the observed differences in phenotype in different mouse 
studies are mild between KO and WT mice. Effects on serum and liver lipids, especially TG, are 
consistently observed though, which might indicate that GADD45β is indeed involved in the 
regulation of hepatic lipid metabolism. On the other hand it seems as if GADD45β plays not only a 
role in acute stress of nutrients depletion, but has also a crucial function in regulating insulin 
sensitivity in chronic stress of nutrient overload (obesity). With gain of function experiments we 
could attenuate both the defects in lipid handling and insulin signalling, but currently we are not 
able to say how GADD45β mediates its effect. Thus, questions that rise when analysing and 
discussing the results of this work are whether and how the observed effects on lipid and glucose 
homeostasis can be linked. The role of the insulin signalling pathway is hereby still enigmatic and 
not taken for granted. As mentioned there are postulations about non-canonical, insulin-
independent effects on glucose production. These are partially based on the fact that insulin does 
not only mediate its regulatory function in a direct way on the liver, but also by indirect means on 
other organs. As such, it is postulated that a non-autonomous pathway exists which includes 
adipose signalling to hepatocytes via free fatty acids. The inability of adipose tissue, particularly 
visceral adipose, in the insulin resistant state to suppress NEFA production leads to hepatic 
NEFA oversupply and thus impaired insulin suppression of hepatic glucose production through an 
as yet undefined mechanism [129-131]. 
ER stress links obesity and insulin resistance [362]. Obesity is associated with the activation of 
cellular stress signalling and inflammatory pathways, and one key player in the cellular stress 
response is the ER [363,364]. Cells adapt to ER stress through activation of the unfolded protein 
response (UPR) as a protective mechanism. Obesity and its associated increase in FA flux to the 
liver lead to ER stress. ER stress in turn has been shown to promote lipid accumulation. This 
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situation results in a vicious cycle and promotes the development of insulin resistance. Mice 
deficient in X-box–binding protein–1 (XBP1), a transcription factor that modulates the ER stress 
response, develop insulin resistance [37]. GADD45β has a XBP1 binding domain [314], thus 
giving an alternative explanation for increased insulin resistance in GADD45β KO mice which also 
show TG accumulation upon fasting (Fig. 28A). Hence, GADD45β might link lipid excess to insulin 
resistance via ER stress and UPR. However, which exact function it confers in this context is not 
clear. GADD45β is a stress-induced gene with a protective role under mild or acute xenotoxic 
stress. Under chronic or more severe stress however, it might promote cell death. It has been 
shown in drosophila that mild irradiation induces D-GADD45 which promoted stress resistance 
[210]. Furthermore, GADD45β confers protection against liver toxicity, as fasted GADD45β KO 
mice had exaggerated liver damage in response to sub-lethal acetaminophen administration (data 
not shown), indicative of a role for GADD45β in stress-resistance also in mammals. Similar effects 
can be observed in the mouse and human and are described with the phenomena of hormesis, 
wherein low dose toxins or mild stress induce an adaptive (hormetic) response, which in turn 
helps to cope with more severe or harmful factors. This concept can also be applied to metabolic 
disorders [365]. It is proposed that efficient adaptation to life-style-induced cellular stress, such as 
inflammation, mitochondrial dysfunction or ER stress, mediates the resistance to obesity and 
NAFLD. As such, cells adapt to ER stress through UPR which in turn might protect the organism 
of insulin resistance and glucose intolerance [37,366-368]. However, if the UPR fails to alleviate 
ER stress, the cell will undergo apoptosis. GADD45β expression might be stimulated upon lipid-
induced ER stress to exert a protective, so far unknown role. In GADD45β KO mice this missing 
hormetic response leads to more lipid accumulation and ER stress and as consequence to more 
insulin resistance. When the cell cannot handle the stress anymore, it will eventually die, a 
consequence also inherent to GADD45β.  
One might criticize that the described conclusions are based on fasting and feeding studies which 
are two types of metabolic challenges. However, one has to keep in mind that the mouse is not 
only undergoing fasting and feeding cycles throughout the day, but also while being fed a high fat-
diet. On the surface it might look as if this constant overeating is overcoming this cycle, but in fact 
also while being on high-fat diet the mouse has times of more and times of less nutrients available 
for their organs, even though these fluctuations might be lessened. Consequently, the organism 
has not only an affected lipid handling under fasting conditions when GADD45β is absent, but 
also under high-fat diet feeding, which might converge with aggravated insulin signalling and 
impaired glucose homeostasis (Fig. 82). 
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Figure 82: Effects of GADD45β induction on metabolic homeostasis. Gadd45β is induced in a fasting-
feeding cycle dependent manner, when fasting leads to nutrient stress situations. Gadd45β supports the 
organism to adapt to changing lipid supply, which also affects glucose homeostasis and leads to an overall 
correct metabolic function (green arrows). If Gadd45β is absent (indicated by the red cross), this adaptation 
response is impaired (red arrows), resulting in aberrant metabolic homeostasis characterised by 
dysregulated lipid and glucose metabolism. How Gadd45β mediated its effect on lipid and glucose 
homeostasis is not known. 
In summary, the results at hand demonstrate the possibility of a novel connection between lipid 
accumulation and insulin resistance via the stress-induced gene GADD45β. This is thereby the 
first report of a GADD45 protein to be involved in system and liver adaptation to the stress of 
nutrient deprivation and overload. Further investigation should be done to elucidate the specific 
site of GADD45β action. This might help to find novel targets and sites for pharmacological 
intervention in the aim for a treatment of metabolic disorders. 
4.5 Outlook 
Since most experiments utilised whole-body knockout mice, it cannot be excluded that the effects 
on lipid and glucose homeostasis are influenced by alterations in other organs than the liver. 
While we could show, that (1) the fasting-induced upregulation of Gadd45b was liver-specific and 
intrinsic to hepatocytes, and that (2) we could partially rescue the observed effects with liver-
specific GADD45β overexpression, experiments with hepatocyte-specific knockdown of 
GADD45β should be repeated. We have already produced the tools for a loss of function study 
(an AAV bearing a miRNA against GADD45β) and tested them in pilot studies for their 
functionality. We aim to use them in the context of a HFD, where a significant worsening of insulin 
sensitivity with GADD45β KO was observed. Since this study was terminated in the fed state, the 
24 hours fasting (GADD45β KO), db/db and rescue studies however the fasted state, mice should 
be sacrificed after 24 hours food withdrawal to examine if this dietary challenge reveals a 
difference in serum and liver metabolites between the treated groups. 
Even though depletion of GADD45β was not accompanied by a compensatory induction of the 
other family members GADD45α and GADD45γ, it cannot be ruled out that the presence of either 
of them influences the response of the animals towards changes in nutrient supply and during the 
stage of disease and aging. Indeed, GADD45γ was the initial gene to be found inflexibly 
dysregulated in db/db mice, and we could also show this induction pattern in aged mice. 
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Furthermore, GADD45γ has been already described to exert a role in metabolic adaptation [230]. 
Moreover, GADD45 proteins can form homo- and hetero-dimers [150,151]. Hence, the exclusive 
involvement of GADD45β in the observed effects on lipid and glucose homeostasis can only be 
confirmed by using a GADD45β(-/-)/GADD45γ(-/-) double KO strategy. To avoid only getting 
female DKO mice (GADD45γ KO male mice cannot form gonads [257]), one can either use 
adeno-associated virus (AAV) to knockdown GADD45γ in GADD45β KO males, or one might 
generate liver-specific DKO using the Cre-lox technology [369-371]. Thereby two loxP sites 
(specific 34-base pair sequences consisting of an 8-bp core sequence, where recombination 
takes place) flanking one or two exons of GADD45β/γ are inserted into the genome, and the 
mouse carrying the floxed allele (GADD45β/γfl/fl) is subsequently crossed with a albumin-Cre 
mouse to generate a hepatocyte-specific knockout (GADD45β/γfl/fl albumin-CRE+) since the Cre 
recombinase under the control of the albumin promotor mediates a deletion of the floxed 
segment. 
Since transcriptional regulation does not seem to be affected, GADD45β might exert its function 
by interacting with proteins, thereby either stimulating or inhibiting their activity as it has been 
shown for MEKK4 [165] and MKK7 [199]. Thus, one might identify binding partners of GADD45β. 
This can be done in several approaches [372]. One common assay is the yeast-2-hybrid screen 
(Y2H). Yeast cells are transfected with two plasmids, one encoding the bait, which is the protein 
of interest fused with the DNA-binding domain of a yeast transcription factor like Gal4, and one 
encoding the prey, which is a library of cDNA fragments linked to the activation domain of the 
transcription factor. Transcription of reporter genes only occurs when bait and prey interact with 
each other and form a functional transcription factor [373]. A modification of the Y2H screen is the 
mammalian-2-hybrid screen, which is based on the same principle but can be performed in cell 
lines and hence may better mimic actual in vivo interactions [374,375]. Positive interaction 
partners can be confirmed by protein complex-immunoprecipitation with concomitant detection via 
immunoblotting. Thereby, the endogenous (not overexpressed and not tagged) protein of interest 
is isolated with a specific antibody from cell or tissue lysates and interaction partners which stick 
to this protein are subsequently identified by Western Blotting. For screening approaches, affinity 
purification of the tagged protein of interest coupled to its interacting protein followed by mass 
spectrometry can be performed [376,377]. It would be interesting to see whether GADD45β 
indeed is involved in the uptake and esterification of FA by binding some of the key enzymes 
responsible for these processes (e.g. CD36, FABP4, FATP and ACS, or 1-glycerol-3-phosphate 
acyltransferase (GPAT), diglyceride acyltransferase (DGAT) and acyl-glycerol-3-phosphate 
acyltransferase (AGPAT)), which have been implicated in the development of steatosis and 
insulin resistance [378,379], or whether GADD45β has an influence on proteins of the insulin 
signalling pathway, or both. In this context, one might also perform metabolomic profiling in order 
to find intermediates that accumulate upon KO depletion [380-383]. 
To close the circle it is not only interesting to find the downstream effector of GADD45β, but also 
which upstream regulator(s) might mediate GADD45β induction. We question a hormonal control, 
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such as insulin, but think that a senor for nutrient depletion or overload might signal via 
GADD45β. A prominent candidate in this regard is AMP-activated protein kinase (AMPK), which 
is a crucial cellular energy gauge and activated upon nutrient deficiency. It indeed mildly induced 
Gadd45b mRNA expression. It is known that AMPK induces p53 activation and promotes survival 
[384]. On the other hand GADD45α has a p53-binding element in the third intron [168] and p53 
can contribute to the positive regulation of the promoter [385]. Since GADD45 proteins are 
structurally similar, GADD45β might be induced via AMPKp53. Alternatively, also a transcription 
factor might be triggering the effects via GADD45β. One might perform a large-scale RNA 
interference (RNAi) screen in AML12 cells. In this method micro RNA (miRNA) or small interfering 
RNA (siRNA) are used for post-transcriptional gene silencing typically by causing the destruction 
of the messenger RNA (mRNA). By introduction selective miRNA or siRNA into the cell one can 
suppression the expression of specific genes and find out, for example, which transcription factor 
is responsible for the induction of GADD45β during nutrient deprivation [386,387]. 
4.6 Summary and Conclusion 
In summary, we could demonstrate that GADD45β is a stress-induced gene in mouse and human 
which is differentially expressed in disease and ageing. We could show for the first time that 
GADD45β exerts a protective effect on the adaptive metabolism during the stress of nutrient 
deprivation and nutrient oversupply. Even though the exact underlying mechanisms are still to be 
unravelled, the absence of GADD45β led to an accumulation of triglycerides in the liver upon food 
deprivation and to an increased insulin resistance in times of nutrient overload. Gain-of-function 
experiments could reverse the dysregulated fasting lipid handling in GADD45β KO mice and 
improve insulin sensitivity in obese-diabetic db/db mice. Hence, we conclude that GADD45β may 
be a missing link between lipid and glucose homeostasis under conditions of nutrient stress which 
protects from ageing-related metabolic dysfunction. 
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5. METHODS 
5.1 Molecular Biology and Biochemistry 
5.1.1 Bacterial Work 
5.1.1.1 Transformation of Eschericha Coli 
Sure 2 supercompetent cells were used for the cloning of DNA fragments for the production of 
AAV, for all other cloning procedures DH5α or TOP10™ E. coli cells  were used. All cells were 
transformed by chemical transformation. Therefore, 50 µl cells were thawed on ice and incubated 
with either 0.1-1 μg plasmid DNA or 1-5 μl of ligation reaction for 20-30 min on ice. Following a 
short heat shock for 45 seconds at 42°C in a water bath and a cool down on ice for 2 minutes, 
250 µl of either LB medium (for DH5α or TOP10™) or SOC medium (for Sure 2) was added. The 
mix was then incubated at 37°C and slight shaking for another hour. Afterwards, 200 µl of cell 
suspension was spread on agar plates containing the required antibiotics. Plates were incubated 
at 37°C overnight for bacterial growth and stored at 4°C. 
5.1.1.2 Bacterial liquid cultures 
Single colonies were picked with a sterile pipette tip and transferred to 5 ml of LB medium with the 
appropriate antibiotics. These small scale cultures were incubated over night at 37°C with shaking 
(~160 rpm). For large scale liquid cultures, either small scale liquid cultures, which have been pre-
incubated for only 5-8 hours, or an inoculation loop full of cells from a glycerol stock were directly 
given to 200-2000 ml of LB medium, depending on the required DNA yield. Subsequently, the 
cultures were incubated over night at 37°C with shaking (~160 rpm). 
5.1.1.3 Preparation of bacterial glycerol stocks 
For long term storage small scale cultures were mixed 1:1 with 50% glycerol and kept at -80°C.  
5.1.1.4 Preparation of plasmid DNA from Eschericha Coli 
Small scale plasmid preparation (Mini Prep)  
4 ml of small scale bacterial liquid cultures was used for the plasmid preparation using the 
Qiaprep Plasmid Miniprep Kit provided by Qiagen following the manufacturer’s instruction. The 
DNA was eluted with 50 μl H2O and stored at -20°C.  
 
Large scale plasmid preparation (Maxi or Mega Prep)  
Plasmid preparation from large scale bacterial liquid cultures was performed using the Qiaprep 
Plasmid Maxi- or Megaprep Kit provided by Qiagen following the manufacturer’s instruction. The 
DNA was eluted with 200 µl or 800 μl 1x TE buffer, respectively, and stored at -20°C. 
5.1.2 DNA work 
5.1.2.1 Preparation of genomic DNA 
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DNA for genotyping 
200 ml of NID buffer + 2 µl Proteinase K was added to a piece of mouse tip and incubated over 
night at 56°C with slight shaking. The next day, the digestion was stopped by cooking the 
samples for 10 min at 95°C. After cooling down on ice, 2 µl of the digest was used for PCR. 
DNA from liver tissue 
20 mg of pulverised liver tissue was digested in 500 μl lysis buffer + 0.5 mg/ml proteinase K for 3 
hrs at 60°C and subsequently overnight at 56°C with shaking. Genomic DNA was extracted by 
adding 500 μl phenol/chlorophorm/isoamylalcohol (25:24:1), vortexing and centrifugation for 10 
minutes at 13.000 rpm, 4°C. The upper phase was transferred to a new tube and the extraction 
step was repeated. The upper phase was transferred to a new tube with 500 μl chloroform. After 
spinning again for 10 minutes at 13.000 rpm, 4°C, the upper phase was given to 500 μl 
isopropanol. After vortexing the DNA was pelleted during an incubation at -80°C for 30 minutes, 
followed by spinning for 45 minutes at 13000 rpm, 4°C. The pellet was washed with 75% ethanol, 
dried, and resuspended in 100 μl TE buffer. For complete resuspension the DNA was incubated 
at 60°C for 2 hours and afterwards stored at 4°C until use. For qPCR, 50 ng/ml was used. 
5.1.2.2 Determination of DNA concentration 
DNA concentration and the degree of contamination with salts or proteins were determined with 
the NanoDrop ND-1000 spectrophotometer. 1 µl of DNA solution was used for each 
measurement, with the according solvent as blank. The DNA concentration was measured at 260 
nm, potential contaminations between 220 and 300 nm.  
5.1.2.3 DNA sequencing 
DNA was diluted to 800 ng in 10 µl H2O and sent to the company LGC genomics (Berlin) for 
sequencing. Primers at 5 pmol/μl were added either directly or by the company. Primers used for 
sequencing are listed in the material part 6.8.  
5.1.2.4 PCR 
DNA from plasmids or genomic DNA was amplified by polymerase chain reactions using a 
thermocycler (T3000, Biometra) and Phusion polymerase (Finnzymes). The primers used are 
listed in the material part 6.8. 
A typical PCR reaction is shown below: 
DNA from plasmid 
 Amount Final concentration 
5x Phusion GC buffer 10 µl 1x 
10 mM dNTP 1 µl 0,2 mM 
10 µM Primer for 2,5 µl 0,5 µM 
10 µM Primer rev 2,5 µl 0,5 µM 
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DMSO 1,5 µl  
Phusion (2000 U/ml) 0,5 µl 20 U/ml 
DNA 2 µl 100 ng 
Double distilled water 30 µl  
total 50 µl  
 
Gadd45b genotyping 
 Amount Final concentration 
5x Phusion GC buffer 4 µl 1x 
10 mM dNTP 0,5 µl 0,25 mM 
10 µM Primer Gadd45b_for 0,5 µl 0,25 µM 
10 µM Primer Gadd45b_rev 0,5 µl 0,25 µM 
10 µM Primer Gadd45b_neo 0,5 µl 0,25 µM 
Phusion (2000 U/ml) 0,2 µl 20 U/ml 
DNA 2 µl  
Double distilled water 11,8 µl  
total 20 µl  
 
Gadd45g genotyping 
 Amount Final concentration 
5x Phusion GC buffer 4 µl 1x 
2 mM dNTP 4 µl 0,4 mM 
100  µM Primer Gadd45g_for 0,1 µl 0,5 µM 
100 µM Primer Gadd45g_rev 0,1 µl 0,5 µM 
100 µM Primer Gadd45g_pgk 0,1 µl 0,5 µM 
Phusion (2000 U/ml) 0,2 µl 20 U/ml 
DNA 2 µl  
Double distilled water 9,5 µl  
total 20 µl  
 
A typical PCR reaction was programmed as followed: 
Step Temperature Time 
1. Denaturation 98°C 30 sec 
2. Denaturation 98°C 5 sec 
3. Primer annealing 55 – 65°C 20 sec  
4. Extension 72°C 20 sec 
5. Go to 2  25x 
6. Extension 72°C 5-10 min 
7. Hold 4°C ∞ 
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The annealing temperature was adjusted depending on the length and G/C content of the 
primers. The extension time was adjusted depending on the size of the desired PCR product. 
For genotyping the program was as followed: 
Step Temperature Time 
8. Denaturation 98°C 30 sec 
9. Denaturation 98°C 15 sec 
10. Primer annealing 57°C 15 sec  
11. Extension 72°C 45 sec 
12. Go to 2  40x 
13. Extension 72°C 3 min 
14. Hold 4°C ∞ 
 
5.1.2.5 Purification of PCR fragments 
DNA from PCR reactions was purified using the QIAquick PCR purification kit provided by Qiagen 
following the manufacturer’s instructions. DNA was eluted in 30 μl H2O.  
Alternatively, fragments were purified by gel extraction as described below. The amplified DNA 
product for genotyping was not purified. 
5.1.2.6 Agarose gel electrophoresis 
Agarose gel electrophoresis was used to separate DNA fragments. The percentage of the gel 
depends on the DNA fragments to be separated. Usually a 1-2% agarose gel was made. Since 
the DNA fragments for genotyping are rather small (~130 – 268 bp), a 3% agarose gel was used 
therefore. The agarose was dissolved in 1x TAE, and 1 μg/ml ethidium bromide was added to the 
still liquid but not too hot agarose solution. 20 μl of DNA sample were mixed with 4 μl of 6x 
Orange G loading dye and separated at 80-130 V. Gel pictures were taken under UV light (254 
nm) with the Gel imager (Intas). 
The genotyping results were as followed: 
Gadd45b: WT  130 base pairs 
  KO  190 base pairs 
  Heterozygous both band 
Gadd45g: WT  268 base pairs 
  KO   217 base pairs 
  Heterozygous both bands 
5.1.2.7 Gel extraction of DNA 
DNA fragments were isolated from agarose gels under a UV lamp using a scalpel and purified 
using the QIAquick Gel Extraction Kit, according to the manufacturer’s instructions. 
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5.1.2.8 DNA restriction 
DNA restriction was performed by using restriction enzymes from New England Biolabs. The 
enzymes were used at a concentration of 10-20 U per μg DNA with the corresponding buffers 
provided. Reactions were incubated at the required temperatures for 1-12 h. 
5.1.2.9 DNA ligation 
Ligation of insert and vector DNA was performed using a T4 DNA ligase (Invitrogen). The molar 
ratio of insert to vector was adjusted to 3:1 applying the following formula:  
 
�
100 vector [ng] x insert [bp]
vector [bp]
� x 3 = insert [ng] 
 
2 U enzyme was used in 1x ligase buffer for the ligation reactions which were performed in 20 μl 
total volume and incubated for 1 hour at room temperature. After the ligation reaction, the enzyme 
was heat inactivated for 10 minutes at 65°C. 
5.1.3 RNA work 
5.1.3.1 RNA isolation 
RNA isolation from cell culture samples  
After aspirating the medium from each well, the cells were washed once with PBS. Afterwards 1 
ml Qiazol™ Lysis reagent was added per well. The cells were lysed and scratched from the plate 
using a pipette and transferred into DNase/RNase-free reaction tubes. The obtained cell lysates 
were stored at -80°C or immediately used for RNA isolation, as described for liver samples.  
 
RNA isolation from liver samples  
Liver was first homogenised using the TissueLyser™ (Qiagen). Through mechanical force the 
tissue was pulverized in grinding jars. Therefore, all instruments were cooled in liquid nitrogen to 
avoid a thawing of the frozen tissue. To extract total RNA from pulverized liver, approximately 50 
mg of liver were transferred into a 2 ml RNase/DNase-free reaction tube containing a stainless 
steel bead. 1 ml of Qiazol™ Lysis (Qiagen) reagent was added directly. The samples were lysed 
using the TissueLyser™ for 2 times 30 seconds at a frequency of 30 Hz. The homogenate was 
transferred into a fresh 1.5 ml RNase/ DNase-free safe-lock tube containing 200 μl of chloroform. 
Mixtures were vigorously inverted 15 times and incubated on ice until the phases started to 
separate. Then the lysates were centrifuged for 30 minutes at 13,000 rpm. The upper aqueous 
solution containing the RNA, was carefully transferred into a fresh RNA-free reaction tube 
containing 500 μl of iso-propanol and incubated at room temperature for 10 minutes, followed by 
a 10 minutes centrifugation step at 12,000 rpm. The supernatant was discarded and the pellet 
was washed once with 1 ml of 75% ethanol. The ethanol was carefully removed using a pipette. 
The pellet was briefly air-dried (max. 2 minutes) at 55°C and re-solubilised in 100 µl water. To 
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increase solubilisation, the RNA was incubated at 55°C for 10 min. The samples were stored at -
80°C or directly used for cDNA synthesis. 
For RNAseq expression profiling, RNA isolated using Qiazol™ Lysis reagent was purified using 
the RNeasy Mini purification kit provided by Qiagen. RNA was transferred to into a fresh reaction 
tube containing 525 μl of 100 % ethanol. RNA was then purified following the manufacturer’s 
instruction. The optional DNA digestion step was included. RNA was eluted in 60 μl H2O. 
5.1.3.2 Determination of RNA concentration 
As for DNA, the RNA concentration and the degree of contamination with proteins or ethanol were 
determined with the NanoDrop ND-1000 spectrophotometer. 1 µl of RNA solution was used for 
each measurement. The RNA concentration was measured at 260 nm, potential contaminations 
was assessed with the ratio 260 nm/280 nm. 
5.1.3.3 Assessment of RNA quality 
Agarose gel electrophoresis was used to assess RNA quality. Therefore, 1% agarose gels were 
made with RNase free agarose in 1x TBE buffer made with DEPC-water. The chamber and tools 
for the electrophoresis were washed in DEPC-water and 10 µM NaOH for 30 minutes before use. 
500 ng RNA sample were added to 10 μl RNA denaturing buffer and incubated for 10 minutes at 
65°C and 2 min on ice. Since this buffer contains already ethidium bromide, no additional 
ethidium bromide was added to the gel. The quality of the RNA was determined visually by 
estimating the ratio between 28S to 18S ribosomal RNA, which is 2:1 for intact RNA. 
5.1.3.4 cDNA Synthesis 
cDNA synthesis was performed using the cDNA synthesis kit (Fermentas). 2 µg of RNA was used 
for the reaction. Specifically, the reaction volume was first adjusted to 10 μl per sample using 
RNase/DNase-free water and 1 μl of oligo(dT)18 primers were added. To allow for oligo annealing 
to the mRNA poly-A tails, reactions were incubated at 65°C for 10 min. Afterwards, 4 μl 5 x 
reaction buffer, 2 μl 10 mM dNTP mix, 1 μl Ribolock™ Ribonuclease inhibitor and 2 μl M-MutLV 
reverse transcriptase were added to each reaction. As a negative control for contamination one 
sample without reverse transcriptase was included. With this mix the following program was run 
on a thermocycler (T3000, Biometra): 
Temperature Time 
37°C 1 h 
70°C 10 min 
4°C ∞ 
 
After completion, cDNA samples were diluted 10 fold in RNase-free water and stored at -20°C or 
used directly for quantitative real-time PCR. 
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5.1.3.5 Quantitative PCR 
In general, 5 μl of the diluted cDNA samples were used for quantitative PCR and technical 
duplicates of all samples were performed. Water was used as a negative control and samples 
containing no reverse transcriptase served as controls for genomic DNA contamination. 15 μl 
PCR master mix per well was transferred into a MicroAmp Optical 96 well reaction plate and then 
the sample was added. Quantitative PCR was performed using the StepOnePlus Real Time PCR 
System (Applied Biosystems). RNA expression data were quantified according to the method as 
described elsewhere [388,389] and normalized to RNA levels of TATA-box binding protein (TBP) 
if not indicated otherwise. 
Taqman 
The TaqMan probes were obtained either from Applied Biosystems or MWG and are listed in the 
material section. Depending on the used TaqMan probes two different master mixes were 
prepared.  
Probe/company Master Mix per reaction 
Life Technologies™ 10 μl TaqMan® Gene Expression Master Mix 
 0,5 μl TaqMan® Primer/Probe Set 
  4,5 μl dH2O 
Eurofins MWG Operon 10 μl TaqMan® Gene Expression Master Mix 
 1,0 μl Forward Primer (10 μM) 
 1,0 μl Reverse Primer (10 μM) 
 0,5 μl Probe (5 μM) 
 2,5 μl dH2O 
 
The qPCR program was as followed: 
Temperature Time 
50°C 2 min 
95°C 10 min 
95°C 15 sec 
60°C 1 min 
 
SYBR 
The SYBR probes used were obtained from Qiagen and are listed in the material section. A 
master mix was prepared containing 10 µl 2x QuantiTect SYBR Mix, 2 µl 10x QuantiTect Primer 
Assay and 3 µl dH2O. 
 
 
 
40x 
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The qPCR program was as followed: 
Temperature Time 
95°C 15 min 
94°C 15 sec 
55°C 30 sec 
42°C 30 sec 
 
5.1.3.6 Gene expression profiling with RNAseq 
For expression profiling of liver transcripts, RNA was isolated from liver samples of 6 GADD45β 
KO and 6 GADD45β WT male mice which were starved for 24 hours as described in 5.2.3. The 
RNA isolation procedure was performed as described in 5.1.3.1. An equal amount (1 µg) of RNA 
from two non-littermate WT or two non-littermate KO mice were pooled for sequencing, but KO 
and WT were from the same litter. The sequencing was performed at the Genomics and 
Proteomics Core Facility of the dkfz. Specifically, they performed a single read, 50 bp multiplexed 
run on 3 HiSeq lanes without reading direction with subsequent poly-A purification. The analysis 
of differentially expressed transcripts was performed by Dr. Emil Karaulanov from the Institute of 
Molecular Biology, Mainz. He checked the sample consistency and data quality with FastQC 
(Bioinformatics Group at the Babraham Institute, UK, 
http://www.bioinformatics.bbsrc.ac.uk/projects/fastqc/) and QualiMap 
(http://qualimap.bioinfo.cipf.es/) [390]. His analysis focused on differential expression, 
visualisation and pathway/network analysis with special interests in transcription factors and 
receptors. His strategy was to perform several parallel workflows with different popular and 
established software tools and then compare the results in order to filter the robust (consensus) 
hits. More precisely, he used TopHat and Genomatix GMS for read mapping and CuffDiff (v1.0.3, 
Galaxy) and DESeq (v1.10.1, Genomatix) for differential expression analysis. Afterwards, he 
filtered consensus DE hits, performed annotation, visualised and further analysed them. A false 
positive rate of a=0.01 with FDR correction was applied to determine significance. Pathway and 
gene function analysis was performed with the Kyoto Encyclopedia of Genes and Genomes 
(KEGG, http://www.genome.jp/kegg/) and DAVID Bioinformatics Resources 6.7 (National institute 
of allergy and infectious diseases, NIH, http://david.abcc.ncifcrf.gov). 
5.1.4 Protein work 
5.1.4.1 Preparation of protein extracts 
Protein extracts from cells 
Embryonic Kidney (HEK) cells were washed once with PBS and lysed by the addition of an 
appropriate volume of 2 x SDS sample buffer. Samples were boiled for 10 min at 95°C and stored 
at -20°C until further use. 
Protein extracts from tissue samples 
40x 
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50 mg of liver powder was transferred to a 2 ml safe-lock tube containing a stainless bead and 
lysed after the addition of 700 µl ice cold RIPA buffer containing phosphatase and proteinase 
inhibitors for 2x 30 seconds at 30 Hz with the TissueLyserTM. The protein concentration was 
determined using the BCA kit (Pierce, see 5.1.4.2) and subsequently adjusted to 2 mg/ml for 
SDS-PAGE with water and 5x SDS sample buffer. Afterwards the samples were boiled for 10 min 
at 95°C. 
5.1.4.2 Determination of Protein Concentration 
Protein concentrations were determined using the BCA kit (Pierce) following the manufacturer’s 
protocol. Specifically, protein lysates were diluted 1:20 to fall into the linear range of the assay, 
and the BCA reagents were mixed 1:50 (B:A). In addition to the samples, 10 μl of different BSA 
concentrations ranging from 0 to 2 μg/ml were loaded to obtain a standard curve. 200 μl of the 
reagent was added to 10 µl of sample and standard. The plate was incubated at 37°C for 30 
minutes and measured in the Mithras LB-940 plate reader at 562 nm. Blank values were 
subtracted and the standard curve was subsequently used to determine the protein 
concentrations of the samples. 
5.1.4.3 SDS Polyacrylamide Gel Electrophoresis (SDS-PAGE) and Immunoblotting 
30 µg of protein was loaded onto a 6-15% SDS-polyacrylamide gel depending on the size of the 
protein to be identified and quantified. Following table gives an overview of the SDS-gel 
composition: 
Compound Stacking gel Separation gel   
 5% 6% 12% 15% 
H2O 1,4 ml 2,6 ml 1,6 ml 1,1 ml 
30% Bisacrylamide 0,33 ml 1,0 ml 2,0 ml 2,5 ml 
1 M Tris (pH 6,8) 0,25 ml - - - 
1,5 M Tris (pH 8,8) -  1,3 ml 1,3 ml 1,3 ml 
10% SDS 0,02 ml 0,05 ml 0,05 ml 0,05 ml 
10% APS 0,02 ml 0,05 ml 0,05 ml 0,05 ml 
TEMED 0,002 ml 0,004 ml 0,002 ml 0,002 ml 
 
After running for 1 hour at 120 V, proteins were blotted onto a PVDF membrane (small proteins) 
or a nitrocellulose membrane (medium sized and large proteins) in a wet blotting procedure for 
1,5 h at 80 V in transfer buffer. PVDF membranes were activated with methanol prior to use. 
Membranes were subsequently blocked by incubation in 5% milk or 5% BSA dissolved in TBS-T 
for 1 hour. Specific primary antibodies diluted in 5% milk or BSA, according to the manufacturer’s 
recommendations, were incubated with the membranes overnight at 4°C. The membranes were 
washed with TBS-T the next day and incubated with the secondary antibody conjugated to horse 
radish peroxidase (HRP) at a dilution of 1:5000 for 1 hour. To detect specific bands the enhanced 
chemiluminescence system (ECL) Western Blotting Detection Reagent was applied. The 
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chemiluminescent signal produced by the blots was detected with the ChemiDoc detector 
(BioRad). Exposure times differed based on the quality of specific antibodies and protein 
concentrations. Densitometric analysis of protein expression levels was done with Image Lab™ 
Software (BioRad) and normalized to levels of valosin-containing protein (VCP). 
5.1.5 Liver work 
5.1.5.1 Isolation of Hepatic Lipids from Liver Tissue Samples 
Extraction of lipids from pulverised liver tissue was performed by using a 1:2 mixture of 
methanol/chloroform (v:v) with subsequent equilibration with a saline solution, when the mixture 
partitions into two layers, of which the lower is composed of chloroform-methanol-water and 
contains all of the lipids [391]. Therefore, 50 mg of pulverized liver sample (weight was noted) 
was added into a 2 ml safe-lock tube containing 1.5 ml chloroform/methanol and a stainless steel 
bead. The tissue was homogenized using the TissueLyser system two times for 30 seconds at 30 
Hz. Thereafter, the samples were briefly spun down and mixed at 1400 rpm for 20 minutes on a 
heat block (Thermomixer) at room temperature. Afterwards, the samples were centrifuged at 
13000 rpm for 30 minutes. 1 ml of the supernatant was transferred to a new 1,5 ml tube 
containing 200 μl 150 mM (0.9%) sodium chloride solution. The mix was spun down at 2000 rpm 
for 5 minutes at room temperature. 200 μl of the lower organic phase were transferred to a fresh 
tube containing 40 μl of a Triton-X 100/chloroform (1:1 v/v) mixture. The chloroform was 
evaporated overnight in a SpeedVac and the remaining triton-lipid solution was resuspended in 
200 μl water on a rotation wheel for 1 hour at room temperature. These extracts were used to 
determine non-esterified fatty acids, cholesterol and triglyceride levels in the liver as described in 
5.1.6. For longer storage, extracts were kept at -80°C. 
5.1.5.2 Isolation of Hepatic Glycogen from Liver Tissue Samples 
Liver glycogen was extracted from snap frozen and pulverized liver tissue. About 45-55 mg of 
tissue (exact values were noted down) were added to a 2 ml safe-lock tube containing a stainless 
steel bead and 500 μl 30% Potassium Hydroxide. The tissue was homogenized with the 
TissueLyser 2x 30 seconds at a frequency of 30 Hz. The obtained homogenates were transferred 
to fresh safe-lock tubes and incubated at 95°C for one hour. Glycogen was precipitated by adding 
1,4 ml of 95% ethanol and storing the tubes at -20°C for 30 minutes. Afterwards the samples were 
spun down for 20 minutes at 3000xg. The resulting pellets were first washed in 95% ethanol and 
then dissolved in 250 μl H2O for 30 minutes at 37°C with mild shaking (350 rpm).  
For measuring liver glycogen content the dissolved glycogen had to be digested with 
amyloglucosidase. Therefore, 50 μl of the glycogen solution were mixed with 250 μl 
amyloglycosidase solution (10-20 Units/ml Amyloglycosidase from Aspergillus niger (Sigma-
Aldrich) dissolved in 0,2 M NaAc pH 4,8). The digestion was performed overnight at 37°C with 
shaking. The samples were neutralized by adding 6 µl of 30% KOH.  
The resulting glucose was measured using the Glucose (HK) Assay Kit (Sigma-Aldrich). Hereby, 
glucose is phosphorylated by ATP into glucose-6-phosphate in a reaction catalyzed by 
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hexokinase and subsequently further processed into 6-phosphogluconate by NAD+, which is 
catalyzed by glucose-6-phosphatase dehydrogenase. The consequent increase in absorbance at 
340 nm is directly proportional to the original glucose concentration in the sample. The assay was 
performed with 20 μl of glycogen digest according to the manufacturer’s instructions. For fed mice 
digests were diluted 1:4 prior to assaying. The glucose liver sample concentration was 
determined using a glucose standard curve. 
5.1.6 Metabolit assays 
5.1.6.1 Determination of Free Fatty Acid Levels 
Non-esterified (or free) fatty acids were determined in serum and liver lipid extraction samples 
using a 2-step colorimetric assay with 2 reads at 540 nm from WAKO (NEFA kit) following the 
manufacturer’s instructions. Hereby, NEFA are first converted by acyl-CoA synthetase (ACS) into 
acetyl-CoA, which is subsequently metabolised in several steps involving H2O2 into a 
quinoneimine dye, which can be quantified. 2 μl of serum sample and 4 µl of liver lipid extract 
were measured in duplicates alongside a water control and the NEFA standard (oleic acid 1 
mmol/l). For serum samples the free fatty acid concentration was determined according to the 
formula: 
sample OD – blank OD
standard OD – blank OD
 x standard conc. [mM] = sample conc. [mM] 
 
For liver lipid extracts also the dilution factors (1,125 and 1280 (organic phase out of 1600 µl 
tissue homogenate)) from the lipid extraction procedure and the weight of the liver used for the 
assay were included into the calculation. 
5.1.6.2 Determination of Triglyceride and Glycerol Levels 
Triacylglycerides (TG or triglycerides) in serum and liver lipid samples were quantified using a 2-
reaction assay with 2 reads at 540 nm from Sigma (TG determination kit) according to 
manufacturer’s instructions. This colorimetric assay is based on the separation of TG into its basic 
components: one glycerol and three fatty acids molecules by a lipase and measuring the glycerol 
after being metabolised into a quinoneimine dye involving H2O2. 2 μl of serum sample or lipid 
extract were pipetted in quadruplicates alongside a water control and the TG standard (2,5 mg/ml 
TG including 0,26 mg/ml free glycerol) into a transparent 96-well plate. 100 μl free glycerol 
reagent were added to two of the replicates (blank value), while to the remaining two replicates 
100 μl of TG reagent were added. This mixture contains the enzyme lipase, which catalyses the 
release of fatty acids from TGs. In order to determine the TG levels (TG-bound glycerol), free 
glycerol values were subtracted from the total glycerol measurement. For serum samples the TG 
concentration was determined according to the formula: 
sample OD – blank OD
standard OD – blank OD
 x standard conc. [mM] = sample conc. [mM] 
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For liver lipid extracts also the dilution factors (1,125 and 1280 (organic phase out of 1600 µl 
tissue homogenate)) from the lipid extraction procedure and the weight of the liver used for the 
assay were included into the calculation. 
5.1.6.3 Determination of Cholesterol Levels 
Liver or serum cholesterol concentrations were determined using a colorimetric assay with 1 read 
at 492 nm from Randox (cholesterol determination kit) following the manufacturer’s instructions. 
Hereby, cholesterol esters are separated into fatty acids and free cholesterol, which is further 
metabolised into a quinoneimine dye in two subsequent reactions involving H2O2. 3 μl of serum 
sample or 4 µl of lipid extract were measured in duplicates alongside a water control and the 
cholesterol standard (5,1 mmol/l). For serum samples the cholesterol concentration was 
determined according to the formula: 
sample OD – blank OD
standard OD – blank OD
 x standard conc. [mM] = sample conc. [mM] 
 
For liver lipid extracts also the dilution factors (1,125 and 1280 (organic phase out of 1600 µl 
tissue homogenate)) from the lipid extraction procedure and the weight of the liver used for the 
assay were included into the calculation. 
5.1.6.4 Determination of Ketone Bodies Levels 
The concentration of ketone bodies in the serum was determined using a kinetic assay with 2 
reads at 405 nm from WAKO (Autokit Total Ketone Bodies) following the manufacturer’s 
instructions. The principle of the assay is an enzymatic reaction where the rate of Thio-NADH 
production depends on the concentration of total ketone bodies in the sample and can be 
determined using a photometer. A standard curve was prepared by serially diluting the calibrator 
provided in the kit. 2 μl of serum sample was used for measuring absorbance at 405 nm and the 
concentration determined according to the formula: 
sample OD – blank OD
standard OD – blank OD
 x standard conc. [mM] = sample conc. [mM] 
 
5.1.6.5 Determination of Serum Insulin Levels 
Serum insulin levels were determined using an ELISA kit (ALPCO) following the manufacturer’s 
instructions. 5 μl of each sample or standard (provided in the kit) were used for the measurement 
of absorbance at 450 nm. Insulin concentrations were calculated using the standard curve 
resulting from the standards provided with the kit. Some of the used samples needed to be 
diluted, especially from mice fed a high fat diet for 4 months or db/db mice, in order to fit the 
concentrations within the standard curve of the assay. 
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5.1.6.6 Determination of Serum ALT Levels 
Serum levels of Alanine Aminotransferase (ALT) were determined by a kinetic calorimetric assay 
in order to estimate liver damage. Serum ALT levels were assessed using the Infinity ALT Liquid 
Stable Reagent (Thermo Electron, Melbourne) following the manufacturer’s instructions, 
measuring absorbance after 1 minute and after another 9 minutes incubation time at 355 nm 
(instead of 340 as stated in the instructions). This caloric assay is based on ALT’s ability to 
catalyse the conversion of L-alanine and 2-oxoglutarate into pyruvate and L-glutamate. Pyruvate 
is then reduced to lactate by lactate dehydrogenase (LDH) present in the kit with the 
simultaneous oxidation of NADH to NAD+, and the reaction is monitored by measuring the 
decrease in absorbance due to the oxidation of NADH. The activity was then calculated as 
change in absorbance per min multiplied by a factor (total reaction volume (105 µl) x 1000 divided 
by absorption coefficient of NADH at 355 nm (4,76) x sample volume (5 µl) x reading path length 
(0,4 cm) which equals 11029,4). Hence, ALT activity is calculated with the following formula: 
Δ absorbance x 11029,4
9 min
 = activity �
U
L
� 
5.1.6.7 Determination of Liver and Serum Amino Acid and Acyl Carnitine Levels 
In general, liver and serum levels of amino acids and acyl carnitines were determined by our 
collaborator Dr. Jürgen Okun and his technician Kathrin Schmidt at the University Children’s 
Hospital in Heidelberg. They developed an electrospray-ionisation mass spectrometry (ESI-
MS/MS) technique for acyl carnitine and amino acid determination in plasma according to a 
modified protocol used for these derivatives in dried blood spot. The ESI-MS/MS technique is not 
able to separate isobaric compounds e.g. leucine / isoleucine but gives for all the other amino 
acids reliable results within 2,5 minutes. Sample preparation contains an extraction and a 
derivatization step which was also performed by our collaborators.  
Serum samples were directly sent to them for a duplicate measurement. 5 µl of serum was used 
for one experimental run which contained measurement of amino acids and acyl carnitines. Liver 
homogenates were achieved by lysing 50 mg of pulverized liver sample mechanically using the 
TissueLyser in 10 volumes of PBS containing protease inhibitors (i.e. 500 µl to 50 mg). 
Afterwards, these extracts were centrifuged at 4°C at 17000 x g and the supernatant used for 
analysis. 
For analysis of the obtained data, acyl carnitine and amino acid concentrations were normalized 
to total acyl carnitines and total amino acids, respectively, due to a high scatter between the 
different groups. 
For the starvation experiment with GADD45β WT and KO mice, serum alanine and branched 
chain amino acids were measured using a colorimetric assay from BioVision (L-alanine Assay Kit 
and Branched Chain Amino acid Assay Kit). Serum samples were deproteinised with PCA using 
the Deproteinizing Sample Preparation Kit (Biovision) according to the manufacturer’s 
instructions prior of measuring the amino acids. Assay reagents preparation and procedure were 
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performed according to the manufacturer’s instructions. The concentrations were determined with 
the use of a standard curve with the standard being provided with the kit. 
5.1.6.8 Determination of Blood Glucose Levels 
Blood glucose levels were determined using a drop of blood obtained from the tail vein and an 
automatic glucose monitor (One Touch, Lifescan). 
5.2 Cell Biology 
5.2.1 Cell culture conditions 
All experiments with eukaryotic cells were performed under sterile conditions. Cells were 
cultivated at 37°C, 5% CO2 and 95% humidity. All media and additives were warmed to 37°C prior 
to use. Cells were cultivated in 6-well or 12-well plates or 15 cm cell culture dishes. A list of the 
media used for cell culture experiments is shown below: 
Cell line  Medium FCS Antibiotics Further additives 
HEK293 DMEM 10% 1% P/S  
HEK293A DMEM 10% 1% P/S 1% NAA 
HEK293A AD titration DMEM 2% 1% P/S 1% NAA 
HEK293T DMEM 10% 1% P/S 1% NAA 
Hepa1c1 DMEM 10% 1% P/S 1% NAA 
Hepa1c1 starvation HBSS 1% 1%  
AML12 DMEM/F-12 10% 1% P/S ITS, Dexamethasone 
5.2.2 Thawing of cells  
Eukaryotic cells were stored in liquid nitrogen tanks in 1 ml aliquots containing about 1*106 cells in 
freeze medium (DMEM, 20% FCS, 10% DMSO). Following thawing at 37°C, cells were carefully 
mixed with 10ml pre-warmed culture medium and centrifuged for 3 minutes at 2000 rpm to 
remove DMSO. The pellet was resuspended in 10 ml medium. Those 10 ml were distributed to 
two 15 cm tissue culture plates (3 ml and 7 ml) containing 20 ml culture medium. 
5.2.3 Determination of cell number 
The cell counting system Countess® (Life Technologies) was used to determine cell number and 
viability. For this, 10 μl of Trypan Blue (Life Technologies) were mixed with 10 μl of cell 
suspension. 10 μl of this mixture were transferred onto a Countess® slide and loaded into the 
counter for measurement. 
5.2.4 Cultivation of Human Embryonic Kidney (HEK), HEK293A and HEK293T cells 
HEK293 cells were cultivated on 15 cm cell culture plates in 25 ml culture medium (DMEM 4,5 
mg/l glucose and additives). They were passaged twice a week with a split factor of 1:10 – 1:20.  
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For passaging, the cells were washed from the cell culture plate using 10 ml of the culture 
medium they were growing in and were pelleted by centrifugation at 2000 rpm for 3 minutes. 
Subsequently, the pellet was resuspended in 10 ml fresh culture medium and 500 μl of the cell 
suspension was plated onto a 15 cm cell culture plate containing 24,5 ml culture medium. 
5.2.5 Cultivation of Hepa1c1 cells 
Hepa1c1 cells were maintained and propagated in 15 cm dishes containing 25 ml culture medium 
(DMEM plus additives). For passaging, the cells were first washed in 1x PBS and trypsinized, 
then the detached cells were resuspended in 10 ml of fresh medium. Cells were pelleted by 
centrifugation at 2000 rpm for 3 minutes and subsequently resuspended in 10 ml fresh medium. 
Cells were split twice a week by the factor 1:10. 
5.2.6 Cultivation of AML12 cells 
AML12 cells were cultivated in 15 cm culture plates containing 25 ml of culture medium 
(DMEM/F-12 supplemented with 0,005 mg/ml insulin, 5 ng/ml transferrin, 5 ng/ml selenium (ITS, 
Roche) and 40 ng/ml dexamethasone). Cells never exceeded a confluency of 80 ‐ 90% and were 
never cultured longer than passage 20. They were split 1:10 twice a week by first washing them in 
1x PBS and trypsinizing them, then the detached cells were resuspended in 10 ml of fresh 
medium. 
5.2.7 Transient transfection of HEK cells 
HEK293 cells were transfected with DNA for the production of Adenovirus and Adeno-associated 
virus (see 5.3.1. and 5.3.5, respectively) either using Lipofectamine 2000 transfection reagent 
(Invitrogen) or the PEI method, respectively. 
For the production of adenovirus 1 µg of plasmid and 3 µl Lipofectamine were used for 
transfection. Lipofectamine was added to 250 μl of serum free Opti-MEM medium. The mixture 
was combined with DNA which was diluted in the same medium, and the mixture was incubated 
at room temperature for 20 minutes to allow complex formation. The DNA/Lipofectamine 
complexes were added dropwise to the cells in antibiotic-free medium. Medium change to the 
normal culture medium was performed the following day. 
For the production of AAV 1 µg of DNA and 8 µl of PEI were used for transfection. In one tube the 
plasmid DNA was topped up with water to 20 ml and mixed with 20 ml 300 mM NaCl. In another 
tube 18 ml PEI, 2 ml water and 20 ml 300 mM NaCl were mixed. Both mixtures were combined 
and incubated at room temperature for 10 minutes to allow complex formation. In the meantime, 
medium of the cells was changed. Afterwards, the mixture was added drop wise to the cells. Cells 
were harvested 48 hours post-transfection. 
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5.2.8 Transient transfection of Hepa1c1 cells 
Hepa1c1 cells were used for the in vitro induction of Gadd45b and subsequent functionality test of 
the generated miRNA against Gadd45b. Therefore, the plasmid containing the Gadd45b miRNA 
sequence (pcDNA6.2GW/EmGFP-miR mGadd45b) or the empty vector 
(pcDNA6.2/GWEmGFPmiR-NC) or a positive control (vector encoding eGFP to verify that 
transfection worked) were transfected into the cells. For higher transfection efficiency 
Lipofectamine 2000 transfection reagent was used. One day prior of transfection, cells were 
seeded onto 12-well plates at 1x105 cells per well in normal growth medium without antibiotics. 
The next day, 2µl Lipofectamine was added to 100 μl of serum free Opti-MEM medium. The 
mixture was combined with 800 ng DNA which was diluted in the same medium, and the mixture 
was incubated at room temperature for 20 minutes to allow complex formation. 200 µl of the 
DNA/Lipofectamine complexes were added drop wise to the cells in antibiotic-free medium. 12 
hours later the medium was changed either to normal culture medium (DMEM with additives) or to 
starvation medium (HBSS with additives). Cells were harvested 8 hours later in 2x sample buffer 
containing urea to stabilize the proteins. 
5.2.9 Nutrient withdrawal of AML12 cells 
To determine which nutrient is causing the potent upregulation of Gadd45b, AML12 cells were 
used [248]. In a series of experiments cells were incubated with specified culture media which 
were depleted of different nutrients and Gadd45b mRNA expression was measured. For that 
purpose, a culture medium on the basis of the composition of DMEM/F-12 was made which 
contained all the basic components crucial for the survival of the cell. It is called “PBS full” in this 
work and described in the following table: 
Component Stock conc.  Volume End conc. 
DPBS 10x 25 ml 1x 
Glutamine 100x 2,5 ml 1x 
Essential Amino Acids 50x 5 ml 1x 
NEAA 100x 2,5 ml 1x 
Vitamins 100x 2,5 ml 1x 
Glucose 2 M 2,2 ml 17,5 mM 
HEPES 1 M 3,75 ml 15 mM 
Sodium Pyruvate 100x 2,5 ml 1x 
Purine/Pyrimidine 1000x 0,25 ml 1x 
Lipid Mixture 1 10 mg/L each linoleic, linolenic, 
oleic, palmic and stearic acid 
1,25 mg/L each 0,05 mg/L 
P/S 100x 2,5 ml 1% 
FCS 10x 25 ml 10% 
Dexamethasone 250 µM 0,102 ml 1,02 x 104 mM 
I T S 1000x 0,25 ml 1x 
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Sodium Bicarbonate 7,5%= 890 mM 4 ml 14,3 mM 
Water  170,70 ml  
Total  250 ml  
In a first experiment an induction of Gadd45b by the addition of “PBS full” had to be excluded. 
Therefore, AML12 cells were seeded onto 6-well plates and the next day, when they were ~75% 
confluent, the medium was changed to either DMEM/F-12 or “PBS-full”. Cells were harvested 
after 8 or 24 hours with Qiazol Lysis Reagent (after washing 1x with PBS) followed by RNA 
extraction, cDNA synthesis and RT-qPCR for the Gadd45b expression.  
In a follow-up experiment the combination of all those components whose concentration in the 
body changes depending on the nutritional status and which could cause an induction of 
Gadd45β was reduced in the culture medium. Therefore, a medium containing all components 
essential for growth (so-called “Base medium”) and a medium containing all variable components 
(so-called “Supplement medium”) were made. The composition is listed below: 
2x base medium Stock conc.  Volume 2x conc. End conc. 
DPBS 10x 50 ml 2x 1x 
Vitamins 100x 5 ml 2x 1x 
HEPES 1000 mM 7,5 ml 30 mM 15 mM 
P/S 100 5 ml 2% 1% 
Dialysed FCS 10 50 ml 20% 10% 
Dexamethasone 250000 nM 0,204 ml 204 nM 102 nM 
I T S 1000x 0,5 ml 2x 1x 
Sodium Bicarbonate 890 mM 8 ml 28,6 mM 14,3 mM 
Water  123,76 ml   
Total  250 ml   
 
2x suppl.  medium Stock conc.  Volume 2x conc End conc. 
Glutamine 100x 5 ml 2x 1x 
Essential Amino 
Acids 
50x 10 ml 2x 1x 
NEAA 100x 5 ml 2x 1x 
Glucose 2 M 4,4 ml 35 mM 17,5 mM 
Sodium Pyruvate 100x 5 ml 2x 1x 
Purine/Pyrimidine 1000x 0,5 ml 2x 1x 
Lipid Mixture 1 10 mg/L each linoleic, 
linolenic, oleic, palmitic 
and stearic acid 
2,5 mg/L 
each 
0,1 mg/L 0,05 mg/L 
Water  217,63 ml   
Total  250 ml   
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Dialysed FCS was used to significantly reduce the concentrations of small molecules such as 
amino acids, hormones and cytokines. The two media were mixed 1:1, 1:2, 1:10, 1:20 or 1:100 in 
order to get a final concentration of the variable nutrients of 100%, 50%, 10%, 5% or 1%, 
respectively. Cells were seeded as mentioned before and incubated with the different media for 8 
hours before harvest. 
In a third experiment the cells were incubated in culture media depleted in one specific nutrient 
and Gadd45b mRNA levels were measured. The “Base media” was prepared as before. The 
“Supplement media” was lacking one component which was added to a final concentration of 1% 
after both media were mixed in a 1:1 ratio. Therefore, 7 different “Supplement media” had to be 
made, each missing another component. A “Supplement medium” containing all nutrients was 
included in the experimental setup. The cells were incubated with the culture media for 8 hours 
before harvest. 
In a last experiment, cells were incubated in media missing two components. Therefore 
“Supplement media” were made lacking two nutrients. The “Base medium” was the same as 
before. Both media were mixed 1:1 and given to the cells for 8 hours before harvest. 
5.2.10 Infection of cells with adenovirus 
To test whether adenovirus administration leads to an overexpression of GADD45β 3x 105 
HEK293 cells were seeded on 6-well plates and infected with different amounts of adenovirus 
(AD- GADD45β OE and AD-NC as control) 12 hours after plating. MOIs of 0.1, 1 and 10 were 
used (MOI = cells in well/virus ifu per µl). The desired amounts of virus were diluted in DMEM 
culture medium and added to the cells. Cells were incubated 24 hours until harvest. 
5.3 Virus biology 
5.3.1 Cloning of adenoviruses 
Adenoviruses were used for the overexpression of GADD45β in the murine liver. The BLOCKiT™ 
Adenoviral RNAi Expression System was used to generate adenoviruses either overexpressing 
murine GADD45β or harbouring a non-specific sequence as control. Forward and reverse 
oligonucleotides against the target gene sequence (mGadd45b_for and mGadd45b_rev, see 
Material section) were annealed on the pCMV-SPORT6-mGadd45b vector and the Gadd45b 
sequence isolated via Phusion PCR. The DNA was then cloned into the pENTR-Flag vector 
harbouring the CMV promoter according to the manufacturer’s instructions. The correct resulting 
constructs were first confirmed by restriction digestion and sequencing (primer CMV-for and 
TkpA-rev, see Material section), and then recombined with the pAd/BLOCK-iT™ DEST vector, 
which contains the adenovirus serotype 5 DNA, but lacks the E1 and E3 genes that are required 
for viral replication. The viral vector containing the Gadd45b sequence was confirmed via 
sequencing (primer CMV-for). The vector was linearized by restriction digest using the enzyme 
PacI and transfected into HEK 239A cells using Lipofectamine reagent according to the 
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manufacturer’s instructions. 1 µg of Pac I-digested pAd/BLOCK-iT™-DEST expression plasmid 
and 3 µl Lipofectamine were used for transfection (for further details, see section 5.2.7). 
HEK293A cells express the viral E1 and E3 genes necessary for viral outbreak, allowing the virus 
to expand in this cell line. Viral plaques appeared 6 to 10 days after transfection and cells started 
to detach from the cell culture dish. Once about 70% of cells were floating, they were harvested.  
5.3.2 Adenovirus harvest 
HEK293A cells were harvested, when 70-90% were rounded up and had detached from the plate. 
Remaining adherent cells were washed of the plate by squirting them off the plate with a 10 ml 
tissue culture pipette in the medium they were cultivated in. The medium was collected from 
twenty 15 cm cell culture plates per virus and centrifuged for 10 minutes at 2000 rpm. The 
supernatant was discarded and the cell pellet was resuspended in 3 ml PBS-TOSH buffer per 
virus and shock frozen in liquid nitrogen. Three subsequent freeze and thaw cycles led to a lease 
of the virus from the cells. For that, the cell suspension was thawed at 37°C with vigorous 
vortexing and then shock frozen in liquid nitrogen. After cell lysis the mixture was centrifuged at 
3000 rpm for 5 minutes, to remove cell debris. The crude supernatant was stored at -80°C or 
directly used for purification using a caesium chloride gradient. 
5.3.3 Adenovirus purification 
Caesium chloride (CsCl) gradient centrifugation is a type of density gradient centrifugation for the 
purification of viral particles. Virus lysates from twenty 15 cm culture dishes were thawed on ice. 
PBS-TOSH was added to a final volume of 20 ml. Gradients were prepared in ultracentrifuge 
tubes (Beckmann Polyallomer 25mm x 89 mm) and were balanced after addition of each solution. 
All solutions were adjusted to pH 7.2. The first gradient was layered with 9 ml 4.4 M CsCl, 9 ml 
2.2 M CsCl and 20 ml virus in PBS-TOSH. After ultracentrifugation (2 hours, 4 °C, 24000 rpm, 
Beckmann XL-70, SW28 rotor) a clear virus band was visible between the 4,4 M and 2,2 M 
caesium chloride layers. The virus band was removed by piercing the tube with a 5 ml syringe. 
The obtained virus (about 3 – 3,5 ml) was mixed with an equal volume of saturated caesium 
chloride solution and transferred into a 12 mL centrifuge tube (Beckmann Polyallomer 14mm x 89 
mm). The second gradient was layered with 6-7 ml virus in CsCl, 2 ml 4,4 M CsCl und 2 ml 2,2 M 
CsCl. Following the second ultracentrifugation (3 hours, 4 °C, 35000 rpm, SW40Ti rotor) the virus 
band could be seen between the 4 M and 2,2 M CsCl layers. The band was removed with a 1 ml 
syringe in the smallest possible volume (~700 µl). To remove CsCl from the viral solution, viruses 
were transferred to a dialysis membrane and dialyzed against 1 litre PBS containing 10 % 
glycerol (v/v) 2 times (1 and 24 hours) at 4°C. After dialysis, aliquots of 20–100 μl were prepared 
and stored at -80°C until further use. 
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5.3.4 Virus Titration 
The Tissue Culture Infectious Dose 50 (TCID50) assay was used to titrate adenovirus. For that 
purpose, 104 HEK293A cells were seeded in 100 μl virus titration medium (DMEM medium 
containing 2% FCS (v/v), 1% penicillin/streptomycin and 1% non–essential amino acids) in each 
well of a 96 well plate and infected with decreasing amounts of virus after 4 hours of adhesion. 
Serial dilutions of the virus from 10-7 to 10-14 were prepared in titration medium and 100 µl of each 
dilution added to the cells. Double measurements were performed for each virus and 100 μl of 
medium without virus were added to negative control wells. 10-12 days after infection and 
incubation at 37°C the plaques were counted using a microscope. Every well in which at least one 
plaque could be detected was considered a positive well. The titre was calculated by the following 
formula:  
Ta= viruses per 100 μl =101+(s-0.5)  
s = sum of positive wells starting from the 10-1 dilution; 10 positive wells per dilution = 1 
T= viruses per 1 ml = 10 x Ta 
5.3.5 Cloning of AAV 
Adeno-associated viruses encoding Gadd45b -specific or non-specific control miRNAs were used 
for long-term hepatocyte-specific inactivation of GADD45β. The BLOCKiT™ Pol II miR RNAi 
Expression System was used to generate the adeno-associated viruses. Oligonucleotide 
sequences were chosen using Invitrogen’s RNAi Designer tool. Forward and reverse 
oligonucleotides against the target gene sequence (miR-Gadd45b_for and miR-Gadd45b_rev, 
see Material section) were annealed and cloned into the pcDNA6.2-GW/EmGFP-miR vector 
according to the manufacturer’s instructions. Subsequently, they were transferred into the 
previously described double stranded pdsAAV-LP1-EGFPmut AAV vector [240,242] using the 
restriction enzymes BglII and SalI. The correct identity of the resulting construct was verified by a 
restriction digestion panel and by sending the DNA to sequencing (primer EGFP-C1-F, see 
Material section). The plasmids encoding the miRNA constructs were contransfected into 
HEK293T cells with the pDGΔVP helper plasmid [277] and a mutated p5E18-VD2/8 expression 
vector [278] encoding AAV2 rep and a mutated AAV8 cap protein (aa 589-592: QNTA to GNRQ). 
The transfection procedure is described in section 5.2.7. 
5.3.6 AAV production 
For virus production, HEK293T cells from five 80-90% confluent 15 cm plates were suspended in 
1100 ml medium (DMEM containing 5% FCS (v/v) and 1% penicillin/streptomycin). 1000 ml of the 
cell suspension was transferred to a 10x cell-stack chamber and 100 ml were transferred to a 1x-
cell stack chamber (control chamber for analysis under the microscope). 24 hours after plating, 
the cells were approximately 70-80% confluent and were transfected with the plasmids encoding 
the viral genes using the PEI method in the amounts stated below.  
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Plasmid Amount (per virus) 
AAV-miRNA expression vector 395 μg 
p5E18 VD2/8 helper plasmid 994 μg 
pDGΔVP helper plasmid 2706 μg 
 
Once the cell monolayer was approximately 90% confluent, cells were washed with PBS, before 
they were released from the plate using 10 ml (1x cell stack) or 100 ml (10x cell stack) trypsin-
EDTA for 2 minutes at 37°C. Fresh medium was added (40 ml or 350 ml respectively) and the 
cells were transferred to a 500 ml conical tube. The chambers were washed with PBS and used 
for a second round of transfection. Cells were centrifuged at 2000 rpm for 10 minutes. The 
supernatant was removed and the pellets were resuspended in 8 ml lysis-buffer containing 150 
mM NaCl and 50 mM Tris-HCl, pH 8,5. The lysates were transferred into 15 ml falcons, vortexed, 
snap-frozen in liquid nitrogen and stored at -80°C. 
5.3.7 AAV purification 
After two subsequent rounds of transfection and harvest, AAV lysates underwent two freeze thaw 
cycles as described before and were then centrifuged at 3500 g for 10 minutes at 4°C. The 
supernatant was collected and the pellets were resuspended in 5 ml lysis buffer and snap-frozen. 
The freeze-thaw cycle was repeated three times followed by a centrifugation at 3500 g for 10 
minutes at 4°C. The supernatants were collected again and the pellets were resuspended in 5 ml 
lysis buffer and snap-frozen as before. Afterwards, the lysates were solubilised using a sonicator 
in a water bath at 48 W for 1 minute. The suspensions were then mixed with 5 mM MgCl2 and 
digested with benzonase (50 U/ml) for 30 minutes at 37°C. This solution was then centrifuged at 
4°C and 3500 g for 10 minutes. The final supernatant was pooled with the two other supernatants 
and the virus was stored at -80°C until purification using an iodixanol gradient. 
Purifying virus by iodixanol gradient leads to a separation of packed and unpacked AAV capsids, 
as they migrate differentially upon ultracentrifugation. The gradient, ranging from 15% iodixanol to 
60% iodixanol, was prepared on top of the viral solution in a Beckman Quickseal tube using a 
Pasteur pipette, as described below. 
Layer (from top to bottom) Component 
15 %-iodixanol dilution (7 ml) 1,75 ml OptiPrep  
5,25 ml PBS-MK-NaCl 
25 %- iodixanol dilution (5 ml) 2,08 ml OptiPrep  
2,29 ml PBS-MK 
12,5 μl phenol red (0,5 %) 
40 %- iodixanol dilution (4 ml) 2,67 ml OptiPrep  
1,33 ml PBS-MK 
60 %- iodixanol dilution (4 ml) 4 ml OptiPrep  
10 μl phenol red (0,5 %) 
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Virus Crude AAV lysate 
About 1 ml of space was left above the gradient. Tubes were sealed and centrifuged in a 50.2 Ti 
rotor at 50000 g and 10°C for 2 hours. Two gradients were run for each virus (two rounds of 
transfection). After centrifugation, the 40% iodixanol layer (~3.5 ml) was carefully collected by 
inserting a 5 ml syringe with a 20G needle from underneath. Aliquots of 15 µl were taken for the 
determination of the virus concentration by qPCR as described in the next section. The rest of the 
virus was kept at -80°C until use. 
5.3.8 AAV titration 
Viral DNA was isolated by mixing 5 μl of virus suspension with 5 μl H2O and 10 μl 2 M NaOH. The 
mixture was incubated at 56°C for 30 minutes and the reaction was then neutralized by adding 10 
μl 2 M HCl. After adding 970 μl H2O, the titre was determined by qPCR using an EGFP standard 
curve. This standard curve was created three independent times by serial dilutions of pdsAAV-
LP1-EGFPmut-miRNC. The qPCR was performed using these standard dilutions and duplicates 
of the samples. The primers used were from Eurofins MWG Operon and are listed in the material 
section. The qPCR was performed as described in 5.1.3.5. 
5.4 Animal experiments 
5.4.1 General procedures and housing 
The animals were housed according to international standard conditions with a 12 hours dark, 12 
hours light cycle and regular unrestricted diet with free access to water if not stated otherwise. 
Animal handling and experimentation was performed in accordance with NIH guidelines and 
approved by local authorities (Regierungspräsidium Karlsruhe). Blood was taken after cervical 
dislocation. Organs including liver, fat pads, and gastrocnemius muscles were collected, weighed, 
snap-frozen in liquid nitrogen and used for further analysis. 
5.4.2 Mouse models 
5.4.2.1 24h fasting 
For a starvation challenge, 11-13 weeks old male GADD45β+/+ and Gadd45β-/- littermates (in 
this work called GADD45β WT and KO, respectively) were used. They were generated as 
described elsewhere [155]. They are inbred with the dkfz facility for many generations and are on 
a pure C57Bl6/J background. They were kept on control diet for a week before food withdrawal. A 
blood sample of 50 µl was taken before the removal of food. The mice were sacrificed 24 hours 
later. The grouping was as follows: 
Genotype  Animals 
GADD45β WT 5 
GADD45β KO 8 
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In another starvation study, male 16 weeks old Gadd45β WT and KO mice were single housed 
and kept on control diet for a week as described. Afterwards, the animals were transferred to the 
PhenoMaster system (TSE). The TSE PhenoMaster is a high-throughput phenotyping platform for 
fully automated metabolic, behavioural, and physiological monitoring. Measured parameters 
included body weight, food and water intake, indirect gas calorimetry and activity. The mice were 
acclimated to that system for 4 days before food withdrawal. 24 hours later food was given back 
and the mice were monitored for another period of 3 days before sacrifice. The grouping was as 
follows: 
Genotype  Animals 
GADD45β WT 4 
GADD45β KO 6 
To study the effect of the other GADD45β family member GADD45γ, 13-20 week old GADD45γ 
WT and KO littermates were also examined under the stress of nutrition deprivation. The 
experimental setting was the same as for the first 24 hour fasting study with GADD45β WT and 
KO mice. Since GADD45γ KO male mice cannot form gonads during embryogenesis and are 
hence not to be called “male” [257], the study was conducted only with female (XX) mice. The 
grouping was as follows: 
Genotype  Animals 
GADD45γ WT 5 
GADD45γ KO 5 
 
5.4.2.2 Methionine/choline deficiency studies 
For a methionine/choline deficiency (MCD) study, mice at an average age of 12 weeks were first 
acclimated for a week on control diet (Con) before switching to either MCD diet or control diet for 
3 weeks. Mice were single housed to determine food intake and feed efficiency and not sacrificed 
in the fasted state. At the beginning and at the end of the study, body composition was measured 
(see 5.4.3.1). The grouping was as follows: 
Genotype  Diet Animals 
GADD45β WT Con 2 
GADD45β WT MCD 2 
GADD45β KO Con 6 
GADD45β KO MCD 6 
 
5.4.2.3 Fasting and Refeeding 
For an extensive fasting and refeeding study, male C57Bl6/J mice at the age of 13 weeks were 
used. Different groups of mice were fasted for 8 hours, 24 hours and 48 hours, respectively, and 
subsequently refed for 1 hour, 6 hours or 24 hours before the sacrifice. The study was performed 
by Drs. Mauricio Berriel Diaz and Julia Jäger who kindly offered liver samples for Gadd45b mRNA 
expression analysis. 
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5.4.2.4 Aging model 
To study the effect of GADD45β in the more natural condition of altered metabolism during aging, 
male C57Bl6/J mice of different ages were faced a feeding and fasting challenge. More 
specifically, the mice were either 22 months old or 12 weeks young and were either fasted for 16 
hours or refed for 6 hours. Dr. Katharina Niopek who has run this study kindly provided cDNA 
from liver samples to study the Gadd45b mRNA expression levels. The grouping was as follows: 
Age  Nutritional status Animals 
22 months 16 hours fasted 5 
22 months 6 hours refed 5 
12 weeks 16 hours fasted 5 
12 weeks 6 hours refed 5 
 
5.4.2.5 Streptozotocin treatment 
Streptozotocin (STZ) is a diabetogenic agent that leads to the destruction of the insulin secreting 
β-cells of the islets of Langerhans in the pancreas by generating ROS [250,392]. Without β-cells 
insulin secretion is shut down and the individual becomes type 1 diabetic. STZ is commonly used 
to induce diabetes in rodent disease models [251]. Male rodents are more susceptible to STZ-
induced hyperglycaemia compared to females [251]. The study was performed by Dr. Anja 
Krones-Herzig and Tjeerd Petrus Sijmonsma and liver samples were kindly offered to measure 
Gadd45b mRNA expression levels. STZ was obtained from Axxora (LKT) and a 6 mg/ml solution 
in sodium citrate (0,05M, pH 4,5, sterile filtered) was freshly prepared. Male 8 weeks old C57Bl6/J 
mice were weighed and 60 mg/kg STZ were injected intraperitoneally on 6 subsequent days. 
Control animals were injected with vehicle (sodium citrate). Diabetes was verified 20 days later by 
measuring blood glucose. To avoid access mortality, Caninsulin® was administered 
intraperitoneally twice a week to stabilize the blood glucose levels around 350 mg/dl. Mice were 
sacrificed 6 months after STZ administration was started. The grouping was as follows: 
Group  Animals 
Vehicle 10 
STZ 13 
5.4.2.6 Obesity models 
db/db mice 
12 week old male BKS.Cg-m+/+ Lepr DB/J (in this work called db/db) or C57Bl6/J control mice 
were acclimated for a week on regular unrestricted diet. After a week food was removed from half 
of the mice in both groups and those animals were fasted for 24 hours before sacrifice. This study 
was performed by my colleague Dr. Roldan de Guia who measured the serum metabolites by 
himself and kindly offered liver, fat and gastrocnemius muscle powder for the analysis of liver 
metabolites and Gadd45b mRNA levels in the different tissues. The grouping was as follows: 
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Genotype  Nutritional status Animals 
WT Random fed 4 
WT 24h fast 4 
db/db Random fed 4 
db/db 24h fast 4 
ob/ob mice 
A similar experiment to the db/db study was performed with B6.Cg-Lepob/J mice (in this work 
called ob/ob). 7 weeks old ob/ob mice or C57Bl6/J control mice were acclimated for two weeks 
before food was removed from half of the mice in both groups. The mice were sacrificed 24 hours 
later. This study was conducted by Dr. Mauricio Berriel Diaz who kindly provided cDNA from liver 
samples to study the mRNA expression of Gadd45b. The grouping was as follows: 
Genotype  Nutritional status Animals 
WT Random fed 4 
WT 24h fast 4 
ob/ob Random fed 4 
ob/ob 24h fast 4 
NZO/NZB mice 
To test whether the Gadd45b mRNA levels were also affected in a third mouse model of obesity, 
New-Zealand-obese (NZO) mice and matching control animals (New-Zealand black, NZB) were 
ordered from Charles Rivers at the age of 12 weeks and maintained on normal chow diet 
acclimation. For a starvation experiment, animals were allowed free access to food or were food 
deprived for 24 hours before sacrifice. This study was also performed by Dr. Mauricio Berriel Diaz 
who kindly provided cDNA from liver samples to study the mRNA expression of Gadd45b. The 
grouping was as follows: 
Genotype  Nutritional status Animals 
NZB Random fed 4 
NZB 24h fast 4 
NZO Random fed 4 
NZO 24h fast 4 
High-fat diet induced obesity 
In high-fat diet experiments, 12 week old male GADD45β WT and KO littermates were acclimated 
on low-fat control diet for a week before fed a high-fat diet (HFD) or low-fat control diet (NFD) for 
a period of 16 weeks. After 4 weeks on diet a glucose tolerance test and after 15 weeks on diet 
an insulin tolerance test was conducted. For details see sections 5.4.3.2 and 5.4.3.3. Furthermore 
at the beginning and at the end of the study, body composition was measured (see 5.4.3.1). The 
grouping was as follows: 
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Genotype  Diet Animals 
GADD45β WT NFD 6 
GADD45β WT HFD 6 
GADD45β KO NFD 8 
GADD45β KO HFD 9 
 
5.4.2.7 Adenovirus injections for GADD45β overexpression 
Pilot studies 
To test for the liver-specific overexpression of GADD45β, 1 x109 infectious units per recombinant 
virus were administered via tail vein injection into GADD45β WT and KO mice one week after 
acclimation on control diet. The virus was diluted in PBS/10% glycerol, pH 7,2, and 100 µl was 
injected into each mouse. Two pilot studies were conducted. For the first study, only 14 weeks old 
GADD45β WT received the AD-GADD45β OE. After another week, fasting was conducted 24 
hours before sacrifice for half of the animals. For the second pilot study, AD-NC and AD-
GADD45β OE particles were administered to 6 months old GADD45β KO mice which were 
sacrificed in the random fed state. For both studies genomic DNA and RNA was extracted to 
measure the hepatic viral load via RT-qPCR (primer pADBlockit-Any provided with the 
BLOCKiT™ Adenoviral RNAi Expression System, Invitrogen) and Gadd45b mRNA levels, 
respectively. The grouping was as follows: 
Genotype  Nutritional status/virus Animals 
GADD45β WT Random fed 2 
GADD45β WT 24h fasted 3 
   GADD45β KO AD-NC 3 
GADD45β KO AD-Gadd45b OE 3 
Rescue experiments 
For studies with overexpression of GADD45β in the murine liver, 1 x109 infectious units per 
recombinant virus were administered via tail vein injection into either male db/db and C57Bl6/J 
control mice or GADD45β WT and KO littermates one week after acclimation on control diet, all at 
the age of 12 weeks. Another week later, mice were fasted for 24 hours before sacrifice. A blood 
sample (50 µl) was always taken before food withdrawal. Additionally, a blood sample was also 
taken from the db/db and control animals before virus injection. The grouping of both studies was 
as follows: 
Genotype  Virus Animals 
WT AD-NC 5 
WT AD-GADD45β OE 4 
db/db AD-NC 6 
db/db AD-GADD45β OE 5 
   
GADD45β WT AD-NC 7 
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GADD45β WT AD-Gadd45b OE 7 
GADD45β KO AD-NC 7 
GADD45β KO AD-Gadd45b OE 8 
 
5.4.2.8 AAV injection for GADD45β knockdown 
Pilot study 
To test for the miRNA-mediated hepatocyte-specific knockdown of GADD45β, 2 x1011 virus 
particles per recombinant AAV were administered via tail vein injection into 6 months old male 
C57Bl6/J mice. The virus with less volume (but same number of viral genomes) was filled up with 
40% iodixanol to 50 µl so that all animals got the same volume of iodixanol. This virus dilution was 
mixed with 50 µl PBS before injection. After three weeks on control diet, fasting was conducted for 
24 hours before sacrifice. Gadd45b mRNA levels were determined in the liver via RT-qPCR. The 
grouping was as follows: 
Virus  Animals 
AAV-NC 3 
AAV-GADD45β KD 5 
HFD-induced obesity 
In another study, hepatocyte-specific GADD45β knockdown was accompanied with HFD 
treatment. After one week of acclimation on control diet, at the age of 9 weeks, 2 x1011 virus 
particles per recombinant AAV were administered via tail vein injection into male C57Bl6/J mice. 
One week later half of the animals switched to HFD. The grouping was as follows: 
Virus Diet Animals 
AAV-NC LFD 8 
AAV-GADD45β KD HFD 8 
AAV-NC LFD 8 
AAV-GADD45β KD HFD 8 
The study was ongoing at the time of preparation of this work. Planned was an insulin tolerance 
test after 15 weeks on HFD and the sacrifice after 16 weeks, after 24 hours of fasting. 
5.4.2.9 Mice for isolation of primary hepatocytes and cell fractionation 
Primary mouse hepatocytes were isolated and cultured as described [393] from 6 male 11 weeks 
old GADD45β WT mice. Half of the animals were deprived of food 24 hours prior to the isolation 
of hepatocytes while the other half had free access to food. The mice were anesthetized by 
intraperitoneal injection of 5 mg 10% ketamine hydrochloride / 100 mg body weight and 1 mg 2% 
xylazine hydrochloride / 100 mg body weight. After opening the abdominal cavity, the liver was 
perfused with HANKS I buffer via the portal vein for 5 minutes at 37°C and subsequently with 
HANKS II buffer for 5-7 minutes until disintegration of the liver structure could be observed. The 
liver capsule was removed and the cell suspension was filtered through a 70 μm cell stainer into a 
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50 ml collection tube. Cells were centrifuged at 30 x g for 3 minutes. The pellet was kept for RNA 
isolation (called hepatocytes) while the supernatant was spun down again at 30 x g for 3 minutes. 
The second pellet was discarded while the supernatant of this second round was centrifuged 
again at 300 x g for 3 minutes. The pellet (called non-parenchymal cells) was kept for RNA 
isolation, cDNA synthesis and RT-qPCR. 
5.4.3 Treatment 
5.4.3.1 Body composition analysis 
Total lean mass and body fat content was determined using an Echo MRITM body composition 
analyser (Echo Medical Systems, Houston). 
5.4.3.2 Glucose Tolerance Test 
In a glucose tolerance test (GTT), glucose is injected into the peritoneum of fasted mice and 
blood samples are taken to determine how quickly the sugar can be cleared from the blood. 
Improved insulin signalling results in lower glucose levels as the sugar load induces a better 
clearance from the blood stream. The animals were transferred to fresh cages with no food and 
fasted for 6 hours prior to the GTT. Before food withdrawal, a blood sample (50 µl) was taken and 
the initial blood glucose levels were determined by cutting the tail tip with a razor blade. Blood 
glucose was measured using a glucometer strip. 5 μl/g body weight of a 20% glucose solution (in 
0,9% NaCl) were then injected (to give a dose of 1g/kg body weight) and the blood glucose was 
monitored after 20, 60 and 120 minutes. 
5.4.3.3 Insulin Tolerance Test 
An insulin tolerance test (ITT) is a procedure in which insulin is injected into the peritoneum of 
fasted mice to assess if it can still induce its full function. If mice are insulin resistant, blood 
glucose levels are elevated over time. The animals were transferred to fresh cages with no food 
and fasted for 6 hours prior to the ITT. Before food withdrawal, the body weight of all animals was 
determined, a blood sample (50 µl) was taken and the initial blood glucose levels were 
determined by cutting the tail tip with a razor blade. Blood glucose was measured using a 
glucometer strip. For the insulin tolerance test a stock solution of 200 mU insulin/ml was prepared 
using 0,9% NaCl. 5 µl per gram body weight of the stock solution, which makes 1 U insulin/kg 
body weight, was injected intraperitoneally. The blood glucose levels were monitored after 10, 20, 
30, 60 and 120 minutes. If the blood glucose levels dropped under 20 mg/dl mice had to be 
rescued by injecting 100 µl of a 20% glucose solution (in 0,9% NaCl) and consequently were 
excluded from the analysis. 
5.4.4 Preparation of Blood serum 
Blood serum was obtained by storing of blood samples at 4°C for 30-60 minutes and subsequent 
centrifugation for 1 hour at 3000 rpm, 4°C. The serum (upper phase) was transferred to a new 
tube and stored at -80°C. 
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5.5 Human subjects 
Liver tissue samples were obtained from 37 Caucasian lean and obese men, 14 with and 23 
without T2D, who underwent open abdominal surgery for Roux-en-Y bypass, sleeve gastrectomy 
or elective cholecystectomy by Prof. Dr. Matthias Blüher and colleagues from the University 
Hospital Leipzig, Germany. Liver biopsy was taken during the surgery, immediately frozen in 
liquid nitrogen and stored at -80°C until further use. The phenotypic characterization of the cohort 
has been performed as described previously [394]. Serum samples were taken between 8 am 
and 10 am after an overnight fast. The study was approved by the local ethics committee of the 
University of Leipzig, Germany (363-10-13122010 and 017-12-230112). All patients gave 
preoperative written informed consent for the use of their samples. The grouping was as follows: 
Glucose Tolerance Body composition Men 
Type 2 diabetes Lean 3 
 Subcutaneous fat 3 
 Visceral fat 8 
Normal glucose tolerant Lean 8 
 Subcutaneous fat 13 
 Visceral fat 2 
 
5.6 Nomenclature of genes and proteins 
In general, mRNA and cDNA transcripts of genes are addressed using italicised characters, 
whereas proteins are addressed using upright characters. Human gene symbols are italicized, 
with all letters in uppercase (e.g. GADD45B); protein designations are the same as the gene 
symbol, but are not italicized, with all letters in uppercase (GADD45β). Mouse gene symbols 
generally are italicized, with only the first letter in uppercase and the remaining letters in 
lowercase (Gadd45b); protein designations are the same as the gene symbol, but are not 
italicized and all are upper case (GADD45β).  
5.7 Statistical Analysis 
Data plotted in figures are mean ± standard error of the mean (SEM). Statistical analyses were 
performed using either a 2-way analysis of variance (ANOVA) with Holm-Sidak-adjusted post-
tests in two-factorial designs, a 2-way repeated measurement  ANOVA with Holm-Sidak-adjusted 
post-tests tests in two-factorial designs when factors of the same subject were determined 
repeatedly at different time points, or t-test in one-factorial designs. Correlation was determined 
using Shearman’s correlation coefficient. p < 0.05 was considered statistically significant. *p < 
0.05, **p < 0.01, ***p < 0.001.  
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6. MATERIAL 
6.1 Buffers and Solutions 
All buffers are 1x and diluted in H2O, unless indicated otherwise. 
Name Component 
2x SDS sample buffer  120 mM Tris /HCl pH 6.8  
4% SDS  
20% glycerol  
200 mM DTT  
0.01% bromophenol blue  
5x SDS sample buffer  250 mM Tris/HCl pH 6.8  
10 % SDS  
50 % glycerol  
0.5 M DTT  
0.01% bromophenol blue  
HANKS I buffer  8 g NaCl  
0.4 g KCl  
3.57 g Hepes  
0.06 g KH2PO4  
0.06 g Na2HPO4 x 2 H2O  
add 1L distilled H2O  
2.5 mM EGTA  
0.1% Glucose  
pH 7.4  
HANKS II buffer  8 g NaCl  
0.4 g KCl  
3.57 g Hepes  
0.06 g KH2PO4  
0.06 g Na2HPO4 x 2 H2O  
add 1L distilled H2O  
3 mg/ml Collagenase CLSII 5 mM CaCl2  
0.1% Glucose  
pH 7.4  
LB medium  10 g/l Trypton  
5 g/l Yeast extract  
10 g/l NaCl  
pH 7.0  
Lysis buffer (AAV) 150 mM NaCl 
50 mM Tris HCl 
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pH 8.5 
Lysis Buffer (DNA extraction) 100 mM NaCl 
10 mM Tris 
15 mM EDTA 
0,5 % SDS 
pH 8,0 
NID buffer 50 mM KCl 
10 mM Tris HCl, pH 8,3 
2 mM MgCl2 
0,1 mg/ml gelatin 
0,45 % NP-40 
0,45 % Tween-20 
Orange G loading dye (6x)  10 mM EDTA  
70% Glycerol  
A pinch Orange G  
PBS (10x)  1.4 M NaCl  
27 mM KCl  
100 mM Na2HPO4  
8 mM KH2PO4  
pH 6.8  
PBS-MK 1x PBS 
1 mM MgCl2 
2,5 mM KCl 
PBS-MK-NaCl 1x PBS 
1 mM MgCl2 
2,5 mM KCl 
1 M NaCl 
PBS-TOSH  30.8 mM NaCl  
120.7 mM KCl  
8.1 mM Na2HPO4  
1.46 mM KH2PO4  
10 mM MgCl2  
pH 7.2, sterile filtrated  
RIPA Buffer 50 mM Tris HCl pH 8,0 
150 mM NaCl 
1 mM EDTA pH 8,0 
1% NP-40 
0,1% SDS 
0,5% Sodium deoxycholate 
RNA denaturing buffer (100 µl) 0,5 µl 10 mg/ml ethidium bromide 
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5 µl 10x MOPS 
50 µl Formamide 
17,5 µl 37% Formaldehyde 
16,7 µl 6x Orange G 
10,3 µl RNase-free water 
SDS running buffer (10x)  0.25 M Tris  
1.92 M Glycine  
1% SDS  
TAE buffer (10x)  400 mM Tris  
1 mM EDTA  
20 mM acetic acid 
pH 8.0  
TBE buffer (10x) 20 mM Tris 
137 mM NaCl 
pH 7,6 
TE buffer (10x) 1 mM EDTA  
10 mM Tris HCl  
pH 8.0  
Transfer buffer  25 mM Tris  
192 mM Glycine  
20% Methanol  
0.01% SDS  
TBS 20 mM Tris 
137 mM NaCl 
pH 7,6 
TBS-T 1x TBS  
0.1% Tween 20   
 
6.2 Chemicals and Reagents 
Chemical/Reagent Distributor 
Acetic acid (99%)  Sigma, Munich  
Acetone  Sigma, Munich 
Acrylamide-bisacrylamide Solution (37.5 : 1)  Carl Roth GmbH, Karlsruhe  
Agarose  Sigma, Munich  
Ammonium persulfate (APS)  Carl Roth GmbH, Karlsruhe  
Antibiotics  Sigma, Munich  
Bovine serum albumin (BSA)  Sigma, Munich  
Bromophenol blue  Sigma, Munich  
Cesium chloride Carl Roth GmbH, Karlsruhe 
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Chloroform  DKFZ  
Desoxynucleotides (dATP, dCTP, dGTP, dTTP)  Roche, Mannheim  
Dexamethasone  Sigma, Munich  
Dimethyl sulfoxide (DMSO) Sigma, Munich 
DTT (Dithiothreitol) Sigma, Munich 
Dulbecco’s modified Eagle’s medium (DMEM)  Invitrogen, Karlsruhe  
Dulbecco’s modified Eagle’s medium (DMEM)/F-12  Invitrogen, Karlsruhe  
Dulbecco's Phosphate Buffered Saline (D-PBS) (10X) Invitrogen, Karlsruhe 
Ethanol (99%)  DKFZ  
Ethidium bromide  Carl Roth GmbH, Karlsruhe  
Ethylenediaminetetraacetic acid (EDTA) Sigma, Munich  
Ethylenglycoltetraacetic acid (EGTA) Sigma, Munich 
Fetal calf serum (FCS)  Invitrogen, Karlsruhe  
Gelatin from bovine skin, Type B Sigma, Munich 
Glucose  Sigma, Munich  
Glycerol  Baker, Deventer, NL  
Glycine Sigma, Munich 
Hank’s balanced salt solution (HBSS) Invitrogen, Karlsruhe 
Hepes  Roth, Karlsruhe  
High Range DNA ladder Fermentas, St. Leon Rot 
Hydrochloric acid (HCl) 37%  Acros Organics, New Jersey, USA  
Igepal (Nonidet NP40)  Sigma, Munich  
Isopropanol  Sigma, Munich  
Insulin (human, 100 units/ml) Lilly Germany, Gießen 
Insulin-transferrin-selenium supplement Roche, Penzberg 
LB-Agar  Carl Roth GmbH, Karlsruhe  
LB-Medium  Carl Roth GmbH, Karlsruhe  
L-Glutamine Invitrogen, Karlsruhe 
Lipid Mixture 1 Sigma, Munich 
Lipofectamine2000 Reagent  Invitrogen, Karlsruhe  
Loading dye solution (6x)  Fermentas, St. Leon Rot  
Low Range DNA ladder Fermentas, St. Leon Rot 
Magnesium chloride (MgCl2)  Merck, Darmstadt  
MEM Amino Acids Solution (50X) Invitrogen, Karlsruhe 
MEM Vitamin Solution (100X) Invitrogen, Karlsruhe 
Methanol (100%)  Sigma, Munich 
Milk powder  Sigma, Munich 
Non-essential amino acids (100x) Invitrogen, Karlsruhe  
Oligo(dT)18 Primer Fermentas, St. Leon Rot 
OptiMEM  Invitrogen, Karlsruhe  
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OptiPrep(R) Density Gradient Medium Sigma, Munich 
Orange G  Sigma, Munich  
Page RulerTM Prestained Protein Ladder  Fermentas, St. Leon Rot  
Penicillin / Streptomycin (P/S)  Invitrogen, Karlsruhe  
Phosphatase Inhibitor Cocktail  Roche, Penzberg  
Polyamine Supplement (1000×) Sigma, Munich 
Polyethylenimine Polysciences Inc., Warrington, US 
Ponceau-S Solution  Sigma, Munich  
Potassium chloride (KCl)  Sigma, Munich  
Potassium dihydrogen phosphate >99% (KH2PO4) Carl Roth GmbH, Karlsruhe 
Proteinase inhibitor cocktail  Roche, Penzberg  
Qiazol Lysis Reagent  Qiagen, Hilden  
RiboLock Ribonuclease Inhibitor  Fermentas, St. Leon Rot  
Sodium bicarbonate solution 7,5% Invitrogen, Karlsruhe 
Sodium chloride (NaCl)  Invitrogen, Karlsruhe  
Sodium deoxycholate 97% Sigma, Munich 
Sodium dodecyl sulfate (SDS)  Gerbu Biotechnik GmbH, Gaiberg  
Sodium fluoride (NaF)  Sigma, Munich  
Sodium hydrogen phosphate dibasic dihydrate 
(Na2HPO4) 
Sigma, Munich 
Sodium hydroxide (NaOH)  Sigma, Munich  
Sodium orthovanadate Sigma, Munich  
Sodium pyruvate Invitrogen, Karlsruhe 
N,N,N’,N’-Tetramethylenediamine (TEMED)  Carl Roth GmbH, Karlsruhe  
Tris base  Sigma, Munich  
Triton X-100  Sigma, Munich  
Trypsin-EDTA solution  Invitrogen, Karlsruhe  
Tween-20  Sigma, Munich  
Urea  Sigma, Munich  
β-Mercaptoethanol (98%)  Sigma, Munich  
Williams Medium E  Sigma, Munich  
 
6.3 Consumabales 
Consumable Distributor 
1-stack cell culture dishes  Sigma, Munich  
10-stack cell culture dishes  Sigma, Munich  
6 well tissue culture dishes  Falcon, Gräfeling-Lochham  
96 well MicroAmp plates  Applied Biosystems  
96-well Microtiter® luminescense plates  Nunc, Wiesbaden  
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Cell strainer (70 µm) Falcon, Gräfeling-Lochham 
Centrifuge tubes (500 ml) Corning, Wiesbaden 
Combitips advanced® (0.5, 5, 10 ml), sterile Eppendorf, Hamburg 
CountessTM cell counting chamber slides Invitrogen, Darmstadt 
Cryo tubes (2 ml)  Cryo tubes (2 ml)  
Dialysis tubing  Carl Roth GmbH, Karlsruhe  
Disposable scalpels  Feather, Cuome, JP  
DNase / RNase free water  Invitrogen, Karlsruhe  
Filters (0.22 μm)  Millipore, Eschborn  
Filters (0.45 μm) Millipore, Eschborn 
Filters (0.8 μm)  Millipore, Eschborn  
Filters (5 μm) Millipore, Eschborn 
Gel staining boxes (Mini)  Carl Roth GmbH, Karlsruhe  
Gloves (Blossom®) Mexpo International, Hayward 
Gloves (Safe Skin Purple Nitrile) Kimberly Clark, BE  
Glucose test stripes, OneTouch® Ultra LifeScan, Neckargemünd 
Insulin Syringes (Micro-FineTM+ Demi) BD Medical, Heidelberg 
Millex-GV filter unit PVDF, 0.22 µm Merck KGaA, Darmstadt 
Mouth protection  Meditrade, Kiefersfelden  
NeedleSterican®, 20G B. Braun, Melsungen 
NeedleSterican®, 27G B. Braun, Melsungen 
Nitrocellulose membrane Schleicher and Schüll, Dassel  
Parafilm  Pechinery Inc., Wisconsin, USA  
Pasteur pipettes  Brand, Wertheim  
PCR tubes  Kisker Biotech, Steinfurt 
Petri dishes  Greiner, Kremsmünster, AU  
Pipette tips (0.1 – 1000 μl)  Starlab, Helsinki, FI  
Pipette tips (0.1 – 1000 μl) (Tip One Filter Tips)  Starlab, Helsinki, FI  
Pipette tips (Electrophoresis / Protein)  Biorad, Munich 
Pipette tips for LiquidatorTM (200 µl) Steinbrenner, Wiesenbach 
Polyallomer tubes (14mm x 89 mm)  Beckmann, Munich  
Polyallomer tubes (25 mm x 89 mm) Beckmann, Munich 
Round bottom tubes (14 ml) Falcon, Gräfeling-Lochham 
Safelock micro test tubes (1.5 ml and 2 ml)  Eppendorf, Hamburg  
Serological pipettes (5 ml, 10 ml, 25 ml, 50 ml)  BD Biosciences, San Jose, USA  
SpeedVac Eppendorf, Hamburg 
Stainless Steel Beads (5 mm) Qiagen, Hilden 
Syringes (5 ml)  Terumo, Leuven  
Syringes (10 ml Luer Lock)  Terumo, Leuven  
Syringes (50 ml)  Terumo, Leuven  
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Test tubes (15 ml and 50 ml)  Falcon, Gräfeling-Lochham  
Tissue culture dishes (10 cm and 15 cm)  Falcon, Gräfeling-Lochham  
WhatmanTM paper  GE Healthcare, Solingen 
 
6.4 Kits 
Kit Distributor 
Alanine Assay Kit BioVison, Mountain View, US 
BLOCK-iTTM U6 RNAi Entry Vector Kit  Invitrogen, Karlsruhe  
Branched Chain Amino Acid Assay Kit BioVison, Mountain View, US 
Cholesterol determination Kit  Randox, Crumlin, UK  
Dnase Set, Rnase-free Qiagen, Hilden 
Enhanced Chemiluminescence (ECL) Kit  Amersham Biosciences, Freiburg  
First Strand cDNA Synthesis Kit  Fermentas, St. Leon-Rot  
Glucose (HK) Assay Kit Sigma-Aldrich, München 
Infinity ALT Kit  Thermo Electron, Melbourne  
Insulin ELISA Kit (mouse) Alpco 
NEFA – C Determination Kit  Wako, Neuss  
Pierce® BCA Protein Assay Kit Thermo Fisher Scientific, Schwerte 
Phusion Polymerase Kit  Finnzymes, Vantaa  
QiaPrep Plasmid Miniprep Kit  Qiagen, Hilden  
QiaQuick Gel Extraction Kit  Qiagen, Hilden 
QIAGEN Plasmid Mega Kit  Qiagen, Hilden 
QiaQuick PCR Purification Kit  Qiagen, Hilden 
QuantiTect SYBR Green PCR Kit Qiagen, Hilden 
RNeasy® RNA Extraction Kit  Qiagen, Hilden 
TaqMan® Gene Expression Master Mix Life Technologies, Damstadt 
Triglycerides Determination Kit  Sigma, Munich 
 
6.5 Antibodies 
All phospho antibodies were diluted in 5% BSA/TBS-T. All other antibodies were diluted in 2% 
skim milk/TBS-T. 
Primary Antibody Dilution Isotope Distributor 
Actin 1:1000 Mouse Sigma, A5441  
Akt 1:1000 Rabbit Cell Signaling, #9272 
Phospho Akt (Ser473) 1:1000 Rabbit Cell Signaling, #9271 
Phospho Akt (Thr308) 1:1000 Rabbit Cell Signaling, #13038 
Flag M2 1:1000 Mouse Sigma, #A8592  
FoxO1 1:1000 Rabbit Cell Signaling,# 9454 
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Phospho FoxO1 (Ser256) 1:1000 Rabbit Cell Signaling,# 9461 
GADD45β 1:250 Goat Santa Cruz, sc-8776 
GSK3β 1:1000 Rabbit Cell Signaling, #9315 
Phospho GSK3β (Ser9) 1:1000 Rabbit Cell Signaling, #9336 
IRS-1 1:1000 Rabbit Cell Signaling, #3407 
Phospho IRS-1 (Ser1101) 1:1000 Rabbit Cell Signaling, #2385 
JNK 1:1000 Rabbit Cell Signaling, #9252 
Phospho JNK (Thr183/Tyr185) 1:1000 Rabbit Cell Signaling, #9255 
Phospho p38 (Thr180/Tyr182) 1:1000 Rabbit Cell Signaling, #9211 
p85 (PI3K) 1:1000 Rabbit Cell Signaling, #4292 
S6K1 1:1000 Rabbit Cell Signaling, #2708 
Phospho S6K1 (Thr389) 1:1000 Rabbit Cell Signaling, #9234 
VCP 1:10000 Mouse Abcam, #ab11433 
 
Secondary Antibody Dilution Isotope Distributor 
Anti-goat, Fc Fragment Specific, 
IgG-HRP 
1:5000 Rabbit Thermo Scientific, #31433 
Anti-mouse IgG-HRP  1:5000 Goat Biorad, #170-6516 
Anti-rabbit, IgG-HRP  1:5000 Goat Biorad, #172-1019 
 
6.6 Enzymes 
Enzyme Distributor 
Amyloglucosidase Sigma, Munich 
Benzonase Sigma, Munich 
Collagenase Type ll  Sigma, Munich  
DNase I Qiagen, Hilden 
Proteinase K Thermo Scientific, Schwerte 
T4 Ligase Invitrogen, Karlsruhe 
 
6.7 Plasmids 
Plamid Distributor 
pCMV-SPORT6 mGadd45b imaGenes, Berlin 
pENTR-Flag Invitrogen, Karlsruhe  
pAd-BlockIT-DEST Invitrogen, Karlsruhe 
pcDNA6.2-GW/EmGFP-miR Invitrogen, Karlsruhe 
pdsAAV-LP1-GFPmut-miR-NC unknown 
pDGΔVP D. Grimm et al., 1998 
p5E18-VD2/8 G.P. Gao et al., 2002 
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6.8 Oligonucleotides 
All oligonucleotides possessed a G/C content between 40% and 60% and were approximately 20-
30bp in length.  
Restriction sites for specific enzymes were added to the cloning primers in 5’→3’ orientation, 
allowing directed insertion into a specific target vector. Six thymidine residues were added to the 
5’ ends of the restriction sites in order to facilitate cleavage. The primers were designed to 
hybridize at temperatures of approximately 60°C. 
 
Oligonucleotide Purpose Sequence (5‘  3‘) 
miR-Gadd45b_for AAV production TGCTGACATTCATCAGTTTGGCCGCCGTTTTGGC
CACTGACTGACGGCGGCCACTGATGAATGT 
miR-Gadd45b_rev AAV production CCTGACATTCATCAGTGGCCGCCGTCAGTCAGT
GGCCAAAACGGCGGCCAAACTGATGAATGTC 
mGadd45b_for AD production TTTTTGCGGCCGCCACCCTGGAAGAGCTGGTGG
CG 
mGadd45b_rev AD production TTTTTCTCGAGTCAGCGTTCCTCTAGAGAGATAT
AG 
Gadd45b_for Genotyping GGGACAGTGAACTGTGCATAAG 
Gadd45b_rev Genotyping CAAGCGATCTGTCTTGCTCA 
Gadd45b_neo Genotyping GCATGCTCCAGACTGCCTT 
Gadd45g_for Genotyping GCTGTGCTTTCCGGAACTGTA 
Gadd45g_rev Genotyping GTGGGCTCTATGGCTTCTGA 
Gadd45g_pgk Genotyping CCTGCCGCCTCATTTGCA 
EGFP-C1-F Sequencing GAAGCGCGATCACATGGTC 
CMV-for Sequencing CGCAAATGGGCGGTAGGCGTG 
TkpA-rev Sequencing GTGGGGTATCGACAGAGTGC 
 
6.9 Taqman and SYBR probes 
6.9.1 Taqman probes from Life Technologies 
Gene Assay ID 
Abca1 mm00442646_m1 
Acly Mm00652520_m1 
Atp6v0d2 Mm01222963_m1 
Cd31 mm01242584_m1 
Cd36 Mm00432403_m1 
Ces4a mm00600647_m1 
Cidec Mm00617672_m1 
Cyp2b9 Mm00657910_m1 
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Cyp2b10 Mm00456591_m1 
Desmin mm00802455_m1 
Emr1 mm00802529_m1 
Fabp5 mm00445880_m1 
Gadd45a Mm00432802_m1 
Gadd45b Mm00435121_g1 
Gadd45g Mm01352550_g1 
GAPDH Mm99999915_g1 
G6Pase Mm00839363_m1 
GCK Mm00439129_m1 
HNF4a mm00433964_m1 
Pck1 mm00440636_m1 
Serpina4-ps1 Mm00657552_m1 
Slco1a1 Mm00649796_m1 
Tsc22d1 mm00493633_m1 
 
6.9.2 Taqman probes from Eurofin MWG 
Gene Sequence 
TBP forward TTGACCTAAAGACCATTGCACTTC 
TBP reverse TTCTCATGATGACTGCAGAAA 
TBP probe 5’FAM‐TGCAAGAAATGCTGAATATAATCCCAAGCG‐3’TAMRA 
EGFP-ANY_for GAGCGCACCATCTTCTTCAAG 
EGFP-ANY_rev TGTCGCCCTCGAACTTCAC 
EGFP-ANY_probe FAM-ACGACGGCAACTACA-TAMRA 
 
6.9.3 SYBR probes from Qiagen 
Gene Assay ID 
Derl3 QT00159880 
Klf12 QT00109487 
Lcn2 QT00113407 
Lcor QT01073541 
Lnpep QT01764812 
N4bp2 QT00306404 
Nudt7 QT00110740 
Onecut1 QT00297815 
Saa2 QT00144151 
Vps13b QT01073247 
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Zbed6 QT02330083 
Zfp369 QT00142401 
 
6.10 Cell lines 
Cell line Distributor 
HEK 293 (human embryonic kidney) cell line ATTC, Wesel 
HEK 293-T (human embryonic kidney) cell line ATTC, Wesel 
HEK 293-A (human embryonic kidney) cell line ATTC, Wesel 
Hepa1c1 mouse hepatoma cell line ATTC, Wesel 
AML12 (alpha mouse liver 12) cell line ATTC, Wesel 
E. coli SURE2® Chemically Competent Cells Qiagen, Hilden 
E. coli TOP 10 Chemically Competent Cells Invitrogen, Karlsruhe 
 
6.11 Animals and Diets 
Mouse Distributor 
BKS.Cg-m+/+ Lepr DB/J (db/db) Charles River, Brussels, Belgium 
B6.Cg-Lepob/J (ob/ob) Charles River, Brussels, Belgium 
New Zealand obese (NZO) Charles River, Brussels, Belgium 
New Zealand black (NZB) Charles River, Brussels, Belgium 
C57Bl6/J Charles River, Brussels, Belgium 
B6.CgGADD45βtm1Daa DKFZ in house breeding 
B6.CgGADD45γtm1Daa Prof. C. Niehrs, IMB Mainz, Germany 
 
Diet Composition (kcal %) Distributor 
Low fat diet (LFD)/Control diet, γ-
irradiated 
Protein: 20  
Carbohydrates: 70 
Fat:10 
Research Diets Inc., New 
Brunswick, US 
High fat diet (HFD), γ-irradiated Protein: 20 
Carbohydrates: 20 
Fat: 60 
Research Diets Inc., New 
Brunswick, US 
Methionine-Choline-Deficient 
(MCD) diet, γ-irradiated  
Protein: 16 
Carbohydrates: 63 
Fat: 21 
Research Diets Inc., New 
Brunswick, US 
Control diet for MCD, γ-irradiated Protein: 16 
Carbohydrates: 63 
Fat: 21 
Research Diets Inc., New 
Brunswick, US 
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6.12 Software 
Software Distributor 
Endnote  Thomson, Carlsbad, USA  
Geneious  Auckland, New Zealand  
Image Lab  Bio-Rad Laboratories  
Microsoft Office  Microsoft, Unterschleißheim  
Photoshop  Adobe, San Jose, USA  
Pubmed  http://www.pubmedcentral.nih.gov  
StepOne Plus  
Applied Biosystems, Darmstadt System 
Software  
 
6.13 Intruments and Equipment 
Equipment Distributor 
Accu-Chek® Performa MIC Roche Diagnostics, Mannheim 
Analytical scales  Satorius, Göttingen  
Bacterial shaker  Infors AG, Böttmingen, CH  
Bunsen Burner Campingaz, Hattersheim 
Centrifuge (2K15)  Sigma, Munich  
Centrifuge (Biofuge fresco)  Heraeus, Hanau  
Centrifuge (Biofuge pico)  Heraeus, Hanau  
Centrifuge (Function Line)  Heraeus, Hanau  
Centrifuge (Micro 22R)  Hettich GmbH & Co, Tuttlingen  
Centrifuge (Super T21)  Heraeus Sorvall, Langenselbold  
ChemiDoc  BioRad, Munich  
CO2-incubator  Sanyo, Munich  
CO2-incubator (Forma Scientific)  Labotect, Göttingen  
Countess Cell counter  Invitrogen, Karlsruhe  
Echo MRITM Analyser Echo Medical Systems, Houston 
Electrophoresis chamber  Steinbrenner, Wiesenbach  
Electrophoresis power supply (Power Pack Basic)  BioRad, Munich  
Electrophoresis power supply (Power Pack HC)  BioRad, Munich  
Freezer, -20°C  Liebherr, Biberach  
Freezer, -80°C (Hera Freeze)  Heraeus, Heilbronn  
Fridge, 4°C  Liebherr, Biberach  
Gel imager  Intas, Göttingen  
Heat block  (Thermomixer comfort) Eppendorf, Hamburg  
Horizontal shaker (Duomax 1030)  Heidolph, Kehlheim  
Hotplate / stirrer  VWR, Darmstadt  
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Incubator (Function Line)  Heraeus, Hanau  
LiquidatorTM 96 Mettler Toledo, Gießen 
Microplate Reader (Spectro Star Omega) BMG Labtech, Ortenberg 
Microplate Reader (Mithras LB 940) Berthold Technologies, Bad Wildbad 
Microscope (Axiovert 40 CFL)  Carl Zeiss, Jena  
Microwave  Bosch, Stuttgart  
Multistep pipette  Eppendorf, Hamburg  
Nitrogen tank  Thermo Electron corp., Erlangen  
pH-meter  VWR, Darmstadt  
Photometer (NanoDrop ND-1000)  Peqlab Biotechnology, Erlangen  
Pipetteboy Integra, Fernwald 
Pipettes (2 μl, 10 μl, 20 μl, 100 μl, 200 μl, 1000 μl)  Starlab, Helsinki, FI  
Multi-Channel pipette 0,5 – 10 µl Eppendorf, Hamburg 
Multi-Channel pipette 10 – 100 µl Eppendorf, Hamburg 
Real time PCR System StepOne Plus  Applied Biosystems, Darmstadt  
Rotating wheel  Neolab, Heidelberg  
Scale  Kern und Sohn GmbH, Balingen  
Scale (BL 1500 S)  Satorius, Göttingen  
Scanner  Epson, Meerbusch  
SDS electrophoresis chambers  BioRad, Munich  
Sonicator BioruptorTM  Diagenode, Liège, Belgium  
Stand  Carl Roth GmbH, Karlsruhe  
Sterile benches (Class II type A/B3)  Sterilgard, Sanford, USA  
Tabletop centrifuges (Mini Spin Plus)  Eppendorf, Hamburg  
Thermocycler (T3000) Biometra, Göttingen 
Tissue Lyser  Qiagen, Hilden  
Titer Plate Shaker Thermo Scientific, Osterode  
Ultracentrifuge (Sorvall WX Ultra 80)  Thermo Scientific, Osterode  
Vacuum pump  Neolab, Heidelberg  
Vortex mixer (REAX 2000)  Heidolph, Kehlheim  
Water bath  Neolab, Heidelberg  
Water bath (WBS)  Fried Electric, Haifa, IL  
Western Blot Chamber  BioRad, Munich  
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9. APPENDIX 
9.1 Glossary 
AA Amino Acid 
AAV  Adeno-associated virus 
AC Acylcarnitine 
ACLY  ATP citrate lyase  
AD Adenovirus 
AICAR Aminoimidazole carboxamide ribonucleotide 
AKT Protein kinase B (PKB) 
ALT  Alanine aminotransferase 
AML12 Alpha mouse liver 12 
AMP  Adenosine monophosphate 
AMPK  AMP-activated kinase 
ANOVA  Analysis of Variance 
ATF Activating transcription factor  
ATP  Adenosine triphosphate  
AU Arbitrary units 
AUC  Area Under the Curve 
aWAT Abdominal white adipose tissue 
BAT Brown adipose tissue 
BCAA Branched-chain amino acid 
BF Body fat 
BMI  Body mass index  
Bp  Base pairs  
BW  Body weight 
C  Celsius  
CAR Constitutive androstane receptor  
CD  Cluster of Differentiation  
cDNA  Complementary DNA 
CE  Cholester-ester  
CETP  Cholesterylester transfer protein  
CMV  Cytomegalovirus 
CVD  Cardiovascular Disease  
DAG Diacylglycerol  
db/db BKS.Cg-Dock7m +/+ Leprdb/J 
DGAT  Diglyceride acyltransferase  
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DMEM  Dulbeccos’s modified eagle medium  
DNA  Deoxyribonucleic acid  
DNL  De novo lipogenesis 
dNTP  deoxyribonucleotide triphosphates  
ECL  Enhanced chemiluminescence  
EDTA  Ethylenediaminetetraacetic acid 
EGFP  Enhanced green fluorescent protein  
ELISA  Enzyme-linked immunosorbent assay  
ER  Endoplasmic Reticulum  
ETC Electron transport chain 
FA  Fatty acids  
FABP  Fatty acid binding protein  
FASN  Fatty acid synthase  
FATP Fatty acid transport protein  
FCS  Fetal calf serum  
FFA Free fatty acid 
Fig  Figure  
FoxO1  Forkhead box protein O1  
FPG Fasting plasma glucose 
G6Pase  Glucose-6-phosphatase 
GADD45α Growth arrest and DNA damage-inducible α 
GADD45β Growth arrest and DNA damage-inducible β 
GADD45γ Growth arrest and DNA damage-inducible γ 
GCM Gastrocnemius muscle  
GS Glycogen synthase 
GSK3β Glycogen synthase kinase 3β 
GTT  Glucose tolerance test 
h  Hour  
HbA1c Glycated hemoglobin 
HBSS Hank’s buffered saline solution  
HDL  High density lipoprotein  
HEK  Human embryonic kidney cells 
HFD  High fat diet  
HGP Hepatic glucose production 
HL  Hepatic lipase  
HOMA  Homeostasis model assessment 
HPRT1 Hypoxanthine-guanine phosphoribosyltransferase 
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HRP  Horseradish peroxidase  
Hz  Hertz 
IDL  Intermediate density lipoprotein  
INFγ Interferone γ 
ip  Intra-peritoneal 
IRE1α Inositol requiring enzyme-1 α 
IRS1 Insulin receptor substrate 1 
ITT Insulin tolerance test 
JNK c-Jun N-Terminal kinase  
KB  Ketone Bodies 
KD Knockdown 
KO knockout 
LB  Ludmilla Broth  
LDL  Low density lipoprotein  
LDLR  LDL receptor  
LM Lean mass 
LPA Lysophosphatidic acid  
LPL  Lipoprotein lipase  
LRP  LDL receptor related protein  
LSR  Lipolysis stimulated lipoprotein receptor  
MC4R Melanocortin 4 receptor  
MCD  Methionine choline deficient diet  
MEKK4 MAP kinase kinase kinase 4 (MTK1) 
Min  Minute  
miRNA  microRNA  
MKK4 MAP kinase kinase 4 
MMS Methyl methanesulfonate  
MOI  Multiplicity of infection 
MRI Magnetic resonance imaging 
mRNA  Messenger RNA  
mTOR Mammalian target of rapamycin  
MTP Microsomal TG transport protein  
NADPH Nicotinamide adenine dinucleotide phosphate 
NAFLD  Non-alcoholic fatty liver disease 
NASH  Non-alcoholic steatohepatitis 
NC  Negative control  
NEAA  Non-essential amino acids  
APPENDIX   
 188 
NEFA  Non-esterified fatty acids  
NFD  Normal fat diet  
NF-κB  Nuclear factor kappa-light-chain enhancer of activated B cells 
NGT Normal glucose tolerance 
NP  Non-parenchymal 
NZB New Zealand Black 
NZO New Zealand Obese 
ob/ob B6.Cg- Leprob/J 
OE  Overexpression  
P/S  Penicillin/Streptomycin 
PA Phosphatidic acid  
PBS  Phosphate buffered saline  
PCA Principle component analysis  
PCK1  Phosphoenolpyruvate carboxykinase 1 (PEPCK) 
PDK  Pyruvate dehydrogenase kinase 
PEI Polyethylenimine 
PIP2 Phosphatidylinositol 4,5-bisphosphate 
PIP3 Phosphatidylinositol (3,4,5)-trisphosphate 
PGC1 PPARgamma co-activator 1 
PI3K Phosphatidylinositol-3-kinase  
PKC Protein kinase C 
PPAR  peroxisome proliferator-activated receptors  
RT-qPCR  Real time quantitative polymerase chain reaction  
RCT  Reverse cholesterol transport  
RER Respiratory exchange ratio 
RNA  Ribonucleic acid 
ROS  Reactive oxygen species 
RQ Respiratory quotient 
SDS  Sodium dodecyl sulfate  
sec  Second 
S6K1 Ribosomal protein S6 kinase 1 
SEM  Standard error of the mean  
SRB1 Scavenger receptor 1 
SREBP1 Sterol Regulatory Element-Binding Protein 1 
STZ  Streptozotocin  
T1D Type 1 Diabetes 
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T2D Type 2 Diabetes 
TCID  Tissue culture infection dose  
TG  Triglyceride  
TGFβ  Transforming growth factor beta  
TNFα Tumor necrosis factor alpha 
TSC1/2 Tuberous sclerosis 1/2 
UCP1 Uncoupling protein 1 
UPR Unfolded protein response 
UV  Ultra Violet  
VCP  Valosin-containing protein  
VLDL  Very low density lipoprotein  
WB  Western Blot 
WHO  World health organisation  
WT Wild type  
 
Abbreviations for acylcarnitines and amino acids can be found in suppl. table 4 and 5, 
respectively. 
 
9.2 Plasmid Maps 
9.2.1 pCMV-SPORT6 
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9.2.2 pENTR-Flag 
 
 
9.2.3 pAd-Block-iTTM-DEST 
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9.2.4 pcDNA6.2-GW/EmGFP-miR 
 
 
 
9.2.5 pdsAAV2-LP1-GFPmut-miR-NC 
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9.3 Supplementary Figures 
Suppl. figure 1: DAVID enrichment analysis of >2fold down regulated genes in the liver of GADD45β 
KO mice. Male GADD45β KO and WT littermates were sacrificed after being fasted for 24h hours. 
Functional annotation analysis on RNAseq hits from Suppl. table 2 was performed with DAVID 
Bioinformatics Resources 6.7 (National institute of allergy and infectious diseases, NIH, 
http://david.abcc.ncifcrf.gov). n=3 per group 
 
 
Suppl. figure 2: Simplified scheme of the insulin signalling pathway. For appreviations see section 9.1. 
 
 
9.4 Supplementary Tables 
Suppl. table 1: Induction of GADD45 proteins by various stressors. Adapted and modified from [208]. 
Stress GADD45 member Reference 
UV-radiation GADD45α, GADD45β, GADD45γ 
PMID: 10327059; 3194391; 8208528; 
11078829; 11251170; 12164919; 
15616591; 15616591 
X-rays GADD45α PMID: 1990262, 11747551 
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α-radiation GADD45α, GADD45β, GADD45γ PMID: 10327059; 11251170; 
11382918; 11873496 
Low-frequency electromagnetic fields GADD45α PMID: 16116041 
Hypoxia GADD45α PMID: 1617653; 18087215 
Peroxynitrite free radicals GADD45α PMID: 11163539 
Hyperosmotic stress GADD45α, GADD45β, GADD45γ PMID: 9593703; 12372778; 
19834918 
Oncogenic stress GADD45α PMID: 12748288 
Low pH GADD45α PMID: 16113055 
Arsenic As(III) GADD45α 
PMID: 10910055; 11429707; 
16814109; 11353140; 12883267; 
15493360 
Sodium arsenite GADD45β PMID: 15797874 
Chromium Cr(VI) GADD45α PMID: 14971655 
Cisplatin GADD45α PMID: 10327059; 8996528 
Methyl methanesulfonate (MMS) GADD45α, GADD45β, GADD45γ PMID: 1990262; 11251170 
Ethanol GADD45α PMID: 16131858 
Cigarette smoke condensate GADD45α PMID: 15208684; 15170813 
Mitomycin C GADD45α PMID: 10327059 
Bacterial lipopolysaccharides GADD45β, GADD45γ PMID: 15797874, 16116230 
Pro-inflammatory cytokines (IL-6, IL-12, IL-
18) 
GADD45β PMID: 18501677; 11175814;  
IL-2, IL-6 GADD45γ PMID: 10490824 
Pro-apoptotic cytokines (TGFβ, TNFα) GADD45β PMID: 8139540; 12456654; 
12933797; 18501677; 15797874 
 
Suppl. table 2: >2fold down regulated genes in the liver of GADD45β KO mice. Male GADD45β KO and 
WT littermates were sacrificed after being fasted for 24h hours. Expression profiling of liver transcripts was 
subsequently performed by RNAseq analysis. Shown are the Fragments Per Kilobase Of Exon Per Million 
Fragments Mapped (fpkm). A false positive rate (FDR) of a=0.01 was applied. n=3 per group. 
Symbol Name Feature Type Entrez Gene ID 
WT 
fpkm 
KO 
fpkm 
KO/WT 
fold 
chang
e 
q value 
(FDR) 
~ 
expression 
level 
4930565N
06Rik 
RIKEN cDNA 
4930565N06 gene 
unclassified 
non-coding 
RNA gene 
68306 0,256 0,021 0,082 0,000271 low 
Atp6v0d2 
ATPase, H+ 
transporting, lysosomal 
V0 subunit D2 
protein coding 
gene 242341 1,130 0,364 0,322 1,36E-07 moderate 
BC00556
1 
cDNA sequence 
BC005561 
protein coding 
gene 100042165 1,384 0,500 0,361 1,15E-11 moderate 
Bmpr2 
Bone morphogenetic 
protein receptor, type II 
(serine/threonine 
kinase) 
protein coding 
gene 12168 2,381 0,800 0,336 2,38E-14 moderate 
Cbl Casitas B-lineage lymphoma 
protein coding 
gene 12402 0,926 0,399 0,431 2,10E-06 low 
Cdk6 Cyclin-dependent kinase 6 
protein coding 
gene 12571 2,553 1,170 0,458 9,35E-07 moderate 
F830016
B08Rik 
RIKEN cDNA 
F830016B08 gene 
protein coding 
gene 240328 4,940 1,154 0,234 0 moderate 
G530011
O06Rik 
RIKEN cDNA 
G530011O06 gene lincRNA gene 654820 0,349 0,100 0,285 0,000946 low 
Gadd45b 
Growth arrest and DNA-
damage-inducible 45 
beta 
protein coding 
gene 17873 3,034 0,000 0,000 5,09E-22 moderate 
Gprin3 GPRIN family member 3 protein coding gene 243385 1,406 0,561 0,399 2,11E-07 moderate 
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Klf12 Kruppel-like factor 12 protein coding gene 16597 6,002 2,973 0,495 2,66E-12 moderate 
Klhl11 Kelch-like 11 protein coding gene 217194 1,627 0,693 0,426 5,02E-06 moderate 
Lcn2 Lipocalin 2 protein coding gene 16819 30,585 11,018 0,360 0 high 
Lcor 
Ligand dependent 
nuclear receptor 
corepressor 
protein coding 
gene 212391 0,689 0,158 0,229 4,47E-12 low 
Lmbrd2 LMBR1 domain containing 2 
protein coding 
gene 320506 8,871 2,987 0,337 0 moderate 
Lnpep Leucyl/cystinyl aminopeptidase 
protein coding 
gene 240028 1,273 0,417 0,328 9,68E-13 moderate 
Mib1 Mindbomb homolog 1 (Drosophila) 
protein coding 
gene 225164 7,297 3,555 0,487 2,91E-12 moderate 
N4bp2 NEDD4 binding protein 2 
protein coding 
gene 333789 4,208 1,923 0,457 1,60E-13 moderate 
Ptar1 
Protein 
prenyltransferase alpha 
subunit repeat 
containing 1 
protein coding 
gene 72351 0,668 0,262 0,393 0,001653 low 
Ptpn4 
Protein tyrosine 
phosphatase, non-
receptor type 4 
protein coding 
gene 19258 0,777 0,383 0,493 0,000509 low 
Rel Reticuloendotheliosis oncogene 
protein coding 
gene 19696 1,198 0,567 0,473 0,000478 moderate 
Sesn3 Sestrin 3 protein coding gene 75747 3,001 1,368 0,456 4,92E-07 moderate 
Themis Thymocyte selection associated 
protein coding 
gene 210757 0,256 0,101 0,396 0,009662 low 
Uhmk1 U2AF homology motif (UHM) kinase 1 
protein coding 
gene 16589 6,640 3,111 0,469 1,00E-09 moderate 
Xpo4 Exportin 4 protein coding gene 57258 1,631 0,805 0,493 2,99E-05 moderate 
Xrn1 5'-3' exoribonuclease 1 protein coding gene 24127 1,605 0,670 0,417 3,81E-10 moderate 
Zbed6 Zinc finger, BED domain containing 6 
protein coding 
gene 667118 4,443 0,416 0,094 0 moderate 
Zfp369 Zinc finger protein 369 protein coding gene 170936 1,452 0,431 0,297 2,35E-11 moderate 
Zfp433 RIKEN cDNA 1700123A16 gene 
protein coding 
gene 73610 3,310 1,530 0,462 5,09E-10 moderate 
 
Suppl. table 3: >2fold up regulated genes in the liver of GADD45β KO mice. Male GADD45β KO and 
WT littermates were sacrificed after being fasted for 24h hours. Expression profiling of liver transcripts was 
subsequently performed by RNAseq analysis. Shown are the Fragments Per Kilobase Of Exon Per Million 
Fragments Mapped (fpkm). A false positive rate (FDR) of a=0.01 was applied. n=3 per group. 
Symbol Name Feature Type Entrez Gene ID 
WT 
fpkm 
KO 
fpkm 
KO/WT 
fold 
chang
e 
q value 
(FDR) 
~ 
expression 
level 
Ces4a carboxylesterase 4A protein coding gene 234677 0,413 1,844 4,461 2,41E-14 moderate 
Cgref1 cell growth regulator with EF hand domain 1 
protein coding 
gene 68567 0,824 2,710 3,289 8,82E-12 moderate 
Cidec cell death-inducing DFFA-like effector c 
protein coding 
gene 14311 7,506 18,243 2,430 0 high 
Cntnap1 contactin associated protein-like 1 
protein coding 
gene 53321 0,625 1,767 2,827 2,03E-13 moderate 
Derl3 Der1-like domain family, member 3 
protein coding 
gene 70377 2,600 8,672 3,336 0 moderate 
Lad1 ladinin protein coding gene 16763 1,600 3,434 2,145 1,22E-08 moderate 
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Nudt7 
nudix (nucleoside 
diphosphate linked 
moiety X)-type motif 7 
protein coding 
gene 67528 79,821 
169,65
9 2,125 0 high 
Onecut1 one cut domain, family member 1 
protein coding 
gene 15379 5,009 11,485 2,293 1,82E-13 high 
Peg10 paternally expressed 10 protein coding gene 170676 0,124 0,280 2,265 0,003468 low 
Pfkfb3 
6-phosphofructo-2-
kinase/fructose-2,6-
biphosphatase 3 
protein coding 
gene 170768 1,360 2,767 2,034 0 moderate 
Pitx3 
paired-like 
homeodomain 
transcription factor 3 
protein coding 
gene 18742 2,540 5,657 2,227 1,50E-07 moderate 
Serpina1
2 
serine (or cysteine) 
peptidase inhibitor, 
clade A (alpha-1 
antiproteinase, 
antitrypsin), member 12 
protein coding 
gene 68054 1,915 4,000 2,089 3,19E-09 moderate 
Serpina4-
ps1 
serine (or cysteine) 
peptidase inhibitor, 
clade A, member 4, 
pseudogene 1 
pseudogene 321018 7,210 36,964 5,127 0 high 
Slc35f1 solute carrier family 35, member F1 
protein coding 
gene 215085 0,030 0,197 6,524 4,88E-05 low 
 
Suppl. table 4: Correlation analysis of liver GADD45B levels and parameters to assess the diabetic 
status of lean and obese men with and without Type 2 Diabetes. Diabetic and healthy patients were 
pooled for the analysis and only separated by their body composition into lean men or men with 
subcutaneous (SC) or visceral (VIS) fat. Correlation was determined using Shearman’s correlation 
coefficient.  
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Suppl. table 5: Acylcarnitines and their full names. 
Abbreviation Name 
C0 free Carnitine 
C2 Acetylcarnitine  
C3 Propionylcarnitine  
C4 Butyrylcarnitine  
C5 Isovalerylcarnitine  
C6 Hexanoylcarnitine  
HMB 2-OH-3- Methyl-butyrylcarnitine 
C5OH 3-OH-Isovalerylcarnitine 
C8:1 Octenoylcarnitine  
C8 Octanoylcarnitine  
C10:1 Decenoylcarnitine 
C10 Decanoylcarnitine  
MMA (C4DC) Methylmalonylcarnitine  
Glut (C5DC) Glutarylcarnitine  
C12 Dodecanoylcarnitine  
MeGlut 3-Methylglutarylcarnitine 
3HMG 3-Hydroxy-3-methylglutarylcarnitine 
C14:1 Myristoleylcarnitine 
C14 Myristoylcarnitine  
C14OH 3-OH-Myristoylcarnitine 
C16:1 Palmitoleylcarnitine  
C16 Palmitoylcarnitine  
C16OH 3-OH-Palmitoylcarnitine 
C16:1OH Hydroxyhexadecenoylcarnitine 
C18:2 Linoleylcarnitine 
C18:1 Octadecenoylcarnitine 
C18 Stearoylcarnitine  
C18:1OH 3-OH-Octadecenoylcarnitine 
C18OH 3-OH-Stearoylcarnitine 
 
Suppl. table 6: Amino acids and their full names. 
Abbreviation Name 
Ala Alanine 
Arg Arginine 
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Asa Asparagine 
Asp Aspartic Acid 
Cit Citrulline 
Glu Glutamic Acid 
Gly Glycine 
Hci Homocysteine 
His Histidine 
Leu/Ile Leucin/Isoleucin 
Met Methionine 
Orn Ornithine 
Phe Phenylalanine 
Pro Proline 
Pyg Pyridylglycine 
Thr Threonine 
Trp Tryptophan 
Tyr Tyrosine 
Val Valine 
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